Skin Disorders, Atopic Manifestations and Primary Immunodeficiency Diseases: Identifying clinical features and common pathways of immune dysregulation to improve diagnosis and personalized treatment by Wit, J. (Jill) de
Skin Disorders, Atopic Manifestations and Primary Immunodefi ciency Diseases
Identifying clinical features and common pathways of immune dysregulation to improve 
diagnosis and personalized treatment
Jill de Wit
Skin Disorders,  










it Jill de Wit
Identifying clinical features  
and common pathways 
of immune dysregulation 
to improve diagnosis and 
personalized treatment

Skin Disorders, Atopic Manifestations and Primary Immunodeficiency Diseases
Identifying clinical features and common pathways of immune dysregulation to improve 
diagnosis and personalized treatment
Jill de Wit
ISBN/EAN: 978-94-6361-499-3
Lay-out and printing by Optima Grafische Communicatie (www.ogc.nl)
Copyright © 2021 J. de Wit, Rotterdam, The Netherlands
For all articles published or accepted, the copyright has been transferred to the respective 
publisher. No part of this thesis may be reproduced, stored in a retrieval system or transmit-
ted in any form or by any means without permission from the author or, when appropriate, 
from the publishers of the publications.
Skin Disorders, Atopic Manifestations 
and Primary Immunodeficiency Diseases
Identifying clinical features and common pathways of immune dysregulation to 
improve diagnosis and personalized treatment
Huidaandoeningen, atopische manifestaties 
en primaire immuundeficiënties
Identificatie van klinische kenmerken en gemeenschappelijke processen van immuundys-
regulatie ter verbetering van diagnostiek en gepersonaliseerde behandeling
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de rector magnificus
Prof.dr. F.A. van der Duijn Schouten
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op





Promotor Prof. dr. S.G.M.A. Pasmans
Overige leden Prof. dr. E.P. Prens
Prof. dr. P.M. van Hagen
Dr. E.F. Knol
Copromotoren Dr. V.A.S.H. Dalm
Dr. J.E.E. Totté
CONTENTS
Chapter 1 General introduction 7
Chapter 2 Skin disorders are prominent features in primary 
immunodeficiency diseases: a systematic overview of current 
data
25
Chapter 3 3.1 Skin disorders in primary immunodeficiency diseases: highly 
prevalent and early presenting clinical features
71
3.2 Atopic manifestations are underestimated clinical features in 
various primary immunodeficiency disease phenotypes
99
Chapter 4 Molecular clustering of genes related to the atopic 
syndrome: towards a more tailored approach and 
personalized medicine?
99
Chapter 5 The prevalence of antibody responses against Staphylococcus 
aureus antigens in patients with atopic dermatitis: a 
systematic review and meta-analysis
139
Chapter 6 6.1 Targeted anti-staphylococcal therapy with endolysins in 
atopic dermatitis and the effect on steroid use, disease 
severity and the microbiome: study protocol for a 
randomized controlled trial (MAAS trial)
165
6.2 Endolysin treatment against Staphylococcus aureus in adults 
with atopic dermatitis: a randomized controlled trial
181
Chapter 7 General discussion 201















The human immune system is comprised of a complex network that involves lymphoid 
organs, cells, humoral factors and cytokines. The essential function of the immune system 
in host defense is to protect against invading pathogens, including bacteria and viruses, 
and foreign bodies. The immune system can be divided in two categories; the innate or 
nonspecific immunity and the adaptive or specific immunity. The innate immune response 
forms the host’s first line of defense and consists of physical and chemical barriers (skin and 
mucosa), effector cells (e.g. granulocytes, macrophages and dendritic cells), antimicrobial 
peptides (e.g. defensins and cathelicidins), soluble mediators (e.g. cytokines and comple-
ment) and cellular receptors (e.g. Toll-like receptors (TLRs)) that can provide immediate and 
non-specific response to a wide array of pathogens.1 The adaptive or acquired immune re-
sponse forms the second line of defense and consists of antigen-specific reactions through 
highly specialized T lymphocytes and B lymphocytes.2 Whereas the innate response is 
rapid, the adaptive response may take days to weeks to develop. Moreover, after an initial 
pathogen encounters, adaptive immune cells can persist in the host for life, providing 
immunological memory and the capacity for rapid response in the event of re-exposure.
Primary immunodeficiency diseases (PIDs) are characterized by a compromised or en-
tirely absent function of a part of the immune system, which makes people vulnerable 
for infections. In patients with a PID, the types of infections depend on the underlying 
immunological defects. For example, patients with a humoral immunodeficiency due to a 
defect in B lymphocyte function are at increased risk for recurrent infections predominantly 
caused by extracellular, encapsulated bacterial pathogens, mainly of the upper and lower 
respiratory tract and gastrointestinal tract. On the other hand, patients with a cellular 
immunodeficiency, i.e. defect in T lymphocyte function, have an increased risk of infections 
caused by intracellular pathogens, including Herpes simplex virus, Mycobacterium, Listeria 
and intracellular fungal infections.
PrImary ImmunodefIcIency dIseases
PIDs encompass a heterogeneous group of more than 430 inheritable defects of immunity 
caused by variants in genes encoding functional proteins of human immune cells.3-5 How-
ever, with the increasing power of next-generation sequencing the number of recognized 
genetic disorders is even expanding.5 The incidence of symptomatic PIDs is estimated at 
1 in 2,000 live births with a prevalence of 1 in 10,000-12,000 in the general population, 
of which the majority is due to highly consanguineous populations in the Middle East/
Northern African region.4,6,7 PIDs are clinically typically characterized by an increased risk of 
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recurrent and/or severe infections. In addition, patients may suffer from autoimmune and 
autoinflammatory complications and have an increased risk of development of (hematologi-
cal) malignancies and allergic disorders.8-10 Autoimmune disorders, such as type 1 diabetes 
mellitus, rheumatoid arthritis and psoriasis, are the result of an immune response directed 
against normal bodily constituents, called auto-antigens. In autoinflammatory disorders, 
like familiar mediterranean fever (FMF) and tumor necrosis factor receptor-associated 
periodic syndrome (TRAPS), the innate immune system is abnormally activated, leading to 
recurrent episodes of fever and inflammation.11 Autoimmune as well as autoinflammatory 
conditions are characterized by disruption of the normal function of the immune system, 
also called immune dysregulation. Interestingly, various forms of immune dysregulation, 
both as primary or as accompanying symptoms next to the immunodeficiency, occur in 
many PIDs and, therefore, PIDs could be considered as immune dysregulation syndromes.12
Currently, PIDs are classified into ten main groups of PID according to the predominant 
immunological mechanisms that are disrupted and their most relevant clinical features.3 
These groups include (i) immunodeficiencies affecting cellular and humoral immunity; (ii) 
combined immunodeficiencies with associated or syndromic features; (iii) predominantly 
antibody deficiencies; (iv) diseases of immune dysregulation; (v) congenital defects of 
phagocyte number, function or both; (vi) defects in intrinsic and innate immunity; (vii) 
autoinflammatory disorders; (viii) complement deficiencies; (ix) bone marrow failure; and 
(x) phenocopies of PID. The primary humoral immunodeficiencies are categorized within 
the predominantly antibody deficiencies (PADs) and are characterized by B lymphocyte 
abnormalities that result in decreased numbers or impaired function of B lymphocytes, low 
immunoglobulin (Ig) levels or both. On a global scale, PADs form the largest PID phenotype 
as more than 60% of the PIDs diagnosed in clinical practice consist of a humoral im-
munodeficiency.13-18
One of the clinical hallmarks of PIDs is an increased susceptibility to infections. Therefore, a 
PID should be considered when a patient has recurrent, severe, prolonged and/or difficult-
to-treat infections. Based on these clinical findings, ten general warnings signs of PID have 
been composed by the European Society for Immunodeficiencies (ESID), mainly focusing on 
the presence of infectious complications, to raise the suspicion of a PID.19 These warning 
signs include (i) four or more new ear infections within one year; (ii) two or more serious 
sinus infections within one year; (iii) two or more months on antibiotics with little effect; 
(iv) two or more pneumonias within one year; (v) failure of an infant to gain weight or 
grow normally; (vi) recurrent, deep skin or organ abscesses; (vii) persistent thrush in mouth 
or fungal infection of the skin; (viii) need for intravenous antibiotics to clear infections; (ix) 
two or more deep-seated infections including septicemia; and (x) a family history of PID. In 
case of presence of two or more warning signs, the suspicion for a PID should be raised. 
11
General introduction
However, despite use of these warning signs to improve earlier recognition of an underly-
ing PID, diagnosis of PIDs is still delayed. The diagnostic delay, i.e. the time between onset 
of the first symptoms and diagnosis, of PIDs in the Netherlands may be up to 14.5 years 
for defects in innate immunity.13 As a consequence, these inherited PIDs are diagnosed at 
a median age of 19.0 years.13
Diagnostic delay in PIDs results in persistence of symptoms, irreversible organ damage and 
dysfunction, recurrent hospitalizations, and functional limitations of patients, which all 
contribute to a lower quality of life for both mental and physical components as compared 
with healthy controls and patients with other chronic diseases.20-24 Therefore, early recog-
nition of PIDs is crucial and the identification of new PID-characteristic symptoms as early 
warning signs for suspicion of PIDs could aide earlier diagnosis.
Skin disorders in primary immunodeficiency diseases
It has been well recognized that a wide spectrum of both infectious and noninfectious skin 
disorders are common in PIDs and may be among the presenting clinical manifestations.25-30 
Overall, Staphylococcus (S.) aureus-induced skin infections, such as folliculitis and skin 
abscesses, are the most common infectious skin disorders reported in PIDs, like leukocyte 
adhesion defects (LADs), chronic granulomatous disease (CGD), severe congenital neu-
tropenia and hyper IgE syndrome (HIES).31-33 Known noninfectious skin disorders include 
autoimmune, autoinflammatory, malignant and allergic manifestations, which could all be 
attributed to immune dysregulation. Dermatitis is described as one of the most prominent 
noninfectious skin manifestations in PIDs.30
The relation between skin disorders and PIDs has been investigated in few studies. Studies 
in PID cohorts from Iran and Mexico have demonstrated that skin manifestations preceded 
and were the basis for PID diagnosis in 31.8% and 78.9% patients, respectively.26,27 In 
addition, Aghamohammadi et al. have shown that in patients with severe and/or therapy 
refractory dermatitis an underlying PID could be detected in 8% of the patients, including 
HIES and Wiskott-Aldrich syndrome (WAS).34 Although skin conditions seem to be fre-
quently occurring in PIDs and may even precede the diagnosis of a PID, they are currently 
not considered as one of the warning signs for PIDs.
Atopic manifestations in primary immunodeficiency diseases
Atopic manifestations consist of atopic dermatitis (AD), food allergy (FA), asthma and al-
lergic rhinitis (AR). In general, patients with severe dermatitis frequently have an atopic 
constitution and tendency towards development of other atopic manifestations.35,36 The 
atopic manifestations encompass allergic disorders, which are already known as prevalent 
comorbidities in various PIDs.4,30,37 Nonetheless, a narrative review reported occurrence of 
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these manifestations mainly in immunodeficiencies affecting cellular and humoral immu-
nity, like DOCK8 deficiency, and combined immunodeficiencies (CIDs) with associated or 
syndromic features, such as Comèl Netherton syndrome.30 Other original studies reported 
atopic manifestations most commonly in CIDs and, albeit in lower frequencies, in PADs, 
like selective IgA deficiency.38-54 However, original data on atopic manifestations in PIDs 
are limited, mainly based on small numbers of PID patients and the diagnosis of atopic 
manifestations is generally not based on diagnostic tests.
atoPIc syndrome
Atopy is the genetic predisposition to produce specific IgE following exposure to allergens. 
This predisposition results in the development of AD, FA, asthma and AR: the atopic syn-
drome.55 The worldwide prevalence of these manifestations in children varies between 
15-20%, 1-10%, 3-29% and 9-15%, respectively, and in adults between 1-3%, 3-4%, 
2-12% and 7-42%, respectively.56-60 The atopic march characterizes the course of atopic 
manifestations over time, generally starting with AD in infancy and followed by FA, asthma 
and AR later in childhood.61 However, it is known that the atopic march not always follows 
the classic sequence and may occur at any age.62,63 Furthermore, not all atopic patients will 
develop the complete spectrum of atopic manifestations.61
Subgroups of the atopic phenotype, termed endotypes, are possibly responsible for the 
heterogeneous presentation of the atopic syndrome. These endotypes are the result of 
variations in physiological, biological, immunological and/or genetic mechanisms, as in-
volved in the multifactorial pathogenesis of atopic manifestations.64 Various genetic loci 
associated with multiple atopic manifestations have been identified in recent years based 
on genome-wide association studies showing common genetic mechanisms involved.65-74 
Additionally, immune dysregulation plays an important role in the pathogenesis of the 
atopic syndrome. The major immunological abnormality consists of enhanced IgE produc-
tion against environmental antigens triggering the release of inflammatory mediators, 
including histamine, in the skin, gastrointestinal tract, lungs and nose.75 The abnormal 
regulation of antigen-specific IgE production in patients with atopic manifestations seems 
to be the result of a preferential presence of CD4+ T lymphocytes producing interleukin 
(IL)-4 and IL-5, but not interferon γ (IFN-γ), which suppresses IgE synthesis.76-78
Interestingly, atopic manifestations are prevalent comorbidities in various (monogenic) 
PIDs, which may be due to overlapping pathogenic pathways. Therefore, current insights 
in the pathways involved in PIDs could be used to define the endotypic profile of atopic 
patients in more detail, contributing to determination of more homogeneous subclasses of 
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these patients. Subsequently, pathway-targeted or even gene-targeted treatment strate-
gies could be developed to personalize treatment regimens for the atopic syndrome based 
on endotype profiles.
atoPIc dermatItIs
AD is an important cutaneous manifestation within the atopic syndrome and one of the 
most common chronic inflammatory diseases. It is characterized by intense itch, erythema 
and scaling. Symptoms generally start in infancy with a relapsing-remitting course, but 
may occur at any age.79 Based on genetic and epidemiological data, AD is found to be 
associated not only with the atopic syndrome but also with systemic immune-mediated 
inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease. 
This suggests that AD should be considered as manifestation of systemic inflammation 
rather than being inflammation limited to the skin.80,81
AD has a multifactorial pathogenesis characterized by three major pathophysiological 
changes consisting of (i) abnormalities of the skin barrier; (ii) changes in the immune 
response; and (iii) alterations in the skin microbiome.
Abnormalities of the skin barrier
The healthy skin forms the first line of defense of the body against harmful stimuli from 
the environment, like irritants, allergens, antigens and microorganisms. Furthermore, it 
prevents the body from excessive water loss. The impaired barrier function in AD enables 
environmental stimuli to penetrate into the skin and subsequently provoke an immune 
reaction. Various abnormalities in the skin barrier function, including an increased skin pH, 
reduced expression of antimicrobial peptides and a breach in epidermal lipids resulting in 
increased skin permeability, have been associated with development of AD.82-85 Addition-
ally, a filaggrin deficiency, which is involved in skin hydration and water retention within 
the epidermis, was found as most important genetic risk factor for AD.83,86
Changes in the immune response
Exposure to microorganisms through an impaired skin barrier initiates a rapid innate 
immune response preventing further invasion of these microorganisms. Both skin tissue 
damage and invading microorganisms stimulate TLRs, which are expressed by keratino-
cytes and antigen-presenting cells in the skin.87 This leads to a release of inflammatory 
mediators that enhances the strength of tight junctions to limit penetration of allergens 
and microorganisms. Patients with AD, however, were shown to have decreased function 
of TLR2 and TLR9, which leads to alterations in the skin microbiome, increased penetra-
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tion of microorganisms and more severe inflammation.87,88 Accordingly, a genome-wide 
association study in AD identified candidate genes involved in regulation of the innate host 
defense and T lymphocyte function. This emphasizes the contribution of immunological 
processes in the pathogenesis of AD.65
In AD, the nonlesional skin shows increased numbers of T helper (Th) lymphocytes, like 
Th2, Th17 and Th22, representing in a pro-inflammatory state.80 Enhanced penetration 
of environmental stimuli through the impaired skin barrier stimulates additional Th2 cell 
migration into the skin and subsequent acute inflammation.89 These AD lesions are pre-
dominated by production of pro-inflammatory cytokines, including IL-4, IL-13 and IL-31, 
which further modulate the skin barrier function, amongst others, by suppressing filaggrin 
expression and inhibiting the production of antimicrobial peptides. Chronic inflammation 
promotes a shift towards a Th1 cell immune response controlled by IL-12 production by 
dendritic cells, possibly stimulated by S. aureus.90 The Th1 cells in chronic AD lesions pro-
duce IFN-γ, which inhibits keratinocyte differentiation resulting in skin hyperplasia.
The humoral immune response is also involved in AD. Penetration of allergens through 
the skin leads to Th2 cytokine production. These cytokines stimulate IgE production by 
B lymphocytes. Many patients with AD show high IgE levels against specific allergens, 
like food allergens or inhalant allergens.91-93 Moreover, some patients with AD also have 
increased IgE against microbial antigens, suggesting that microbes act as allergens instead 
of antigens.94-99 In addition to the increased IgE levels in AD, IgG antibody production 
was found to be stimulated in response to contact with food antigens, leading to a pro-
inflammatory response and phagocytosis of the antigen.100 Furthermore, IgG levels against 
microbial antigens on the skin of AD patients are found to be higher than in controls.101 
Further identification of antibody responses against microbial antigens could help us to 
better understand how microbes interact with the immune system and potentially induce 
inflammation in AD.
Alterations in the skin microbiome
Multiple studies have described alterations of the skin microbiome in patients with AD, 
predominantly consisting of an overgrowth of S. aureus on both the lesional and nonle-
sional skin accompanied by reduced diversity of commensal bacteria.102,103 Moreover, S. 
aureus colonization was found to be positively correlated with AD severity, with patients 
having a higher S. aureus load during flares.102,104 A birth cohort study, which aimed to 
identify the role of the skin microbiome in AD, found that S. aureus colonization and lower 
number of commensal Staphylococcus species at the age of two to three months were 
correlated with development of AD later in life.105 These findings suggest that cutaneous 
dysbiosis, including abundance of S. aureus, plays a role in initiation of AD. However, a 
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systematic review found that not only S. aureus is involved in the dysbiosis in AD, but also 
other species, including S. epidermidis, Propionibacterium and Malassezia.106
Some mechanisms by which S. aureus interacts with the skin barrier and immune system 
have been unraveled. For example, S. aureus can aggravate skin inflammation via the pro-
duction of enterotoxins that stimulate the release of pro-inflammatory cytokines.90,102,104,107 
Furthermore, S. aureus produces α-toxin that induces keratinocyte damage.108 However, 
the importance of S. aureus colonization in the complex pathogenesis of AD, as compared 
with the other involved genetic and immunological factors, remains poorly understood.106
Interaction between skin barrier, immune system and skin microbiome
The above described pathophysiological components within the multifactorial pathogen-
esis of AD seem to interact in a multidirectional way. Pro-inflammatory cytokines cause 
skin barrier impairment, while, on the other hand, an increased skin permeability results 
in environmental stimuli penetrating through the skin and provoking an immune reac-
tion.109,110 Both alterations in the immune system and skin barrier impairment might favor 
S. aureus colonization and staphylococcal antigens contrarily seem to interact with the 
immune system and skin barrier.103,108,111 However, studies on the interaction between the 
immune system and S. aureus are still scarce. Further evaluation of the antibody response 
against antimicrobial antigens could provide insights in the antigens that are expressed 
by the skin microbiome in vivo and will reveal how the immune system of AD patients 
counteracts these antigens. Thereby, the contribution of each of the three factors to the 
AD phenotype is still unknown.
As previously described, S. aureus is abundant in the skin microbiome of AD patients, which 
could therefore be a target for treatment in AD. Current long-term anti-staphylococcal 
treatment strategies, like antibiotics, have the disadvantages of affecting the commensal 
microbiota and inducing bacterial resistance.112-114 In this context, it would be interesting 
to study the effect of an endolysin selectively targeting S. aureus on AD symptoms in a 
randomized controlled trial (RCT).
aIms of the thesIs
-	 To evaluate whether skin disorders and atopic manifestations are prognostic warning 
signs for PIDs in order to shorten the diagnostic delay.
-	 To define homogeneous endotypes within the atopic phenotype based on known 




-	 To provide an overview of the antibody responses against S. aureus antigens, as most 
abundant microorganism in patients with AD, in order to gain insight into the interac-
tion between the immune system and skin microbiome in the pathogenesis of AD.
-	 To study the effect of a targeted intervention against S. aureus on AD symptoms in 
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Skin disorders are prominent features 
in primary immunodefi ciency diseases: 











Primary immunodeficiency diseases (PIDs) are characterized by an increased risk of infec-
tions, autoimmunity, autoinflammation, malignancy, and allergic disorders. Skin disorders 
are also common clinical features in PIDs and may be among the presenting manifesta-
tions. Recognition of specific PID-associated skin conditions in combination with other 
clinical features as described in the currently used warning signs could raise suspicion of 
an underlying PID.
Objective
We aimed to provide a systematically obtained overview of skin disorders and their preva-
lence in PIDs. Secondary, the prevalence of Staphylococcus (S.) aureus–associated skin 
disorders and atopy was reviewed, as these are the most prominent skin features in PIDs.
Methods
A systematic search was performed in EMBASE, MEDLINE, Web of Science, Cochrane, and 
Google Scholar (up to May 9, 2018). All original observational and experimental human 
studies that address the presence of skin disorders in PIDs were selected. We rated study 
quality using the Institute of Health Economics Quality Appraisal Checklist for Case Series 
Studies.
Results
Sixty-seven articles (5030 patients) were included. Study quality ranged from 18.2% to 
88.5%. A broad spectrum of skin disorders was reported in 30 PIDs, mostly in single 
studies with a low number of included patients. An overview of associated PIDs per skin 
disorder was generated. Data on S. aureus-associated skin disorders and atopy in PIDs were 
limited.
Conclusion
Skin disorders are prominent features in PIDs. Through clustering of PIDs per skin disorder, 
we provide a support tool to use in clinical practice that should raise awareness of PIDs 
based on presenting skin manifestations.
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Systematic review on skin disorders in primary immunodeficiency diseases
IntroductIon
Primary immunodeficiency diseases (PIDs) represent a heterogeneous group of inherited 
disorders caused by mutations in genes encoding functional proteins of the immune cells. 
Based on registries and epidemiologic surveys, it has been suggested that six million people 
are living with a PID worldwide, whereas only 27.000-60.000 patients have been identified 
to date.1 PIDs are usually characterized by recurrent and/or severe infections as well as an 
increased risk of autoimmunity, autoinflammation, malignancy and allergic disorders.2-4 
Moreover, both infectious and noninfectious skin disorders are common in PIDs and may 
be among the presenting clinical manifestations.5-8 Staphylococcus (S.) aureus induced 
skin infections are the most common infectious skin disorders reported in PIDs, including 
leukocyte adhesion defects (LAD), chronic granulomatous disease (CGD), severe congenital 
neutropenia and hyper immunoglobulin (Ig) E syndrome (HIES).9-11 On the other hand, 
dermatitis is one of the most prominent noninfectious skin manifestations in PIDs and 
may be part of the atopic syndrome.12 Patients with an atopic constitution show next 
to atopic dermatitis (AD) tendency towards development of food allergies, asthma and 
rhinoconjunctivitis.13
Based on previous narrative reviews without a systematic approach, S. aureus skin infec-
tions, dermatitis and other skin disorders as well as atopy seem to be all fairly common 
in patients with a PID, but are also frequently described in the general population.12 
Therefore, it is of importance to realize that presence of specific skin symptoms alone does 
not necessarily point towards a PID. However, recognition of specific skin conditions in 
combination with other clinical features suggestive of an immunodeficiency should raise 
awareness to an underlying PID and may facilitate earlier diagnosis of PIDs.14
The aim of this review was to provide a systematically obtained overview of skin disorders 
and their prevalence in patients with PIDs. Focusing on two prevalent skin disorders in PIDs, 




This review with a systematic approach was conducted and reported according to the 
Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines, where ap-
plicable.15 All original observational and experimental human studies were included. We 
selected both articles reporting skin disorders in patients with PIDs and articles present-
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ing a differential diagnosis of a specific skin disorder that includes a PID. No restrictions 
were made with respect to publication date and language. We excluded case reports (<5 
patients), conference abstracts, letters and editorials as the quality of these types of ar-
ticles can be highly variable. Also articles describing acquired immunodeficiencies, articles 
reporting skin disorders in PIDs that developed after or during treatment/intervention and 
articles in which the description of skin disorders in PIDs was not part of the results section 
were excluded. Data on skin disorders were only extracted if at least five patients per PID 
were reported.
Study participants
Patients of all ages with a PID according to Picard et al.16 from both hospital setting and 
general population were included.
Study outcomes
The primary outcome is the presence of skin disorders in PIDs. Secondary outcomes include 
the prevalence of skin disorders in PIDs, S. aureus-associated skin disorders in PIDs, and 
PIDs associated with an atopic constitution (i.e. atopic dermatitis, food allergy, asthma, 
rhinoconjunctivitis).
Search strategy
The electronic search was conducted in EMBASE, MEDLINE, Web of Science, Cochrane, 
and Google Scholar up to May 9th 2018 (Appendix 1). The search was composed of terms 
of the categories primary immunodeficiency, skin disorder, Staphylococcus aureus and 
atopy supplemented by specific PIDs and skin disorders based on recent literature.12,17-19
Study selection and data extraction
All studies identified in the systematic search were screened for relevance by title and 
abstract. Duplicates and studies that did not meet our inclusion criteria were excluded 
(Appendix 2). Remaining articles were assessed for eligibility by full text review. Further-
more, a cross-reference check was performed to identify other eligible studies based 
on the reference lists of all included articles and relevant review articles. Translation of 
non-English studies was conducted officially. Study selection and data extraction were 
performed independently by two researchers (JdW and JvV, JdW and RB or JvV and RB). 
Disagreements were resolved and consensus was reached. If one population was described 
in different articles, we included the study with the most detailed description of the results. 
The methodological quality of the individual articles was rated using the Institute of Health 
Economics (IHE) Quality Appraisal Checklist for Case Series Studies (Appendix 3).20
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Analysis of data
The prevalence of skin disorders in PIDs was extracted from the included studies. If re-
quired, the prevalence was calculated with the available raw data. Because the reported 
number of patients with a PID was mainly low, the proportion of patients with a PID 
and skin disorders was descriptively presented. Proportions of skin disorders in PIDs were 
compared with the prevalence of skin disorders in the general population.21-26 Data from 
the general population were based on a birth cohort in Finland (n=1932, age 45-47 years) 
and a Dermatology outpatient clinic in Turkey (n=11 040, age 1-99 years).21,22 In addition, 
a nationwide study of Furue et al.23 reported the prevalence of cutaneous disorders in 
67 448 Japanese patients of all ages. In the study of Verhoeven et al.24, the skin disease 
prevalence per 1000 patient-years in family practices in the Netherlands was converted to 
a point prevalence in the general population (n=501, age 18-97 years). Finally, two studies 
from the United States of America and the United Kingdom performed in 1978 and 1976 
showed the prevalence of skin disorders in community studies in respectively 20749 (age 
1-74 years) and 614 (age 15-74 years) patients.25,26
results
Study characteristics
The literature search identified 15 871 studies. Removal of duplicates resulted in 12 834 
studies. Screening on title and abstract yielded 86 full-text articles of which 36 articles 
remained after full-text screening. Finally, after cross-reference check, a total of 67 articles 
(5030 patients) were included for further analysis (Figure 1). Skin disorders in patients with 
PIDs were described in 67 articles, and three articles reported PIDs as part of the differential 
diagnosis of a specific skin disorder. Fifty-seven studies showed a mean percentage of 
males of 62.2%. Both children and adults were included with a mean age of 15.8 years, 
reported in 26 articles. The IHE Quality Appraisal Checklist for Case Series Studies ranged 
from 18.2% to 88.5% (Table S1).
Skin disorders and their prevalence in primary immunodeficiency diseases
Thirty individual PIDs and their related skin manifestations were found. We categorized 
the skin disorders in 15 main groups and in 20 more specific subgroups (Table 1). The skin 
disorders per PID were mainly reported in single studies. Therefore, meta-analysis was not 
possible. The presence of skin telangiectasia, café au lait macules and hypopigmented 
macules in ataxia-telangiectasia (AT), skin abscesses in HIES, atopic dermatitis in hypogam-
maglobulinemia, atopic dermatitis, alopecia (areata), vitiligo and psoriasis in selective IgA 
deficiency (SIgAD), alopecia, vitiligo and nail dystrophy in autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy (APECED) and abscesses and granuloma in CGD were 
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confirmed in at least three articles. All reported skin disorders per PID were used to provide 
an overview of PIDs per skin disorder group (Figure 2).
Staphylococcus aureus-associated skin disorders in primary 
immunodeficiency diseases
Skin disorders associated with S. aureus in PIDs were reported in six articles (Table S1). 
In HIES unspecified, 4/7 patients with a papulopustular eruption had a positive S. aureus 
culture.36 S. aureus was also found positive in patients with AD-HIES and a papulopustular 
rash (2/5), eczematous dermatitis (20/20), cold abscesses (20/20) or wounds (3/4).39,41 
Renner et al.44 described that skin abscesses were frequently due to S. aureus infections in 
autosomal recessive HIES (AR-HIES). In Comèl-Netherton syndrome 8/9 described patients 
showed recurrent or persistent S. aureus skin infections once skin lesions had developed.49 
Lastly, S. aureus was isolated in 1/4 patients with CGD and suppurative dermatitis.80
Figure 1. Flow chart of search strategy and study selection
31






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Primary immunodeficiency diseases associated with atopy
The prevalence of at least two atopic symptoms (i.e. eczema, food allergy, asthma and/
or rhinoconjunctivitis) in PIDs was described in 17 articles (Table S1). Cohen et al.30 found 
no atopy in patients with AT. In HIES unspecified, AD-HIES and AR-HIES, all of the atopic 
symptoms, if reported, were present in about half of the patients.35,39-43 Renner et al.49 de-
scribed the presence of atopy in most Comèl-Netherton patients. The number of patients 
with eczema, food allergy, asthma, and rhinoconjunctivitis were presented in two studies 
with hypogammaglobulinemia patients.52,53 Eight studies reported the prevalence of atopy 
in a total of 398 patients with SIgAD, in which 11.6% (46/398) patients had eczema, 3.4% 
(9/263) had food allergy, 37.1% (43/116) had asthma, and 20.0% (55/275) had rhinocon-
junctivitis.52,58-60,62 In IgM-deficient patients, eczema, asthma, and rhinoconjunctivitis were 
prevalent symptoms.52 Immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome (IPEX) patients were mainly positive for eczema.70 Eight of 48 CGD patients 
had eczema and one out of 18 had rhinoconjunctivitis.78 Finally, Aderibigbe et al.86 have 
shown that one to three out of eight patients with Phospholipase C Gamma 2 (PLCG2) 
gene associated antibody deficiency and immune dysregulation (PLAID) had eczema, food 
allergy, asthma, and/or rhinoconjunctivitis.
dIscussIon
This review demonstrates that skin disorders are common symptoms in both children and 
adult patients with PIDs based on data from 67 systematically selected studies. Only a few 
PIDs related to S. aureus-associated skin disorders or atopy were reported in mainly single 
studies.
This is the first review using a systematic approach without limitations on skin disorders 
or PIDs. Therefore, we managed to obtain a complete spectrum of skin disorders in PIDs. 
A recent study of Ettinger et al.92 that focused on PIDs and the respective gene defects 
included an overview of PIDs per skin disorder in a nonsystematic approach. Although 
some PIDs are characterized by skin disorders, such as telangiectasia in AT and granuloma 
in CGD, the novelty of this review is showing an overview of all skin disorders in PIDs 
including skin disorders of which an association with a PID was not yet known.
Furthermore, we succeeded in composing an overview of PIDs per skin disorder that could 
serve as a valuable support tool for PID awareness in clinical practice and for registries. In 
the Netherlands, the diagnostic delay in PIDs (i.e. time period between the date of onset of 
first symptoms and the date of diagnosis) ranges from 0 to 14.5 years and is dominated by 
the defects in innate immunity (14.5 years), HIES (10.5 years) and hypogammaglobulinemia 
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(10.0 years).93 Moin et al.6 and Berron-Ruiz et al.7 reported that in, respectively, 31.8% and 
78.9% of the PIDs the cutaneous alterations preceded and were the basis for the clinical 
immunological diagnosis. Increased attention for these cutaneous manifestations as signal 
function of PIDs in combination with presence of the current warning signs for the suspi-
cion of PIDs might improve earlier diagnosis of PIDs. These warning signs include (a) four 
or more new ear infections within 1 year; (b) two or more serious sinus infections within 1 
year; (c) two or more months on antibiotics with little effect; (d) two or more pneumonias 
within 1 year; (e) failure of an infant to gain weight or grow normally; (f) recurrent, deep 
skin or organ abscesses; (g) persistent thrush in mouth or fungal infection on skin; (h) 
need for intravenous antibiotics to clear infections; (i) two or more deep-seated infections 
including septicemia; and (j) a family history of PID.94 In addition, narrowing the number of 
eligible PIDs through clustering of skin disorders could further reduce the diagnostic delay 
in PIDs. Using the multi-stage diagnostic protocol of de Vries4 or the phenotypic approach 
for PID classification and diagnosis by Bousfiha et al.95, the diagnosis of suspected PIDs 
or PID-classes based on clinical symptoms could be confirmed with laboratory tests. For 
example, a first diagnostic step in case of a supposed antibody deficiency or neutropenia 
could be blood count and differentiation, IgG, IgA, IgM and IgE. In case of a possible 
combined immunodeficiency disease, these tests should be supplemented by lymphocyte 
subpopulations.
Our review has some limitations. First of all, exclusion of case reports describing fewer than 
five cases in our analysis might have resulted in loss of information about skin disorders in 
rare PIDs. However, the quality of case reports is highly variable, potential publication bias 
plays a role, and thus, exclusion of these case reports might have improved the reliability 
of this review. Furthermore, through the addition of selected PIDs and skin disorders to 
our electronic search we could have caused a selection bias. Although we used a cross-
reference check, we cannot exclude that we might have missed some articles. Thirdly, 
demonstrating that specific skin disorders are characteristic for PIDs was not possible. We 
could only compare the presence of a number of skin disorders in patients with a PID with 
the prevalence of skin disorders in the general population based on six studies varying in 
publication year and age of the studied population.21-26 However, most of these skin dis-
orders were more prevalent in patients with a PID compared with the general population. 
Lastly, the reliability of the description of skin disorders might be questioned since in only 
27 of the 67 included articles the department of Dermatology was involved. Probably, the 
described skin disorders were not all diagnosed by a dermatologist, but by an immunolo-
gist or pediatrician. Moreover, the majority of studies did not use skin biopsy to confirm the 
diagnosis of the cutaneous manifestations histopathologically. In severe combined immu-
nodeficiency (SCID) patients, it was shown by Denianke et al.96 that clinically comparable 
skin lesions could demonstrate different histopathological images, possibly due an altered 
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immune system. Subsequently, the reported clinical diagnosis of skin disorders reported in 
articles included in this review might not correlate with the corresponding histopathologi-
cal diagnosis as well.
Because most PIDs are rare, reliable prevalence of skin disorders in PIDs can only be ob-
tained by reporting skin disorders on an international basis. The international PID database 
of The European Society for Immunodeficiencies (ESID) registers, among others, data on 
warning signs of PIDs. These warning signs give only attention to infectious skin disorders. 
Noninfectious cutaneous symptoms are not included. Based on data of this review we 
suggest to start to collect more detailed data on all skin disorders in the ESID registry.
Future research is needed to validate these data and support an association between 
specific cutaneous symptoms and PIDs. Given the low number of articles reporting S. 
aureus-associated skin disorders and atopy in PIDs, more data have to be collected to 
further improve earlier recognition of PIDs. In addition, data on S. aureus-associated skin 
disorders might provide new treatment options for skin disorders, such as targeted therapy 
directed against S. aureus.
Conclusion
This review with a systematic approach shows that skin disorders are a prominent feature 
in PIDs. Earlier diagnosis of PIDs can be facilitated by recognition of specific skin conditions 
as signal function of PIDs in combination with the current warnings signs for PIDs or by rec-
ognizing PID specific clusters of skin conditions. We provide a support tool to use in clinical 
practice that should raise awareness of PIDs based on the presenting skin manifestations. 
Limited data are available on S. aureus-associated skin disorders and atopy in PIDs.
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Figure S1. Skin disorders in patients wit a primary immondeficiency disease
 
a. Exfoliative erythroderma in Omenn syndrome b. Dermatitis in Comèl Netherton syndrome
 
c. Exfoliative erythroderma in Comèl Netherton syndrome d. Urticaria in common variable immunodeficiency
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e. Alopecia in immunodysregulation polyendocrinop-
athy enteropathy X-linked syndrome
f. Onychodystrophy in immunodysregulation polyen-
docrinopathy enteropathy X-linked syndrome
g. Discoid lupus erythematosus in chronic granuloma-
tous disease
h. Thrush in chronic mucocutaneous candidiasis
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Appendix 1. Selected terms of primary immunodeficiency disease and skin 
disorder used for the electronic search
Primary immunodeficiency disease Skin disorder
Agammaglobulinemia Abscess
Autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy
Albinism
Ataxia-telangiectasia Basal cell carcinoma
Chediak-Higashi syndrome Café-au-lait
Chronic granulomatous disease Candidiasis
Chronic mucocutaneous candidiasis Carcinoma
Common variable immunodeficiency Decubitus
DiGeorge syndrome Depigmentation disorder
Griscelli syndrome Dermatitis
Hermansky-Pudlak syndrome Ecthyma
Hyper IgE syndrome Eczema
Hyper IgM syndrome Erythroderma
Hypogammaglobulinemia Granuloma
Idiopathic CD4+ lymphocytopenia Hyperkeratosis
IgA deficiency Hyperpigmentation
IgM deficiency Hypopigmentation
Interleukin-1 receptor-associated kinase-4 deficiency Infection
Immunodysregulation polyendocrinopathy enteropathy 
X-linked syndrome
Lupus erythematosus
Leukocyte adhesion defect Lymphoma
Comèl-Netherton syndrome Melanoma
PLCG2 associated antibody deficiency and immune 
dysregulation
Panniculitis
Severe combined immunodeficiency Pigment disorder
Transporter-associated-with-antigen deficiency Pyoderma
Warts, hypogammaglobulinemia, immunodeficiency and 
myelokathexis syndrome
Small vessel vasculitis






Systematic review on skin disorders in primary immunodeficiency diseases




·	 Original observational and experimental human studies which assess the presence of 
skin disorders in patients with a primary immunodeficiency disease.
·	 Original observational and experimental human studies which report a differential 
diagnosis of a specific skin disorder that includes a primary immunodeficiency disease.
Exclusion criteria
·	 Case reports (<5 patients per primary immunodeficiency disease), conference abstracts, 
letters, editorials and review articles.
·	 Studies reporting only a genetic mutation (suggestive for a primary immunodeficiency 
disease) instead of a primary immunodeficiency disease as clinical diagnosis.
·	 Studies reporting skin disorders in primary immunodeficiency diseases that developed 
after and/or during treatment or intervention.
·	 Studies in which the description of skin disorders in primary immunodeficiency diseases 
was not part of the results section.
Participants
Inclusion criteria
·	 Patients of all ages with a primary immunodeficiency disease according to Picard et al. 
both in hospital setting and the general population.16
Exclusion criteria




·	 Primary: An overview of the presence of skin disorders described in patients with a PID, 
in order to compose a differential diagnosis of primary immunodeficiency diseases per 
skin disorder.
·	 Secondary: The prevalence of skin disorders in primary immunodeficiency diseases, S. 
aureus associated skin disorders in primary immunodeficiency diseases and primary im-
munodeficiency diseases associated with an atopic constitution (i.e. atopic dermatitis, 
food allergy, asthma, rhinoconjunctivitis).
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Appendix 3. Quality assessment score
Institute of Health Economics (IHE) Quality Appraisal Checklist for Case Series Studies
Stars indicate the points allocated if the item criterion is met.20 A maximum score of 13 can be allocated in 
each article.
Criteria that are not applicable are excluded.
Study objective
1. Was the hypothesis/aim/objective of the study clearly stated?
Yes: The hypothesis/aim/objective of the study was clearly reported (includes patients, intervention and 
outcome). «
Partial: Only one or two components (patients, intervention, or outcome) were included. «
No: The hypothesis/aim/objective was not reported.
Study design
2. Was the study conducted prospectively?
Yes: It was clearly stated that the study was conducted prospectively. «
Unclear: Unclear or no information was provided.
No: The study clearly stated it was a retrospective study.
3. Were the cases collected in more than one centre?
Yes: Cases were collected in more than one centre (multicentre study). «
Unclear: Unclear where the patients came from.
No: Cases were collected from one centre.
4. Were patients recruited consecutively?
Yes: There was a clear statement or it was clear from the context that the patients were recruited 
consecutively; or the study stated that all eligible patients were recruited. «
Unclear: No information was provided about the method used to recruit patients in the study.
No: The study clearly stated that patients were not recruited consecutively; or the patients were recruited 
based on other criteria such as access to intervention determined by the distance or availability of resources.
Study population
5. Were the characteristics of the patients included in the study described?
Yes: All of the most relevant characteristics of the patients were reported (for example, number, age, gender, 
ethnicity, severity of disease/condition, comorbidity, or etiology). «
Partial: Some, but not all, of the most relevant characteristics were reported. ½«
No: Only the number of patients was reported.
Note: Assessor(s) should decide which aspects are important before using the checklist.
6. Were the eligibility criteria (i.e. inclusion and exclusion criteria) for entry into the study clearly 
stated?
Yes: Both inclusion and exclusion criteria were reported. «
Partial: Either the inclusion or exclusion criteria were reported. ½«
No: Neither inclusion nor exclusion criteria were reported.
Note: Assessor(s) should decide which aspects are important before using the checklist.
7.
Did patients enter the study at a similar point in the disease?
Yes: It was clear from the baseline data presented in the study (for example, tables of patients’ characterises) 
that the majority (at least 80%) of patients entered the study at a similar point in terms of the duration and 
severity of the disease/condition and the presence of co-morbidities/complications. «
Unclear: There was no baseline information on patients’ characteristics to make a judgment.
No: There was a wide range in the severity of the disease/condition and co-morbidities/complications in 
patients at baseline.
Note: Assessor(s) should decide which aspects are important before using the checklist. It might be useful to 
discuss with specialists to determine the most important aspects that should be considered.
Outcome measures
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10. Were relevant outcome measures established a priori?
Yes: All relevant outcome measures were stated in the introduction or methods section. «
Partial: Some, but not all, of the relevant outcome measures were stated in the introduction or method 
section. ½«
No: None of the relevant outcome measures were stated in the introduction or method section.
12. Were the relevant outcomes measured using appropriate objective/subjective methods?
Yes: All relevant outcomes were measured with appropriate methods. These measures can be objective 
(for example, gold standard tests or standardized clinical tests), subjective (for example, self-administered 
questionnaires, standardized forms, or patient symptoms interview forms), or both. «
Partial: Some, but not all, relevant outcomes were measured with appropriate methods. ½«
No: The methods used to measure the relevant outcomes were inappropriate.
Note: Assessor(s) should decide which methods are appropriate before using the checklist.
Results and conclusions
15. Was follow-up long enough for important events and outcomes to occur?
Yes: It was clear from the information provided that the follow-up period was long enough for the majority 
(at least 80%) of patients, to allow for important events and outcomes (for example, changes in clinical 
status, adverse events) to occur. «
Unclear: The length of follow-up was not clearly reported.
No: It is clear from the information provided that the follow-up period was not long enough to allow for 
important events and outcomes to occur.
Note: Assessor(s) should define the appropriate duration of follow-up for each outcome of interest (for 
example, short-term and long-term adverse events).
16. Were losses to follow-up reported?
Yes: The number or proportion of patients lost to follow-up was clearly reported; the authors reported 
outcome results on all patients initially included; or the number lost to follow-up can be subtracted from the 
number of patients enrolled and the number of patients included in the final analysis. «
Unclear: There was a discrepancy between the number or proportion of patients reported in tables, figures, 
and text.
No: The number or proportion of patients lost to follow-up was not reported.
19. Were the conclusions of the study supported by the results?
Yes: The conclusions of the study were supported by the evidence presented in the results and discussion 
sections. «
Unclear: Unclear conclusion statement that makes it difficult to link the presented evidence to conclusions.
No: The conclusions were not supported by the evidence presented in the results and discussion sections.
Competing interests and sources of support
20. Were both competing interests and sources of support for the study reported?
Yes: Both competing interests and sources of support (financial or other) received for the study were 
reported; or the absence of any competing interest and source of support was acknowledged. «
Partial: Either the competing interest or source of support was reported. ½«
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The atopic syndrome consists of heterogeneous manifestations, in which multiple associ-
ated genetic loci have recently been identified. It is hypothesized that immune dysregula-
tion plays a role in the pathogenesis. In primary immunodeficiency diseases (PIDs), which 
are often monogenic immunodysregulation disorders, the atopic syndrome is a frequently 
occurring comorbidity. Based on the genetic defects in PIDs, novel gene/pathway-targeted 
therapies have been evaluated, which could be relevant in the atopic syndrome as well.
Objective
We aimed to define subclasses within the atopic syndrome based on the expression profiles 
of immune cell lineages of healthy mice.
Methods
Overlap between known atopy-related genes as described in the Human Gene Muta-
tion Database and disease-causing genes of monogenic PIDs was evaluated. Clusters of 
atopy-related genes were based on the overlap in their co-expressed genes using the 
gene expression profiles of immune cell lineages of healthy mice from the Immunological 
Genome Project. We analyzed pathways involved in the atopic syndrome using Ingenuity 
Pathway Analysis.
Results
Twenty-two (5.3%) genes were overlapping between the atopy-related genes (n=160) and 
PID-related genes (n=278). We identified seven distinct clusters of atopy-related genes. 
Functional pathway analysis of all atopy-related genes showed relevance of T helper cell-
mediated pathways.
Conclusion
This study shows a model to define clusters within the atopic syndrome based on gene 
expression profiles of immune cell lineages. Our results support the hypothesis that both 
genetic mechanisms and immune dysregulation play a role in the pathogenesis. It also 
opens up the possibility for novel therapeutic targets and a more tailored approach to-
wards personalized medicine.
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IntroductIon
Atopy is the genetic predilection to produce specific immunoglobulin (Ig) E following 
exposure to allergens. This predisposition results in the development of atopic dermati-
tis (AD), food allergy (FA), asthma, and allergic rhinitis (AR): the atopic syndrome.1 The 
worldwide prevalence of these manifestations in children varies between 15-20%, 1-10%, 
3-29%, and 9-15%, respectively, and in adults from 1-3%, 3-4%, 2-12%, and 7-42%, 
respectively.2-6 Atopic manifestations share a common mechanism involving allergen-
specific IgE, which triggers the release of inflammatory mediators, like histamine, in the 
skin, gastrointestinal tract, lungs and nose. The course of these manifestations over time 
is characterized by the atopic march, generally starting with AD in infancy and followed 
by FA, asthma, and AR later in childhood.7 However, it is known that the atopic march 
not always follows the classic sequence and may occur at any age.8,9 Furthermore, not 
all atopic patients will develop the complete spectrum of atopic manifestations.7 Despite 
its heterogeneous presentation, patients with atopic manifestations are mostly uniformly 
treated with topical or systemic immunosuppressive agents and/or antihistamines resulting 
in varying therapeutic responses as well.10-13
Subgroups of the atopic phenotype, termed endotypes, are possibly responsible for the 
differences in disease manifestations and treatment responses. These endotypes are the 
result of variations in physiologic, biologic, immunologic and/or genetic mechanisms.14 
Various genetic loci associated with both inflammation and multiple atopic manifestations 
have been identified in recent years based on Genome-Wide Association Studies (GWAS), 
showing common genetic mechanisms involved in the atopic syndrome.15-24 Nevertheless, 
the genetics of the atopic syndrome remain complicated for different reasons. For example, 
gene polymorphisms in different genes might cause the atopic syndrome independent of 
each other, and bearing a predisposing gene polymorphism does not necessarily result in 
development of the atopic syndrome.24 The genetic complexity in the atopic syndrome 
possibly results in its heterogeneous clinical phenotype. Defining the endotypic profile of 
atopic patients in more detail contributes to determination of more homogeneous sub-
classes of patients. Subclasses are currently defined based on clinical and immunological 
characteristics, like the type of immune response involved.25 However, stratification of 
atopic patients based on their genetic defect or polymorphism linked to their expression 
profile of immune cell lineages has not yet been investigated. This endotyping approach 
could be of interest as immune dysregulation may play an important role in the pathogen-
esis of the atopic syndrome. Interestingly, the atopic syndrome is a prevalent comorbidity in 
primary immunodeficiency diseases (PIDs), for example in hyper IgE syndrome (HIES), Comèl 
Netherton syndrome, and immunodysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome, which suggests that the atopic syndrome could be caused by a genetic 
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defect in pathways that are also involved in these monogenic PIDs.26,27 This is supported 
by the hypothesis of autoallergy, in which atopy seems to stand at the boundary between 
allergy and auto-immunity, given the presence of IgE antibodies against self-proteins.28-30
Several gene-targeted and/or pathway-targeted treatment strategies for PIDs have recently 
been under clinical evaluation, which could be of clinical benefit in atopy as well. Identi-
fication of genetic pathways for these targeted and personalized treatment modalities is 
therefore essential.
We hypothesized that subclasses within the atopic syndrome exist based on genes that act 
in the same molecular pathway. Additionally, genetic defects in pathways that cause a PID 
might also be involved in the atopic syndrome.
Therefore, the aim of this study was to define subclasses within the atopic syndrome via 
molecular clustering of atopy-related genes based on their expression profiles of immune 
cell lineages. We first evaluated the overlap between atopy-related genes and monogenic 
PID genes. Secondly, we clustered the atopy-related genes based on their expression profile 
of immune cell lineages of healthy mice. Finally, we analyzed the pathways in which the 
atopy-related genes are involved.
materIals and methods
Data collection and content – overlap atopy/primary immunodeficiency 
disease genes
We obtained a complete list of all mutated genes responsible for atopic manifestations 
by performing a comprehensive search in the Human Gene Mutation Database (HGMD, 
HGMD® Professional, https://portal.biobase-international.com) up to August 21th 2018.31 
Genes were searched using the phenotype terms “atopy”, “increased IgE”, “atopic der-
matitis”, “eczema”, “food allergy”, “allergy”, “asthma”, and “allergic rhinitis” (Table S1). 
Atopy-related genes and the number of mutations per gene were extracted. Additionally, 
disease-causing genes of monogenic PIDs were obtained from the phenotypic classifica-
tion for PIDs of the International Union of Immunological Societies (IUIS).32 We performed 
a cross-check on atopy-related mutations in PID genes using HGMD. Overlapping genes 
between both the HGMD and PID lists were identified to select atopy-related with a defect 
in the same gene as a PID.
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Clustering and visualization of atopy-related genes
The atopy-related genes were clustered to identify more homogeneous subclasses of the 
atopic syndrome. Clusters were made based on their gene expression profiles of immune 
cell lineages. Therefore, gene expression data from the Immunological Genome Project (Im-
mGen, http://www.immgen.org) was downloaded from the Genome Expression Omnibus 
(GEO) database accession number GSE15907 and GSE37448. The ImmGen datasets com-
prise the gene expression of a large amount of immune cell lineages (both hematopoietic and 
mesenchymal), that were grouped into 12 cell-populations. Currently, there is limited data on 
the gene expression signatures of human immune cell types. Therefore, immune cell lineages 
of healthy mice were used, which might give insights in atopic processes also applicable in 
human. All atopy-related genes selected via the HGMD query were searched in the ImmGen 
dataset. The top 40 co-expressed genes in mice were extracted per atopy-related gene. These 
genes are of biological interest as co-expressed genes are controlled by the same transcrip-
tional regulatory program, functionally related, or members of the same pathway or protein 
complex as our atopy-related genes of interest.33 We overlaid the co-expressed genes to 
identify genes that occurred in the top 40 lists of multiple atopy-related genes. Based on the 
overlap in co-expressed genes, indicating the degree of similar expression of atopy-related 
genes, the atopy-related genes were clustered in an unsupervised manner. Accordingly, it is 
likely that the clustered atopy-related genes act in the same molecular pathway. The clusters 
were visualized by constructing a correlation network plot using the “qgraph” package in 
RStudio version 3.4.1.34 The lines between the genes were weighted and only correlations 
with a minimum correlation coefficient of 0.65, indicating a strong (positive) relationship, 
were visualized. If the top 40 list of an atopy-related gene did not contain a single overlap-
ping gene, this atopy-related gene was labeled as an unclustered “bin” gene.
To visualize the gene expression profiles of the clusters, a heat map of the gene expression 
per cell lineage was constructed. Therefore, gene expression data were imported into Om-
niviz software version 6.1.13.0. Using Omniviz, the geometric mean of each probeset was 
calculated and transcriptomic data was log2 transformed to normalize the data. Changes 
in gene expression were constituted by deviations from the geometric mean to visualize 
whether genes of immune cell lineages were higher or lower expressed. These deviations 
are visualized in a heat map by a gradient from red (high expression) to blue (low expres-
sion) and ordered per cluster.
Functional pathway analysis
We validated whether the extracted genes from HGMD were atopy-related through 
analysis of the pathways containing these atopy-related genes. As the separate clusters 
included small numbers of genes, all clustered atopy-related genes from HGMD with and 
without unclustered “bin” genes were analyzed using Ingenuity Pathway Analysis (IPA, 
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Qiagen©) software.35 The most important pathways, in which the atopy-related genes were 
involved, were extracted from IPA. The pathways were ranked according to their p-value 
(-log transformed) and the ratio of the atopy-related genes found in each pathway over the 
total number of molecules in that pathway, indicating the signifi cance of the association 
between the atopy-related genes and the identifi ed pathways. A p-value was calculated 
using a Fisher’s Exact test to determine the probability of the association between the 
atopy-related genes and the pathways is explained by a random chance alone. A –log 




The search in HGMD on atopic manifestations retrieved 159 atopy-related genes known 
in human (Table S1). Based on the overview of the IUIS, 278 disease-causing genes of 
monogenic PIDs were obtained.36 During the cross-check on atopy-related mutations in 
PID genes, TRAF3IP2 was identifi ed in which mutations were described that might result 
in an eczema phenotype. This gene did not appear in the search results of HGMD and was 
therefore added to the list of atopy-related genes, resulting in a total of 160 genes for 
further analysis. The top three genes with the highest number of atopy-related mutations 
included STAT3 (n=107), FLG (n=62) and DOCK8 (n=45). Other genes had six or less atopy-
related mutations per gene (Table S1). Twenty-two (5.3%) genes of the atopy (n=160) and 
PID (n=278) lists were overlapping, including ARPC1B, BTK, CASP8, CFTR, CTLA4, DOCK8, 
ICOS, IL10, IL12B, IL12RB1, IL17F, IL21, IL21R, IL7R, ITK, ORAI1, PGM3, SPINK5, STAT3, 
TNFRSF13B, TRAF3IP2 and TYK2 (Figure 1 and Table S1).
Figure 1. Venn diagram il-
lustrating the overlap of the 
primary immunodefi ciency 
disease-related genes and 
the atopy-related genes 
identifi ed in the Human 
Gene Mutation Database
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Clustering of genes
Fifteen (9.4%) of the 160 atopy-related genes were not expressed in the mouse immune 
system, of which immune cell lineages were used in the ImmGen dataset, and were there-
fore excluded from further analysis. As some genes had multiple transcripts and appeared 
more than once in the gene expression dataset, the complete list for clustering resulted 
in 153 probes. Eleven clusters were identified, of which seven clusters included five or 
more genes (clusters A, C, D, F, H, J and K), and 37 non-correlated genes remained as 
“bin” (Figure 2 and 3, Table S1). Based on the gene expression profiles, we identified one 
pair of anti-correlated clusters (clusters D and F), i.e. opposite expression profiles between 
clusters D and F (Figure 3). The 22 overlapping genes between the atopy-related genes 
and monogenic PID genes were localized in two of the seven atopy-related gene clusters, 
including cluster F (n=8) and cluster D (n=3) (Table S1).
Figure 2. Genetic correlation network plot of atopy-related genes
The line width between the atopy-related genes indicate the overlay in the top 40 co-expressed gene lists per 
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Functional pathway analysis
Functional pathway analysis in IPA of the atopy-related genes both with and without tak-
ing unclustered “bin” genes into account resulted in T helper (Th) lymphocyte-mediated 
pathways. Taking all atopy-related genes (n=160) into account, it resulted in the specific 
pathways “T helper lymphocyte differentiation”, “Th1 and Th2 activation pathway”, and 
“Th2 pathway”, in which respectively 22, 28, and 24 atopy-related genes were involved 
(Table S2a). Additionally, pathway analysis of the clustered atopy-related genes only 
(n=108) resulted in the specific pathways “Th1 and Th2 activation pathway” (n=22 genes), 
“T-helper lymphocyte differentiation” (n=16 genes), and “Th2 pathway” (n=19 genes) 
(Table S2b).
dIscussIon
This is the first study that describes clusters in the clinically heterogeneous phenotype 
of the atopic syndrome based on gene expression profiles of immune cell lineages of 
healthy mice. The overlap between atopy-related genes (n=160) and monogenic PID genes 
(n=278) was limited to 22 (5.3%) genes. We identified seven distinct clusters within the 
atopic syndrome based on the expression profiles of atopy-related genes. Functional path-
way analysis of all known atopy-related genes resulted in identification of Th lymphocyte-
mediated processes underlying the atopic syndrome.
The atopic syndrome is a prevalent comorbidity in a number of PIDs, suggesting that the 
atopic syndrome can be a symptom of PIDs and that immune dysregulation plays a role in 
the pathogenesis. Interestingly, the number of overlapping genes in this study was limited 
(5.3%) and did not belong to one PID category according to the IUIS phenotypic classifica-
tion or immunologic component.32 Nonetheless, the overlapping genes were bundled in 
just two of the seven atopy-related gene clusters (cluster D and F), which suggests that 
these endotypes of the atopic syndrome are associated with the predisposition to develop 
a PID. However, atopy-related mutations in these genes might differ from the disease-
causing mutations of the PIDs.
Current literature reports nine PIDs to be possibly related to the atopic syndrome, including 
autosomal dominant HIES (AD-HIES; STAT3), autosomal recessive HIES (AR-HIES; DOCK8), 
Comèl Netherton syndrome (SPINK5), hypogammaglobulinemia, selective IgA deficiency 
(SIgAD), IgM deficiency, IPEX (FOXP3), chronic granulomatous disease (CGD; CYBA, CYBB, 
NCF1, NCF2 and NCF4), and phospholipase C gamma 2 (PLCG2) gene associated antibody 
deficiency and immune dysregulation (PLAID; PLCG2), and 28 additional genetic PID condi-
tions.27,37 Only eight genes (STAT3, DOCK8, SPINK5, FLG, ARPC1B, PGM3, ERBIN, and 
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TYK2) were extracted from HGMD using the atopy phenotype search. Furthermore, only 
two of the 22 overlapping atopy-related and PID-related genes identified in this study were 
reported in literature to be involved in PIDs and the atopic syndrome.27 The discrepancy 
between literature and HGMD could firstly be explained by the recent expansion of novel 
mutations derived from next generation sequencing (NGS). Secondly, the atopic manifesta-
tions in PIDs, as described in literature, might be an occasional finding and not related to 
the disease causing genes of PIDs. Thirdly, the heterogeneous course and presentation 
of the atopic syndrome may make it difficult to associate genetic mutations with atopic 
manifestations. Moreover, the infectious symptoms in PIDs might be a more prominent 
clinical feature than the atopic manifestations, which therefore could have resulted in a 
registration bias.
We found a low number of mutations in most atopy-related genes in human (six or less 
mutations in 157 of the 160 genes), suggesting that other phenomena contribute to the 
disease such as post-translational modifications. Alternatively, various genes that interact 
with environmental factors might be involved in the atopic syndrome, in which each gene 
contributes only to a small amount of the overall disease risk.38 Furthermore, the differ-
ences between the clusters could indicate that immune regulation plays a role in the atopic 
syndrome next to underlying genetic mechanisms.
Strikingly, two of the identified clusters (D and F) have a completely opposite expression 
profile, both in lymphoid and myeloid cell lineages. An explanation for this phenomenon 
may be that both clusters share the same upstream regulator. Depending on a gain or loss 
of function mutation in this enhancer, the gene expression profile can be influenced by an 
agonist or antagonist of this regulator. By performing a functional pathway analysis of the 
atopy-related genes in only clusters D and F, we would explore the functional significance of 
these clusters. The analysis resulted in the pathways “T helper cell differentiation”, “TREM1 
signaling” and “Th1 and Th2 activation pathway”, which is completely corresponding with 
the pathways involved in all atopy-related genes (data not shown). Therefore, we could 
unfortunately not differentiate between the functional significance of all atopy-related 
genes and those included in clusters D and F.
The identified Th lymphocyte-mediated pathway supports the hypothesis that changes in 
the immune system underlie and could be involved in the pathogenesis of atopy. In AD it 
has been previously described that acute skin lesions are characterized by Th2 lymphocyte 
infiltration with a shift towards predominantly Th1 lymphocytes in the chronic phase.39-41 
In addition, asthma was reported as a Th2 lymphocyte -mediated diseases driven by al-
lergen exposure.42 Moreover, patients with FA and AR are characterized by allergen-specific 
Th2 lymphocyte-mediated responses showing that the obtained Th lymphocyte-pathways 
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involved in atopy are in agreement with these of the individual atopic diseases.43-45 In most 
of our identified clusters (except clusters F, G, H, I and J) the atopy-related genes do not 
show increased expression in T lymphocytes (Figure 3). Therefore, genes in these clusters 
might be expressed in immunologic cells that co-interact with T lymphocytes, including Th 
lymphocytes, or in cells that are progenitors of Th lymphocytes.
This study has some limitations. Firstly, as we could not include terms concerning the skin 
barrier in the search, we might have missed gene expression profiles of barrier cells. How-
ever, by using the terms “atopic dermatitis” and “eczema” we have identified important 
barrier genes, like COL6A5, FLG (subtypes), FLG2, and KLK7. Secondly, some discrepancies 
were found in the HGMD database. The genes from the atopic phenotype search did not 
completely overlap with the results from the search on atopy-related mutations per gene. 
Therefore, we identified atopic phenotypes per gene on the results of both searches. Thirdly, 
we clustered genes based on their expression profiles in the ImmGen dataset, which uses 
characterized immune cells of mice. The gene expression profiles of immune cell lineages in 
healthy mice may not be identical to these in (atopic) humans. This explained why we could 
not cluster all human atopy-related genes including FLG, which is an important atopy gene 
based on the number of atopy-related mutations (n=62). Furthermore, the data from mice 
cannot directly be applied for subgrouping of the atopic syndrome in humans. Therefore, 
large cohorts of patients with the atopic phenotype should be sequenced using NGS to in-
vestigate whether atopy clusters could be generated based on the gene expression profiles 
of immune cell lineages of atopic human. Identification of clusters of atopy-related genes 
by NGS potentially opens novel ways to select eligible patients for pharmaceutical studies 
and could predict therapeutic responses.
conclusIon
This study shows a model, using data of healthy mice, to define clusters of the atopic 
syndrome based on gene expression profiles of immune cell lineages. We identified seven 
distinct clusters within the atopic syndrome in which Th lymphocyte-mediated pathways 
were most often involved. This supports the hypothesis that both genetic mechanisms and 
immune dysregulation have a role in the pathogenesis of the atopic syndrome. Our results 
also opens up the possibility for identification of novel therapeutic targets towards a more 
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suPPlementary materIal
Table S1. Atopy-related genes from the Human Gene Mutation Database







ADCYAP1R1 Adenylate Cyclase Activating Polypeptide 1 Receptor 
Type I
Asthma NA A
CCL11 C-C Motif Chemokine Ligand 11 Asthma NA A
COL6A5 Collagen Type VI Alpha 5 Chain Dermatitis 4 A
CTNNA3 Catenin Alpha 3 Food allergy 2 A
FRMD6 FERM Domain Containing 6 Asthma 1 A
KCNMB1 Potassium Calcium-Activated Channel Subfamily M 
Regulatory Beta Subunit 1
Asthma 1 A
LRRC32 Leucine Rich Repeat Containing 32 Dermatitis 6 A
MYLK Myosin Light Chain Kinase Asthma 1 A
NGFR Nerve Growth Factor Receptor Asthma NA A
SELP Selectin P Atopy 1 A
SERPINA1 Serpin Family A Member 1 Asthma 1 A
SERPINE1 Serpin Family E Member 1 Asthma NA A
ST5 Suppression Of Tumorigenicity 5 Asthma 1 A
TWIST1 Twist Family BHLH Transcription Factor 1 IgE NA A
PARP1 Poly(ADP-Ribose) Polymerase 1 Asthma NA B
TUFM Tu Translation Elongation Factor, Mitochondrial Asthma 1 B
FCER1A Fc Fragment Of IgE Receptor Ia Dermatitis 1 C
HRH4 Histamine Receptor H4 Dermatitis NA C
IL1RL1 Interleukin 1 Receptor Like 1 Dermatitis 2 C
IL4 Interleukin 4 IgE
Asthma
3 C










SLC6A12 Solute Carrier Family 6 Member 12 Asthma 1 C
ADRB2 Adrenoceptor Beta 2 Dermatitis
Asthma
2 D
ALOX5 Arachidonate 5-Lipoxygenase Asthma 1 D
ARPC1B† Actin Related Protein 2/3 Complex Subunit 1B Allergy 1 D
BTK† Bruton Tyrosine Kinase Asthma 1 D
CD14 Cluster of Differentiation 14 Molecule Asthma
Rhinitis
NA D
CD86 Cluster of Differentiation 86 Molecule Asthma 1 D
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Table S1. Atopy-related genes from the Human Gene Mutation Database (continued)







CSF1R Colony Stimulating Factor 1 Receptor Asthma 1 D
CYSLTR1 Cysteinyl Leukotriene Receptor 1 Atopy
Asthma
2 D
FCGR2B Fc Fragment Of IgE Receptor IIb Atopy NA D
HLX H2.0 Like Homeobox Asthma 2 D
HNMT Histamine N-Methyltransferase Dermatitis
Asthma
NA D
IL6R Interleukin 6 Receptor Dermatitis NA D
IL18 Interleukin 18 Asthma 1 D
INPP4A Inositol Polyphosphate-4-Phosphatase Type I A Asthma 1 D
IRAK3 Interleukin 1 Receptor Associated Kinase 3 Asthma 2 D
IRF2 Interferon Regulatory Factor 2 Dermatitis 1 D
MMP9 Matrix Metallopeptidase 9 Asthma
Allergy
2 D
MMP12 Matrix Metallopeptidase 12 Asthma NA D
NLRP3 NLR Family Pyrin Domain Containing 3 Food allergy 2 D











ORAI1† Calcium Release-Activated Calcium Modulator 1 Dermatitis 1 D
PLA2G4A Phospholipase A2 Group IVA Asthma 2 D
PLA2G7 Phospholipase A2 Group VII Atopy
Asthma
2 D
PTGER2 Prostaglandin E Receptor 2 Asthma 1 D




TLR2 Toll Like Receptor 2 Dermatitis
Asthma
1 D
TLR6 Toll Like Receptor 6 Asthma 1 D
TLR9 Toll Like Receptor 9 Dermatitis
Asthma
1 D
CCL2 C-C Motif Chemokine Ligand 2 Asthma NA E
CCL7 C-C Motif Chemokine Ligand 7 Asthma 1 E
CTLA4† Cytotoxic T-Lymphocyte Associated Protein 4 Asthma 1 F
EPHX1 Epoxide Hydrolase 1 Asthma NA F
ICOS† Inducible T Cell Costimulator Allergy 1 F
IL2 Interleukin 2 Allergy 2 F
IL7R† Interleukin 7 Receptor Dermatitis NA F
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Table S1. Atopy-related genes from the Human Gene Mutation Database (continued)







IL12RB1† Interleukin 12 Receptor Subunit Beta 1 Dermatitis 1 F
IL17RB Interleukin 17 Receptor B Asthma 1 F
IL21† Interleukin 21 Asthma 1 F
IL21R† Interleukin 21 Receptor IgE 1 F
ITK† Interleukin 2 Inducible T Cell Kinase Asthma 1 F
LTA Lymphotoxin Alpha Asthma 1 F
PDCD4 Programmed Cell Death 4 Asthma 1 F
PECAM1 Platelet And Endothelial Cell Adhesion Molecule 1 Asthma NA F
PPARGC1B Peroxisome Proliferator-Activated Receptor Gamma 
Coactivator 1 Beta
Asthma 2 F
S1PR1 Sphingosine-1-Phosphate Receptor 1 Asthma 2 F




TRAF3IP2† TNF Receptor-Associated Factor 3 Interacting Protein 
2
Dermatitis 2 F
ZPBP2 Zona Pellucida Binding Protein 2 Asthma 2 F
CAT Catalase Asthma 1 G
SMPD1 Sphingomyelin Phosphodiesterase 1 Allergy 1 G
CD53 Cluster of Differentiation 53 Molecule Asthma 1 H
DOCK8† Dedicator Of Cytokinesis 8 IgE 45 H
STK10 Serine/Threonine Kinase 10 Asthma 1 H
TGFB1 Transforming Growth Factor Beta 1 Asthma NA H
TYK2† Tyrosine Kinase 2 IgE 1 H
GSTP1 Glutathione S-Transferase Pi 1 Dermatitis
Asthma
NA I
PGM3† Phosphoglucomutase 3 Atopy
IgE
6 I
CCL5 C-C Motif Chemokine Ligand 5 Dermatitis
Asthma
1 J
CYSLTR2 Cysteinyl Leukotriene Receptor 2 Atopy 1 J
IFNG Interferon Gamma Atopy NA J
IL12RB2 Interleukin 12 Receptor Subunit Beta 2 Atopy 3 J
TBX21 T-Box 21 Asthma 1 J
BDNF Brain Derived Neurotrophic Factor Asthma NA K
CCL26 C-C Motif Chemokine Ligand 26 Asthma 1 K
CDHR3 Cadherin Related Family Member 3 Asthma 1 K
CFTR† Cystic Fibrosis Transmembrane Conductance 
Regulator
Asthma 6 K





Table S1. Atopy-related genes from the Human Gene Mutation Database (continued)







CHIT1 Chitinase 1 Asthma NA K
DBH Dopamine Beta-Hydroxylase Asthma NA K
FLG2 Filaggrin Family Member 2 Dermatitis 1 K
GC GC, Vitamin D Binding Protein Asthma NA K
GSDMA Gasdermin A Asthma 1 K
GSTO2 Glutathione S-Transferase Omega 2 Asthma NA K
IL9 Interleukin 9 Dermatitis 1 K
IL31 Interleukin 31 Dermatitis 1 K
KLK7 Kallikrein Related Peptidase 7 Dermatitis 1 K
NOS1 Nitric Oxide Synthase 1 Asthma 1 K
NOS2 Nitric Oxide Synthase 2 Atopy NA K
PTGDR Prostaglandin D2 Receptor Asthma
Allergy
4 K
PTGDR2 Prostaglandin D2 Receptor 2 Asthma 2 K
SCGB1A1 Secretoglobin Family 1A Member 1 Asthma 1 K
SPINK5† Serine Peptidase Inhibitor, Kazal Type 5 Atopy
Asthma
3 K
TCHHL1 Trichohyalin Like 1 Dermatitis 1 K
TMEM79 Transmembrane Protein 79 Dermatitis 1 K
TRPV1 Transient Receptor Potential Cation Channel 
Subfamily V Member 1
Asthma 1 K
ADAM33 ADAM Metallopeptidase Domain 33 Asthma NA bin
ATG5 Autophagy Related 5 Asthma 2 bin
CASP8† Caspase 8 Asthma NA bin
CD38 Cluster of Differentiation 38 Molecule Asthma 1 bin
CEP68 Centrosomal Protein 68 Asthma 1 bin
CSF2 Colony Stimulating Factor 2 Dermatitis 1 bin
CSTA Cystatin A Dermatitis 1 bin
DEFB1 Defensin Beta 1 Dermatitis NA bin
F2RL1 F2R Like Trypsin Receptor 1 Atopy 1 bin
GRASP General Receptor For Phosphoinositides 1 Associated 
Scaffold Protein
Asthma 1 bin
GSTM1 Glutathione S-Transferase Mu 1 Dermatitis
Asthma
NA bin
HAVCR1 Hepatitis A Virus Cellular Receptor 1 Asthma 3 bin
HMGB1 High Mobility Group Box 1 Dermatitis 3 bin




IL10† Interleukin 10 Asthma NA bin
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Table S1. Atopy-related genes from the Human Gene Mutation Database (continued)







IL12B† Interleukin 12B Dermatitis
Asthma
2 bin
IL17F† Interleukin 17F Asthma 1 bin
KAT6A Lysine Acetyltransferase 6A Food allergy 1 bin
LPL Lipoprotein Lipase Dermatitis NA bin
LTC4S Leukotriene C4 Synthase Asthma
Allergy
2 bin
MAP3K1 Mitogen-Activated Protein Kinase 1 Asthma 1 bin
NAT2 N-Acetyltransferase 2 Asthma 2 bin
NFKBIA Nuclear Factor Kappa B Inhibitor Alpha Asthma 1 bin
NR3C1 Nuclear Receptor Subfamily 3 Group C Member 1 Asthma NA bin
ORMDL3 Orosomucoid Like 3 Asthma 3 bin
PAG1 Phosphoprotein Membrane Anchor With 
Glycosphingolipid Microdomains 1
Allergy 1 bin
PHF11 PHD Finger Protein 11 Dermatitis
Asthma
2 bin
PTGS2 Prostaglandin-Endoperoxide Synthase 2 Atopy
Asthma
NA bin
RBFOX1 RNA Binding Fox-1 Homolog 1 Food allergy 2 bin
SART1 U4/U6.U5 Tri-SnRNP-Associated Protein 1 Atopy 1 bin
SCGB3A2 Secretoglobin Family 3A Member 2 Asthma 1 bin
STAT3† Signal Transducer And Activator Of Transcription 3 IgE 107 bin
TLR1 Toll Like Receptor 1 Asthma NA bin
TNF Tumor Necrosis Factor Asthma NA bin
TNFRSF13B† Tumor Necrosis Factor Receptor Superfamily Member 
13B
Asthma NA bin
TSLP Thymic Stromal Lymphopoietin Asthma 1 bin
ACE Angiotensin I Converting Enzyme Asthma NA NA
CCL3L1 C-C Motif Chemokine Ligand 3 Like 1 Asthma NA NA
CHI3L1 Chitinase 3 Like 1 Asthma 1 NA
CYP2C19 Cytochrome P450 Family 2 Subfamily C Member 19 Asthma NA NA
CYP2J2 Cytochrome P450 Family 2 Subfamily J Member 2 Asthma NA NA
ERBIN Erb-B2 Interacting Protein IgE 1 NA







FLG10.2 Fillagrin Alternative Isoform, Repeat 10.2 Dermatitis NA NA





Table S1. Atopy-related genes from the Human Gene Mutation Database (continued)







GSDMB Gasdermin B Asthma 4 NA
LCE3C Late Cornified Envelope 3C Dermatitis NA NA
MUC7 Mucin 7, Secreted Asthma 1 NA
TLR10 Toll Like Receptor 10 Asthma
Rhinitis
1 NA
VSTM1 V-Set And Transmembrane Domain Containing 1 Dermatitis 1 NA
ACE Angiotensin I Converting Enzyme Asthma NA NA
CCL3L1 C-C Motif Chemokine Ligand 3 Like 1 Asthma NA NA
CHI3L1 Chitinase 3 Like 1 Asthma 1 NA
CYP2C19 Cytochrome P450 Family 2 Subfamily C Member 19 Asthma NA NA
CYP2J2 Cytochrome P450 Family 2 Subfamily J Member 2 Asthma NA NA
ERBIN Erb-B2 Interacting Protein IgE 1 NA







FLG10.2 Fillagrin Alternative Isoform, Repeat 10.2 Dermatitis NA NA
FLG11 Fillagrin Alternative Isoform, Repeat 11 Dermatitis
Asthma
1 NA
GSDMB Gasdermin B Asthma 4 NA
LCE3C Late Cornified Envelope 3C Dermatitis NA NA
MUC7 Mucin 7, Secreted Asthma 1 NA
TLR10 Toll Like Receptor 10 Asthma
Rhinitis
1 NA
VSTM1 V-Set And Transmembrane Domain Containing 1 Dermatitis 1 NA
Abbreviations: NA, not available. 1Genes were not available for clustering because they could not be identified 
in the mouse immune system of ImmGen. †Overlapping genes between atopy-related gene list and PID-related 
gene list (n=22).
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T Helper Cell Differentiation 2,95E01 3,01E-01 IL21, STAT6, IFNG, IL4R, IL12RB1, IL10, IL21R, 
IL6R, IL12RB2, STAT3, TBX21, IL13, IL18, IL2, 
TGFB1, IL12B, NGFR, ICOS, CD86, IL17F, TNF, 
IL4
Th1 and Th2 Activation Pathway 2,84E01 1,51E-01 IL1RL1, IL12RB1, IL31, TBX21, IL2, TGFB1, IL9, 
IL4, STAT6, IFNG, PTGDR2, IL4R, IL10, HAVCR1, 
IL6R, TYK2, IL12RB2, STAT3, TLR9, IL13, TSLP, 
IL18, IL17RB, IL12B, LTA, ICOS, S1PR1, CD86
Th2 Pathway 2,49E01 1,6E-01 STAT6, IFNG, IL4R, PTGDR2, IL12RB1, IL10, 
HAVCR1, IL1RL1, TYK2, IL12RB2, IL31, TLR9, 
IL13, TBX21, TSLP, IL17RB, IL2, TGFB1, IL12B, 
ICOS, IL9, S1PR1, CD86, IL4
1The –log (p-value) indicates the probability of the association of atopy-related genes with the pathway by ran-
dom chance alone. 2The ratio is calculated by the number of atopy-related genes in a given pathway that have 
a –log (p-value) equal to or greater than 1.3 (default cutoff value), divided by the total number of atopy-related 
genes that make up that pathway.
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Th1 and Th2 Activation Pathway 2,37E01 1,19E-01 STAT6, IFNG, PTGDR2, IL12RB1, IL1RL1, TYK2, 
IL6R, IL12RB2, IL31, TBX21, IL13, TLR9, IL18, 
IL17RB, IL2, TGFB1, LTA, ICOS, IL9, S1PR1, 
CD86, IL4
T Helper Cell Differentiation 2,18E01 2,19E-01 IL21, IFNG, STAT6, IL12RB1, IL21R, IL6R, 
IL12RB2, TBX21, IL13, IL18, IL2, TGFB1, NGFR, 
ICOS, CD86, IL4
Th2 Pathway 2,1E01 1,27E-01 STAT6, IFNG, PTGDR2, IL12RB1, IL1RL1, TYK2, 
IL12RB2, IL31, TBX21, IL13, TLR9, IL17RB, IL2, 
TGFB1, ICOS, IL9, S1PR1, CD86, IL4
1The –log (p-value) indicates the probability of the association of atopy-related genes with the pathway by ran-
dom chance alone. 2The ratio is calculated by the number of atopy-related genes in a given pathway that have 
a –log (p-value) equal to or greater than 1.3 (default cutoff value), divided by the total number of atopy-related 
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antigens in patients with atopic 











Staphylococcus (S.) aureus plays a role in the pathogenesis of atopic dermatitis (AD), pos-
sibly via the expression of various virulence antigens. An altered antibody response towards 
these antigens might contribute to inflammation.
Objective
We aimed to provide an overview of the varying prevalence and odds of antibody responses 
against S. aureus antigens in patients with AD.
Methods
Data were systematically obtained from EMBASE, MEDLINE, Web of Science, Scopus, 
Cochrane, PubMed, and Google Scholar up to 12 February 2016. We selected all original 
observational and experimental studies assessing antistaphylococcal antibodies in serum 
of patients with AD. Prevalence and odds ratios (ORs) of immunoglobulin (Ig) E, IgG, IgM, 
and IgA against S. aureus in patients with AD vs. healthy controls were pooled using the 
random-effects model. We calculated I2 statistics to assess heterogeneity and rated study 
quality using the Newcastle-Ottawa Scale.
Results
Twenty-six articles (2369 patients) were included, of which 10 were controlled studies. 
Study quality was fair to poor. Patients with AD had a higher prevalence of IgE against 
staphylococcal enterotoxin (SE)A (OR 8.37, 95% confidence interval 2.93–23.92) and SEB 
(OR 9.34, 95% confidence interval 3.54–24.93) compared with controls. Prevalence of 
antistaphylococcal IgE was 33% for SEA, 35% for SEB and 16% for toxic shock syndrome 
toxin-1. However, study heterogeneity and imprecision should be taken into consideration 
when interpreting the results. Data on IgG, IgM, and IgA, as well as other antigens, are 
limited.
Conclusion
Patients with AD more often show an IgE antibody response directed against S. aureus 
superantigens compared with healthy controls, supporting a role for S. aureus in AD 
pathogenesis.
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IntroductIon
Atopic dermatitis (AD) is a multifactorial disorder that arises from interactions between 
immune dysregulations, genetic predisposition, skin barrier defects and environmental fac-
tors.1,2 Both the lesional and nonlesional skin and the nose of patients with AD are more 
likely to be colonized with Staphylococcus (S.) aureus compared with healthy controls.3 
Recent studies have shown that abundance of S. aureus is associated with AD severity, 
suggesting a causal role for S. aureus in the pathogenesis of AD.2,4-9 However, the exact 
mechanisms by which S. aureus aggravates inflammation in AD are not fully understood.10
S. aureus expresses a variety of virulence factors that could contribute to AD inflamma-
tion. Based on their biological function, these antigens can be divided in four groups: 
(i) Microbial Surface Components Recognizing Adhesive Matrix Molecules (MSCRAMMs) 
such as Clumping factor A (ClfA), which helps S. aureus adhere to the host cells; (ii) cell-
membrane damaging molecules such as alpha toxin, which can induce keratinocyte cell 
death; (iii) household enzymes such as lipase, which provides cell nutrition; and (iv) immune 
modulating proteins (superantigenic and nonsuperantigenic).10-13 The latter include the 
group of staphylococcal superantigens, which have the ability to activate mast cells and T 
lymphocytes directly, resulting in the release of proinflammatory cytokines.5,14-16 Expression 
of these S. aureus antigens varies between the different S. aureus isolates. However, it has 
been proven difficult to identify associations between the genetic composition of S. aureus 
strains and AD.17-22
Evaluation of the antibody response to these S. aureus antigens gives an indication of the 
antigens that are expressed by the bacterium in vivo and will give insight into how the 
immune system of patients with AD counteracts these antigens. This might help us to 
understand the role of S. aureus in AD pathogenesis, as well as the mechanisms by which 
S. aureus causes inflammation. Since 1982, several studies have reported serum antibodies 
against S. aureus in patients with AD.23-35 However, the prevalence of antistaphylococcal 
antibodies in these studies vary widely. This is probably due to low sample sizes and differ-
ent methods used to detect antibodies (e.g. enzyme-linked immunosorbent assay (ELISA) 
or AlaSTAT). Moreover, studies often focus on few antigens and/or antibody classes.
The aim of this systematic review was to provide an overview of the pooled prevalence and 
odds of antibodies (immunoglobulin (Ig) E, IgG, IgM, and IgA) against S. aureus antigens in 
serum of patients with AD compared with healthy controls. Additionally, we reviewed the 




Study participants and outcomes
All original observational and experimental human studies were included. No restrictions 
were made on publication date or language. Case reports were excluded.
Patients of all ages with AD, irrespective of disease severity, and in which anti-S. aureus 
antibodies were measured were included. Healthy controls were defined as persons who 
had neither AD nor an atopic constitution (food allergy, asthma, allergic rhinitis) nor an-
other skin disease.
The primary outcome was the proportion of patients with AD with antibodies (IgE, IgG, 
IgM, and IgA) in serum against S. aureus antigens compared with healthy controls. The 
secondary out-come was the relationship between AD severity and antistaphylococcal 
antibodies.
Search strategy
The systematically electronic search was conducted in EMBASE, MEDLINE, Web of Science, 
Scopus, Cochrane, PubMed, and Google Scholar up to 12 February 2016. A cross-reference 
check was performed to identify other relevant studies.
Study selection and data extraction
Initially, all studies identified in the systematic search were screened for relevance by title 
and abstract. Duplicates and studies that did not meet our inclusion criteria were excluded 
(Appendix 1). The remaining articles were assessed for eligibility by full-text review. Transla-
tion of non-English studies was conducted officially. Study selection and data extraction 
were performed independently by two researchers (FvB and either JT or JdW). Disagree-
ments were resolved and consensus was reached. If one population was described in 
different articles, we included the study with the most detailed description of the results.
The methodological quality of the articles was scored based on an adapted version of the 
Newcastle-Ottawa Scale (NOS).3 Studies could reach a maximum score of nine points for 
case-control studies and five points for uncontrolled studies. Using a scoring algorithm, 
the controlled studies were classified as being of poor, fair or good methodological quality, 
based on their NOS scores (Appendix 2).36 The overall quality of evidence was discussed 
according to the principles of the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) approach (i.e. limitations in study design or execution, inconsis-
tency of results, indirectness of evidence, imprecision, publication bias).37
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Statistical analysis
A meta-analysis was performed using a random-effects model in case of at least two 
available studies. We extracted the prevalence of antistaphylococcal antibodies in patients 
with AD and controls from the included studies. If required, we calculated the prevalence 
with the available raw data. The prevalence of antistaphylococcal antibodies were pooled. 
Furthermore, in controlled studies the prevalence in patients and controls were compared, 
expressed as ORs with a 95% confidence interval (CI). The antibody prevalence was 
descriptively presented for single studies. When the antibody prevalence in the control 
group was 0%, an OR could not be calculated and a continuity correction factor using the 
Mantel-Haenszel method was added to both the patient and control group (based on the 
unbalanced group ratio).38,39
Heterogeneity was assessed using the Higgins I2 test.40,41 However, I2-values should be 
interpreted cautiously in small meta-analyses.42 In case of substantial (I2 50-90%) or con-
siderable (I2 75-100%) heterogeneity, sources were explored using subgroup analyses for 
the variables age, method of antibody identification and geographical region of the study 
centres (≥10 available studies). Possible publication bias was assessed in case of ≥10 studies 
using funnel plots and Egger’s test (p-value <0.05).43,44 Analyses were performed using 
Comprehensive Meta-Analysis version 2.2 (Biostat, Englewood, NJ, U.S.A.). This systematic 
review was conducted and reported according to the Meta-analysis Of Observational Stud-
ies in Epidemiology (MOOSE) guidelines.45
results
Study characteristics and quality
The literature search identified 2789 studies. After removal of duplicates, 1,323 studies 
remained. Screening on title and abstract yielded 113 full-text articles. Finally, 26 articles 
with a total of 2369 patients were included for further analysis (Figure 1).24,25,27-35,46-60 
Twenty-one articles reported the sex of the patients, with a mean percentage of male 
participants of 53.4% (range 28.1-81.8).25,28-30,33-35,46-49,51-60 The mean age was 24.1 years 
(range 4.4-68.9), reported in 15 articles.25,28-30,33,34,46-49,51,53-55,58 Thirteen articles scored the 
AD severity using the Scoring Atopic Dermatitis (SCORAD), with three articles reporting a 
mean of 33.6 (range 32.2-36.0), corresponding to moderate AD.30,32-35,46,47,49-52,57,59,61 Nine 
articles used other scoring criteria for the AD severity.25,28,29,31,48,54-56,58 Most studies were 
conducted in Europe and Asia.
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Methods for identification of antistaphylococcal antibodies consist mainly of radioim-
munoassay (RIA) tests, ELISA, and AlaSTAT, an enzyme immunoassay method for the 
measurement of allergen-specific IgE (Table S1). One study measuring multiple antibodies 
used both a RIA test for IgE and an ELISA for IgG.31 NOS scores of the 11 controlled studies 
were rated as good (n=1), fair (n=5) or poor (n=5).24,25,27-33,36,53,60 The main reason for 
downgrading the quality of these studies was incomparability of the patient and control 
groups. The quality scores of the 15 studies without a control group varied between two 
and four points out of five (Table S1 and Appendix 2).34,35,46-52,54-59
Prevalence of antibodies against Staphylococcus aureus
IgE
Twenty-four studies including 2206 patients reported the prevalence of antistaphylococcal 
IgE. 24,25,27-31,33-35,46-59 These studies predominantly determine the antibody response against 
staphylococcal enterotoxin (SE) A, SEB, SEC, SED, and toxic shock syndrome toxin (TSST)-
1 (19, 23, seven, three and 10 studies, respectively) (Table S2).24,25,27-31,34,35,46-59 Pooled 
prevalence of antistaphylococcal IgE in patients was 33% for SEA (95% CI 23-45; I2 94.23
)24,25,27-30,34,35,46-48,50,51,53,54,56-59, 35% for SEB (95% CI 27-43; I2 91.36)24,25,27-31,34,35,46-59, 14% 
Figure 1. Flow chart of search strategy and study selection
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for SEC (95% CI 8-22; I2 78.26)24,34,46,47,52,56,58, 5% for SED (95% CI 1-16; I2 70.49)24,34,47 
and 16% for TSST-1 (95% CI 10-25; I2 85.28)24,27,34,35,46-48,52,56,58 (Table 1). There was a 
great variation in prevalence between studies (0.8-78.8% for SEA, 1.4-72.9% for SEB, 
5.4-40.0% for SEC, 0.0-10.7% for SED and 1.4-53.3% for TSST-1), probably resulting in 
the substantial to considerable heterogeneity. One study showed a prevalence of 35.8% 
of fibronectin-binding protein (FBP)-specific IgE, another study found a prevalence of 
48.1% of IgE against lipoteichoic acid (LTA).27,33 Undetectable to very low prevalences of 
IgE against the staphylococcal antigens SEE, SEI, SEH, SEK, SEJ, exfoliative toxin (ET)-1 and 
ETA were found in several single studies (Table 2).24,31,47
IgG, IgM and IgA
Prevalence of IgG against S. aureus antigens was determined in four studies.31,32,55,60 The 
pooled prevalence of IgG against SEB, reported in two studies (114 patients), was 64% 
(95% CI 42-81; I2 78.84).55,60 Besides, in single studies the IgG prevalence was 77.0% 
for SEA, 77.0% for TSST-1, and 34.6% for ETA.31,60 IgG subclass 2 (IgG2) was found in 
87.0% of the patients with AD against SEB and in 61.5% against SEC1.32 Only one study 
determined antistaphylococcal IgM, and detect antibodies against SEB in 62.5% of the 
patients with AD (Table 2).55 None of the selected articles studied antistaphylococcal IgA.
Odds of antibodies against Staphylococcus aureus
Of the 26 articles, 11 studies compared patients with AD to healthy controls (759 patients 
vs. 328 controls).24,25,27-33,53,60 Nine studies reported the prevalence of antistaphylococcal 
IgE (596 patients vs. 189 controls).24,25,27-31,33,53 These studies mainly described antibody re-
sponses against SEA and SEB (seven and eight articles, respectively).24,25,27-31,53 Pooled analy-
ses showed that antistaphylococcal IgE was found significantly more often in the serum of 
patients compared with controls, with ORs of 8.37 for SEA (95% CI 2.93-23.92; p<0.001; I2 
0.00)24,25,27-30,53 and 9.34 for SEB (95% CI 3.54-24.93; p<0.001; I2 0.00)24,25,27-31,53 (Table 3). 
The pooled OR of IgE against TSST-1, reported in two studies (83 patients vs. 20 controls), 
was 23.33 (95% CI 0.47-1153.93, p=0.114, I2 0.00) (Table 3).24,27 Prevalences of other 
antigens, including SEC, SED, ETA, ET-1, FBP, and LTA, were described in single controlled 
studies and pooled estimates could not be provided.24,27,31,33 The prevalence of all these S. 
aureus antigens were equal or increased in patients vs. controls (Table 4). As most antibody 
prevalences in control groups were 0%, the ORs could not be calculated. Prevalences of 
IgG in patients and controls were compared in three studies.31,32,60 Compared with controls, 
patients were found to have higher IgG prevalences to ETA and SEB and lower prevalences 
of IgG to SEA and TSST-1.31,60 In patients, the IgG2 prevalence to SEC1 was lower and to 
SEB higher than in controls.32 However, most differences in prevalence between patients 
and controls were small. No studies compared the antistaphylococcal IgM or IgA responses 
between patients and controls.
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Table 1. IgE against staphylococcal enterotoxin (SE) A, B, C and D; and toxic shock syndrome toxin (TSST)-1 in 













All studies 19 1852 0.33 (0.23-0.45) 94.23
Studies including age <18 6 507 0.31 (0.11-0.63) 96.56
Studies including age ≥18 7 859 0.27 (0.17-0.42) 88.22
Studies including RIA methods* 8 1139 0.19 (0.12-0.29) 86.36
Studies including ELISA method 3 169 0.61 (0.34-0.82) 86.83
Studies including AlaSTAT method 6 461 0.42 (0.28-0.57) 89.04
Studies including Immunoblot method 1 27 0.48 (0.30-0.66) -
Studies performed in Europe 11 1220 0.24 (0.16-0.34) 87.87
Studies performed in Asia 7 576 0.51 (0.33-0.70) 93.75
Studies performed in USA 1 56 0.32 (0.21-0.45) -
SEB
All studies 23 2111 0.35 (0.27-0.43) 91.36
Studies including age <18 8 631 0.25 (0.13-0.43) 92.73
Studies including age ≥18 8 968 0.38 (0.29-0.48) 84.70
Studies including RIA methods* 11 1418 0.25 (0.18-0.34) 86.77
Studies including ELISA method 4 209 0.47 (0.24-0.72) 89.39
Studies including AlaSTAT method 6 461 0.48 (0.33-0.64) 90.42
Studies including Immunoblot method 1 27 0.63 (0.44-0.79) -
Studies performed in Europe 12 1304 0.28 (0.21-0.36) 84.70
Studies performed in Asia 10 751 0.48 (0.36-0.61) 90.06
Studies performed in USA 1 56 0.18 (0.10-0.30) -
SEC
All studies 7 540 0.14 (0.08-0.22) 78.26
SED
All studies 3 317 0.05 (0.01-0.16) 70.49
TSST-1
All studies 10 1110 0.16 (0.10-0.25) 85.28
Studies including age <18 5 631 0.13 (0.05-0.28) 85.00
Studies including age ≥18 3 1039 0.12 (0.05-0.27) 84.65
Studies including RIA methods* 6 918 0.12 (0.05-0.25) 90.38
Studies including ELISA method 2 109 0.18 (0.11-0.26) 0.00
Studies including Immunoblot method 1 27 0.41 (0.24-0.60) -
Studies performed in Europe 7 945 0.15 (0.07-0.28) 90.09
Studies performed in Asia 2 109 0.18 (0.11-0.26) 0.00
Studies performed in USA 1 56 0.21 (0.13-0.34) -
Abbreviations: SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin; RIA, radioimmunoassay; 
ELISA, enzyme-linked immunosorbent assay; CI, confidence interval. *CAP fluorescent enzyme immunoassay 
(FEIA), ImmunoCAP, and UniCAP.
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Subgroup analysis
Subgroup analyses of the variables age, method of antibody identification and geographi-
cal region of the study centres were performed to detect possible sources of heterogeneity. 
The prevalence of IgE against SEA, SEB, and TSST-1 did not differ significantly between 
children and adults (31% vs. 27%, 25% vs. 38%, and 13% vs. 12%, respectively). Studies 
using the ELISA method showed higher pooled prevalences of IgE against SEA, SEB, and 
TSST-1 compared with studies using RIA tests (61% vs. 19%, 47% vs. 25%, and 18% vs. 
12%, respectively). Lastly, studies conducted in Asia showed higher pooled prevalences 
of IgE to SEA, SEB, and TSST-1 than studies conducted in Europe (51% vs. 24%, 48% vs. 
28%, and 18% vs. 15%, respectively) (Table 1).














IgE SEE 1 140 0.01
SEI 1 140 0.01
SEH 1 140 0.00
SEK 1 140 0.00
SEJ 1 140 0.00
ETA 1 26 0.00
FBP 1 95 0.36
LTA 1 27 0.48
IgG SEA 1 74 0.77
SEB 2 114 0.64 (0.42-0.81) 78.84
TSST-1 1 74 0.77
ETA 1 26 0.35
IgG2 SEB 1 77 0.87
SEC1 1 78 0.62
IgM SEB 1 40 0.63
Abbreviations: Ig, immunoglobulin; SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, 
exfoliative toxin; FBP, fibronectin-binding protein; LTA, lipoteichoic acid; CI, confidence interval.
Table 3. IgE against staphylococcal enterotoxin (SE) A and SEB and toxic shock syndrome toxin (TSST)-1 in 









Pooled OR in patients 
vs controls (95% CI)
Heterogeneity 
(I2)
SEA 7 475 139 8.37 (2.93-23.92)* 0.00
SEB 8 501 172 9.34 (3.54-24.93)* 0.00
TSST-1 2 83 20 23.33 (0.47-1153.93) 0.00
Abbreviations: SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; OR, odds ratio; CI, confi-
dence interval. *Significant result.
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Relationship between atopic dermatitis severity and antibodies against 
Staphylococcus aureus
Considering the low number of studies reporting a mean SCORAD, we could not calculate 
an overall association between AD severity and antistaphylococcal antibodies. However, 
several individual studies reported a significant association between superantigen-specific 
(e.g. SEA, SEB) IgE and AD severity, measured by SCORAD, the criteria of Rajka or the 
modified Leicester system.29,32,55,58 This association could not be confirmed in four compa-
rable studies.25,28,46,58 Sohn et al.55 looked at IgG against SEB and did not find a relationship 
with AD severity. However, Mrabet-Dahbi et al.32 found that patients with a deficiency 
of antistaphylococcal IgG2 to SEC1 had a more severe AD phenotype. Based on these 
contradictory studies, no conclusions can be drawn about the association between the 
antistaphylococcal antibody response and severity of AD.
Publication bias
Funnel plots of the pooled prevalence of IgE against SEA, SEB, and TSST-1 showed no 
asymmetry. Egger’s tests had intercepts of 0.52 for SEA (95% CI -4.40-5.44, p=0.826), 
-0.44 for SEB (95% CI -3.78-2.91, p=0.789), and -0.82 for TSST-1 (95% CI -4.40-2.76, 
p=0.611) confirming no publication bias.























IgE SEC 1 56 15 0.05 0.0 -
SED 1 56 15 0.05 0.0 -
ETA 1 26 33 0.00 0.0 -
ET 1 56 15 0.02 0.0 -
FBP 1 95 17 0.36 0.0 -
IgG SEA 1 74 111 0.77 0.88 -
SEB 1 74 111 0.73 0.69 -
TSST-1 1 74 111 0.77 0.85 -
ETA 1 26 14 0.35 0.14 -
IgG2 SEB 1 77 27 0.87 0.78 -
SEC1 1 78 28 0.62 0.86 -
Abbreviations: Ig, immunoglobulin; SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, 
exfoliative toxin; FBP, fibronectin-binding protein.
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dIscussIon
This systematic review includes 26 studies and 2352 patients with AD. IgE responses 
against SEA and SEB in serum were found more often in patients with AD than in healthy 
controls. IgE, IgG, and IgM against a very limited panel of other antigens were reported 
in single studies. No data are available on antistaphylococcal IgA. Pooled prevalences of 
antistaphylococcal IgE in patients with AD are 33% for SEA, 35% for SEB, and 16% for 
TSST-1. Substantial to considerable heterogeneity and imprecision (small studies) limit the 
quality of evidence and should be taken into consideration when interpreting the results. 
Subgroup analyses were performed to account for differences in outcome measures (indi-
rectness). Quality of evidence was probably not influenced by publication bias.
Subgroup analyses suggest that the antibody prevalence is dependent on the method of 
antibody identification (ELISA vs. RIA) and the geographical region of the study centres 
(Asia vs. Europe). This is in accordance with the study of Taylor et al.62 that found ELISA 
more sensitive than RIA to detect IgG1 in mice. It might also explain the higher prevalence 
of antibodies in Asia than in Europe, as Asian studies use ELISA techniques more often. 
Furthermore, ethnicity-dependent antibody response has been suggested, at least for TSST-
1.63 Because heterogeneity in subgroup analyses remains high, pooled prevalences and 
odds were probably also influenced by other variables, such as AD severity. Unfortunately, 
we were not able to explore this as only a few studies reported a mean SCORAD. These 
individual studies showed contradictory results about the association between AD severity 
and IgE against predominantly superantigens.
The S. aureus antigens SEA and SEB belong to the group of immune modulators and 
act as superantigens. This indicates that they have the ability to stimulate T lymphocytes 
directly, resulting in T lymphocyte proliferation and cytokine release, causing epithelial 
damage.14-16 The increased anti-SEA and anti-SEB IgE responses could be the result of 
increased expression of these antigens by the S. aureus bacteria in patients with AD, 
indicating SEA and SEB as possible bacterial mechanisms to aggravate or even initiate 
inflammation in AD. However, the studies included in this systematic review predominantly 
examined the prevalence of antibodies against the superantigens SEA, SEB, and TSST-1, 
and other common antigens, such as ClfA and lipase, were not tested. In addition, SEA, 
SEB, and TSST-1 are present in only 14%, 24%, and 14%, respectively, of the S. aureus 
isolates.64 These data suggest a bias in the assessment of staphylococcal antigens and also 
indicate a large genetic diversity amongst the colonized S. aureus strains. Furthermore, 
the increased IgE responses against these antigens may be the result of immunological 
cross-reactivity, where the corresponding antigen-coding genes of SEA, SEB and/or TSST-1 
are not present in the isolate.65-67
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This is the first systematic review summarizing the available data on the prevalence of 
antistaphylococcal antibodies in patients with AD and the involved antigens. The broad 
selection criteria (e.g. all languages, only exclusion of case reports, and nonoriginal studies) 
resulted in collecting the majority of articles about this subject and limiting selection bias. 
However, there are still some limitations in this study. Firstly, most articles did not report 
the AD treatment at time of antibody measurement. The use of antimicrobial therapy 
might decrease the S. aureus load and S. aureus antibody titres.4 In addition, the anti-
inflammatory effect of systemic glucocorticosteroids could cause a decrease in serum an-
tibody concentrations and might also reduce S. aureus.6,68,69 Even emollient monotherapy 
showed a decrease of S. aureus on the skin.70,71 In the studies that did report the treatment 
at baseline, the therapies consist mainly of topical corticosteroids or no treatment at all 
(n=9). Secondly, cut-off values of antibody identification methods were highly variable, not 
mentioned or unclear in and between several methods. Through subgroup analysis, we 
tried to correct for this variability partly. Lastly, mainly antistaphylococcal IgE was assessed, 
of which the choice for determination was often unsubstantiated or based on results of 
previous studies. Patients with AD have frequently high IgE responses to environmental 
antigens, for example S. aureus. In addition, IgG is the most common antibody in the 
extravascular fluid and, among others, plays a role in the neutralization of toxins.72,73
To investigate further the role of (the immune response against) S. aureus in AD patho-
genesis, future studies should focus on other antibody subtypes and other S. aureus 
antigens. IgG subclasses should be measured to detect possible biomarkers for AD severity, 
such as a selective deficiency in IgG2 against SEC1 in the study of Mrabet-Dahbi et al.32 
Furthermore, assessment of the antibody response against other S. aureus antigens, like 
MSCRAMMs, membrane-damaging molecules, housekeeping antigens, and other types of 
immune modulating proteins, might give more insight whether an increased IgE response 
is a secondary phenomenon of increased S. aureus colonization of AD skin.
In conclusion, this systematic review with meta-analysis shows that patients with AD have 
higher prevalences of IgE against the S. aureus antigens SEA and SEB than healthy controls, 
taking the large heterogeneity into consideration. These antigens, belonging to the group 
of immune modulators, are known as superantigens and have the ability to cause inflam-
mation and epithelial damage. This supports a role for S. aureus in the pathogenesis of 
AD. IgE, IgG, and IgM against a very limited panel of other antigens were studied in single 
studies. No data are available on antistaphylococcal IgA.
151
Systematic review on anti-staphylococcal antibodies in atopic dermatitis
references
 1 Bieber T. Atopic dermatitis. N. Engl. J. Med. 2008; 358: 1483-94.
 2 Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting 
paradigms in treatment approaches. J. Allergy Clin. Immunol. 2014; 134: 769-79.
 3 Totte JE, van der Feltz WT, Hennekam M et al. Prevalence and odds of Staphylococcus aureus 
carriage in atopic dermatitis: a systematic review and meta-analysis. Br. J. Dermatol. 2016.
 4 Kong HH, Oh J, Deming C et al. Temporal shifts in the skin microbiome associated with disease 
flares and treatment in children with atopic dermatitis. Genome Res. 2012; 22: 850-9.
 5 Lebon A, Labout JA, Verbrugh HA et al. Role of Staphylococcus aureus nasal colonization in 
atopic dermatitis in infants: the Generation R Study. Arch. Pediatr. Adolesc. Med. 2009; 163: 
745-9.
 6 Brussow H. Turning the inside out: The microbiology of atopic dermatitis. Environ. Microbiol. 
2015.
 7 Kobayashi T, Glatz M, Horiuchi K et al. Dysbiosis and Staphylococcus aureus colonization drives 
inflammation in atopic dermatitis. Immunity 2015; 42: 756-66.
 8 Meylan P, Lang C, Mermoud S et al. Skin Colonization by Staphylococcus aureus Precedes the 
Clinical Diagnosis of Atopic Dermatitis in Infancy. J. Invest. Dermatol. 2017.
 9 Kennedy EA, Connolly J, Hourihane JO et al. Skin microbiome before development of atopic 
dermatitis: Early colonization with commensal staphylococci at 2 months is associated with a 
lower risk of atopic dermatitis at 1 year. J. Allergy Clin. Immunol. 2017; 139: 166-72.
 10 Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr. Allergy 
Asthma Rep. 2015; 15: 65.
 11 Novick RP. Autoinduction and signal transduction in the regulation of staphylococcal virulence. 
Mol. Microbiol. 2003; 48: 1429-49.
 12 Brauweiler AM, Goleva E, Leung DY. Th2 cytokines increase Staphylococcus aureus alpha 
toxin-induced keratinocyte death through the signal transducer and activator of transcription 
6 (STAT6). J. Invest. Dermatol. 2014; 134: 2114-21.
 13 Brauweiler AM, Bin L, Kim BE et al. Filaggrin-dependent secretion of sphingomyelinase protects 
against staphylococcal alpha-toxin-induced keratinocyte death. J. Allergy Clin. Immunol. 2013; 
131: 421-7 e1-2.
 14 Baker MD, Acharya KR. Superantigens: structure-function relationships. Int. J. Med. Microbiol. 
2004; 293: 529-37.
 15 Crossley KB, Jefferson KK, Archer GL et al. Staphylococci in human disease: Wiley-Blackwell. 
2009.
 16 Tomi NS, Kranke B, Aberer E. Staphylococcal toxins in patients with psoriasis, atopic dermatitis, 
and erythroderma, and in healthy control subjects. J. Am. Acad. Dermatol. 2005; 53: 67-72.
 17 Kim DW, Park JY, Park KD et al. Are there predominant strains and toxins of Staphylococcus 
aureus in atopic dermatitis patients? Genotypic characterization and toxin determination of S. 
aureus isolated in adolescent and adult patients with atopic dermatitis. J. Dermatol. 2009; 36: 
75-81.
 18 Yeung M, Balma-Mena A, Shear N et al. Identification of major clonal complexes and toxin 
producing strains among Staphylococcus aureus associated with atopic dermatitis. Microbes 
Infect 2011; 13: 189-97.
 19 Lomholt H, Andersen KE, Kilian M. Staphylococcus aureus clonal dynamics and virulence fac-
tors in children with atopic dermatitis. J. Invest. Dermatol. 2005; 125: 977-82.
Chapter 5
152
 20 Schlievert PM, Case LC, Strandberg KL et al. Superantigen profile of Staphylococcus aureus 
isolates from patients with steroid-resistant atopic dermatitis. Clin. Infect. Dis. 2008; 46: 1562-
7.
 21 Hepburn L, Hijnen DJ, Sellman BR et al. The complex biology and contribution of Staphylococ-
cus aureus in atopic dermatitis, current and future therapies. Br. J. Dermatol. 2016.
 22 Fleury OM, McAleer MA, Feuillie C et al. Clumping Factor B Promotes Adherence of Staphylo-
coccus aureus to Corneocytes in Atopic Dermatitis. Infect. Immun. 2017; 85.
 23 Henocq E, Hewitt B, Guerin B. Staphylococcal and human dander IgE antibodies in superin-
fected atopic dermatitis. Clin. Allergy 1982; 12: 113-20.
 24 Leung DY, Harbeck R, Bina P et al. Presence of IgE antibodies to staphylococcal exotoxins on 
the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J. Clin. 
Invest. 1993; 92: 1374-80.
 25 Tada J, Toi Y, Akiyama H et al. Presence of specific IgE antibodies to staphylococcal enterotoxins 
in patients with atopic dermatitis. Eur. J. Dermatol. 1996; 6(8): 552-4.
 26 Yamada H, Yudate T, Orita T et al. Serum levels of anti-Staphylococcus aureus-specific IgE in 
patients with atopic dermatitis. J. Clin. Lab. Immunol. 1996; 48: 167-75.
 27 Nissen D, Pedersen LJ, Skov PS et al. IgE-binding components of staphylococcal enterotoxins in 
patients with atopic dermatitis. Ann. Allergy. Asthma. Immunol. 1997; 79: 403-8.
 28 Morishita Y, Tada J, Sato A et al. Possible influences of Staphylococcus aureus on atopic 
dermatitis-the colonizing features and the effects of staphylococcal enterotoxins. Clin. Exp. 
Allergy 1999; 29: 1110-7.
 29 Lin YT, Shau WY, Wang LF et al. Comparison of serum specific IgE antibodies to staphylococcal 
enterotoxins between atopic children with and without atopic dermatitis. Allergy 2000; 55: 
641-6.
 30 Zollner TM, Wichelhaus TA, Hartung A et al. Colonization with superantigen-producing 
Staphylococcus aureus is associated with increased severity of atopic dermatitis. Clin. Exp. 
Allergy 2000; 30: 994-1000.
 31 Yagi S, Wakaki N, Ikeda N et al. Presence of staphylococcal exfoliative toxin A in sera of patients 
with atopic dermatitis. Clin. Exp. Allergy 2004; 34: 984-93.
 32 Mrabet-Dahbi S, Breuer K, Klotz M et al. Deficiency in immunoglobulin G2 antibodies against 
staphylococcal enterotoxin C1 defines a subgroup of patients with atopic dermatitis. Clin. Exp. 
Allergy 2005; 35: 274-81.
 33 Reginald K, Westritschnig K, Linhart B et al. Staphylococcus aureus fibronectin-binding protein 
specifically binds IgE from patients with atopic dermatitis and requires antigen presentation for 
cellular immune responses. J. Allergy Clin. Immunol. 2011; 128: 82-91 e8.
 34 Bozek A, Fisher A, Filipowska B et al. Clinical features and immunological markers of atopic 
dermatitis in elderly patients. Int. Arch. Allergy Immunol. 2012; 157: 372-8.
 35 Jinnestal CL, Belfrage E, Back O et al. Skin barrier impairment correlates with cutaneous 
Staphylococcus aureus colonization and sensitization to skin-associated microbial antigens in 
adult patients with atopic dermatitis. Int. J. Dermatol. 2014; 53: 27-33.
 36 McPheeters ML, Kripalani S, Peterson NB et al. Closing the quality gap: revisiting the state of 
the science (vol. 3: quality improvement interventions to address health disparities). Evid Rep 
Technol Assess (Full Rep) 2012: 1-475.
 37 Balshem H, Helfand M, Schunemann HJ et al. GRADE guidelines: 3. Rating the quality of 
evidence. J. Clin. Epidemiol. 2011; 64: 401-6.
153
Systematic review on anti-staphylococcal antibodies in atopic dermatitis
 38 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continu-
ity corrections in meta-analysis of sparse data. Stat. Med. 2004; 23: 1351-75.
 39 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of 
disease. J. Natl. Cancer Inst. 1959; 22: 719-48.
 40 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002; 21: 
1539-58.
 41 Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat. 
Med. 2004; 23: 1663-82.
 42 von Hippel PT. The heterogeneity statistic I2 can be biased in small meta-analyses. BMC Med. 
Res. Methodol. 2015: 35.
 43 Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphi-
cal test. BMJ 1997; 315: 629-34.
 44 Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-
analysis. Stat. Med. 2001; 20: 641-54.
 45 Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and meta-
analyses: the PRISMA statement. Int. J. Surg. 2010; 8: 336-41.
 46 Rojo A, Aguinaga A, Monecke S et al. Staphylococcus aureus genomic pattern and atopic 
dermatitis: may factors other than superantigens be involved? Eur. J. Clin. Microbiol. Infect. 
Dis. 2014; 33: 651-8.
 47 Ott H, Weissmantel S, Kennes LN et al. Molecular microarray analysis reveals allergenand 
exotoxin-specific IgE repertoires in children with atopic dermatitis. J. Eur. Acad. Dermatol. 
Venereol. 2014; 28: 100-7.
 48 Sonesson A, Bartosik J, Christiansen J et al. Sensitization to skin-associated microorganisms in 
adult patients with atopic dermatitis is of importance for disease severity. Acta Derm. Venereol. 
2013; 93: 340-5.
 49 Kou K, Aihara M, Matsunaga T et al. Association of serum interleukin-18 and other biomarkers 
with disease severity in adults with atopic dermatitis. Arch. Dermatol. Res. 2012; 304: 305-12.
 50 Golysheva E, Pampura A, Mokronosova M. Clinical relevance of IgE-antibodies to staphylo-
coccal enterotoxins and malassezia spp in patients with atopic dermatitis. Allergy 2012; 67: 
452-586.
 51 Langer K, Breuer K, Kapp A et al. Staphylococcus aureus-derived enterotoxins enhance house 
dust mite-induced patch test reactions in atopic dermatitis. Exp. Dermatol. 2007; 16: 124-9.
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Table S2. Studies reporting IgE antibodies against Staphylococcus aureus antigens in patients with atopic 
dermatitis















Abbreviations: SE, staphylococcal enterotoxin; TSST-1, toxic shock syndrome toxin 1; ET, exfoliative toxin; FBP, 
fibronectin-binding protein; LTA, lipoteichoic acid.
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Appendix 1. Inclusion criteria for selecting studies for this systematic review
Types of studies
·	 All original observational and experimental human studies which assess the presence of 
anti-staphylococcal antibodies in the serum of patients with atopic dermatitis, reported 
per Staphylococcus aureus antigen.
·	 All study designs, except for case reports.
Participants
·	 Patients of all ages with atopic dermatitis irrespective of disease severity, and presence 
of antistaphylococcal antibodies. Atopic dermatitis diagnosed by a medical doctor.
Controls
·	 Persons who do not have atopic dermatitis neither an atopic constitution (asthma, 
allergic rhinitis, food allergy) or another skin disease.
Outcome measures
·	 Primary: Specific antibodies (IgE, IgG, IgM, IgA) against Staphylococcus aureus anti-
gens.
·	 Secondary: The relationship between atopic dermatitis disease severity and specific 
antibodies (IgM, IgG, IgA, IgE) antibodies against Staphylococcus aureus antigens.
Appendix 2. Quality assessment score
Modified Newcastle-Ottawa quality assessment scale for cohort or cross sectional studies
Stars indicate the points allocated if the item criterion is met. A maximum score of 9 can be 
allocated to each article. Uncontrolled studies can reach a maximum score of 5.
Selection
1. Representativeness of the exposed cohort
a) Truly representative of the general atopic dermatitis population «
b) Somewhat representative of the general atopic dermatitis population «
c) Selected group of atopic dermatitis patients: hospital based, tertiary center, inpatients, 
outpatients)
d) No description of the derivation of the cohort
2. Selection of the non-exposed cohort
a) Representative of the average community (healthy control, community control) «
b) Selected group of controls (hospital controls, other dermatological condition)
c) No description of the derivation of the cohort
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3. Ascertainment of atopic dermatitis
a) Diagnosed by dermatologist «
b) Diagnosed by physician other than dermatologist «
c) Diagnosed by clinical assessment «
d) Based on self-report
e) No description of atopic dermatitis case definition
4. Definition of the non-exposed cohort
a) No history of disease (endpoint) «
b) No description of source
Comparability
1. Comparability of exposed and non-exposed cohorts on the basis of design or analysis
a) Atopic dermatitis patients and healthy controls are matched for age «
b) Atopic dermatitis patients and healthy controls are matched for any additional factor «
c) No controlling for confounding or matching
Outcome
1. Assessment of outcome: measurement method of antibody response against Staphylo-
coccus aureus antigens
a) Determined by ELISA, CAP, RAST, micro-array, AlaSTAT «
b) Not mentioned
2. Treatment during sampling





a) Same rate for both atopic dermatitis patients and healthy controls / no missing data «
b) Different rate for both atopic dermatitis patients and healthy controls, but well de-
scribed / missing data, but well described «
c) Different rate for both atopic dermatitis patients and healthy controls and not explained
d) Not mentioned
Modified Scoring algorithm controlled studies
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Quality rating Points in Selection Domain Points in Comparability 
Domain
Points in Outcome Domain
Good ≥ 3 ≥ 1 ≥ 2
Fair 2 0 ≥ 2




Targeted antistaphylococcal therapy 
with endolysins in atopic dermatitis 
and the effect on steroid use, disease 
severity and the microbiome: study 













Atopic dermatitis (AD) is associated with a reduced skin microbial diversity and overgrowth 
of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the 
complex pathogenesis remains unclear and studies on the effect of antistaphylococcal 
therapy in noninfected AD show contradictory results. Long-term interventions against S. 
aureus might be needed to restore the microbial balance, but carry the risk of bacterial re-
sistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. 
aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins 
has not been reported, nor is it expected, which allows us to study its effect as long-term 
anti-staphylococcal treatment in non-infected AD.
Methods
This is a multi-centre, placebo-controlled, double-blinded and randomized superiority 
trial with a parallel group design. A total of 100 participants, aged 18 years or older, 
diagnosed with moderate-to-severe atopic dermatitis and using a topical corticosteroid 
in the weeks before enrolment are included in the study. The study is executed in the 
Erasmus MC University Medical Center Rotterdam in collaboration with the Havenzieken-
huis Rotterdam. After a two-week run-in period to standardize the corticosteroid use with 
triamcinolone acetonide 0.1% cream, participants will be randomized to either treatment 
with Staphefekt in a cetomacrogol-based cream or a placebo for 12 weeks, followed by an 
eight-week follow-up period. The primary objective is to assess the difference in the need 
for corticosteroid co-therapy between the Staphefekt and the placebo group, measuring 
the number of days per week of corticosteroid cream (triamcinolone) use. Secondary objec-
tives include the difference in use of corticosteroid cream measured in grams, differences in 
clinical efficacy, quality of life (QoL), microbial composition (including S. aureus) between 
the Staphefekt and the placebo group, and the safety and tolerability.
Discussion
The results of this trial will provide data about the effect of long term antistaphylococcal 
therapy with Staphefekt on corticosteroid use, clinical symptoms and QoL in patients with 
moderate-to-severe AD. Additional data about growth characteristics of the skin microbi-
ome, including S. aureus, will give insight in the role of the microbiome as a factor in the 
pathophysiology of AD.
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IntroductIon
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is associated with a re-
duced quality of life (QoL), primarily due to an itchy skin.1-3 The disease is characterised by a 
reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus, a bacterium 
that can aggravate skin inflammation via the production of staphylococcal enterotoxins 
that stimulate the release of pro-inflammatory cytokines.4-7 However, the importance of 
S. aureus colonisation in the complex pathogenesis, compared to the other genetic and 
immunologic factors involved, remains unclear.
Current treatment approaches for AD include topical treatment with emollients and 
anti-inflammatory therapy with (topical) immunosuppressive agents (corticosteroids and 
calcineurin inhibitors), according to the international guidelines.8,9 Antistaphylococcal 
therapy is only recommended in cases of fever or clinically infected skin.8,9 Clinical stud-
ies that evaluated the added value of antistaphylococcal therapy in noninfected AD have 
shown contradictory results. Bath Hextall et al.10 performed a systematic review of 26 
studies and showed that antistaphylococcal agents reduced the amount of S. aureus on 
the skin in AD. However, the bacteriological reduction did not translate into a decrease 
of clinical symptoms. These studies mainly investigated short-term therapies of less than 
one month duration and comprised small and poor-quality studies. As discontinuation of 
therapy after a short treatment period can result in quick regrowth of S. aureus, the results 
of this systematic review do not necessarily mean that anti-staphylococcal agents do not 
work.11 A more recent review of Brüssow et al.12 summarizes two intervention trials that 
reported significant improvement of disease severity in noninfected AD after two and three 
months of therapy with antistaphylococcal therapy (bleach baths).13,14 We hypothesize 
that long-term therapy may be needed to reduce S. aureus overgrowth and maintain a 
stable and balanced skin microbial composition. Ultimately, this could result in disease 
improvement, prevention of AD flares, and less need for (topical) immune suppression. 
However, long-term use of antibiotics can induce bacterial resistance, and both the use of 
antibiotics and dilute bleach baths can cause unnecessary harm to the commensal flora, 
that is hypothesized to have anti-staphylococcal properties.15,16
In the context of the increasing incidence of bacterial resistance, the interest in bacte-
riophages and their endolysins as antibacterial therapy has been renewed.17 Staphefekt 
SA.100 is an engineered chimeric endolysin that specifically lyses the cell membrane of 
S. aureus via endopeptidase and putative amidase activities.18-20 Long-term application of 
Staphefekt on the skin, targeting only S. aureus and leaving skin commensals unharmed, 
may improve long-term AD outcomes, such as the number of disease flares, and may 
reduce the use of topical corticosteroids. Bacterial resistance to Staphefekt or other endoly-
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sins has not been observed and could not be induced, which enables us to study the effect 
of long-term antistaphylococcal treatment in noninfected AD using this endolysin-based 
agent.19,21,22
The aim of this randomized controlled trial, the MAAS trial, is to evaluate the effect of a 
three-month antistaphylococcal therapy with Staphefekt on the frequency and quantity of 
topical corticosteroid use, clinical symptoms and QoL in patients with moderate-to-severe 
AD. In addition, data on the growth characteristics of the skin microbiome, including S. 
aureus, will be collected, which will gain insight into the role of the microbiome as a factor 
in the pathophysiology of AD.
materIals and methods
Design and setting
The MAAS trial (microbiome in atopic dermatitis during antistaphylococcal therapy and the 
effect on steroid use), is a multi-centre, randomized, double-blinded, placebo-controlled 
superiority trial with a parallel group design. The study aims to evaluate the effect of 
Staphefekt on the use of corticosteroids, disease severity, QoL, and composition of the 
microbiome in patients with AD (Figure 1). The study was designed by the department of 
Dermatology of the Erasmus MC University Medical Center Rotterdam and will be executed 
in collaboration with the Havenziekenhuis Rotterdam. Enrolment and follow-up visits take 
place at these two locations. Participants who comply with the criteria for inclusion and 
exclusion will start with a two-week run-in period to standardize the corticosteroid use 
with triamcinolone acetonide 0.1% cream. After completion of the run-in phase, partici-
pants will be randomized to either treatment with Staphefekt or a placebo for 12 weeks, 
followed by an eight-week follow-up period. An Eczema Area Severity Index (EASI) above 
50.0 after the run-in phase is a contraindication for further participation. During the course 
of the study, participants visit the outpatient clinic six times (visit 1 through 6) and data 
will be collected on corticosteroid use, disease severity, QoL, skin microbiome, and adverse 
events.
Ethical considerations
This study follows the Dutch Medical Research Involving Human Subjects Act 1998 (WMO) 
and the principles of the Helsinki Declaration 2008. All study procedures have been re-
viewed and approved by the Medical Ethics Committee of the Erasmus MC University 
Medical Center Rotterdam, the Netherlands (MEC-2016-233). Protocol amendments will 
be submitted for review at the Medical Ethics Committee.
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Participants
This study will enroll adults (18 years or older) diagnosed with atopic dermatitis according 
to the UK working party diagnostic criteria for AD.23-25 Participants are eligible for enrol-
ment if they have a score between 7.1 and 50.0 on the EASI for disease severity. Topical 
corticosteroids must have been prescribed before enrolment. All patients must be able 
to read and understand the patient information and provide written informed consent. 
Patients are not eligible for enrolment if they used (1) systemic antibiotics or corticosteroid 
in the two months prior to enrolment; (2) oral immunosuppressive agents or UV therapy in 
the three months before enrolment; or (3) local antibiotics or Staphefekt (from commercial 
sources) one week before enrolment. Other criteria for exclusion are a known contact al-
lergy to any of the components of the study drug (e.g. propylene glycol), clinically infected 
AD, or the existence of other skin condition(s) that could interfere with the assessment of 
the AD severity.
Figure 1. Flowchart of the study design
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Recruitment, inclusion and consent
Participants with AD will be recruited from the dermatology outpatient clinic of the Erasmus 
MC and the Havenziekenhuis Rotterdam. Furthermore, Dutch dermatologists are informed 
about the study via the Dutch Trial Network and via scientific conferences. Patients with 
AD are informed via the patient support group and via online media, such as DermHome 
(https://www.huidhuis.nl/). In addition, recruiting advertisements will be placed on student 
fora and in local newspapers. Patients who are interested in participation in the trial can 
contact the researcher directly via email or phone. After a first screening with regard to the 
inclusion and exclusion criteria via email or phone, potentially eligible participants receive 
an information letter and will be invited at the dermatology outpatient clinic to further 
assess eligibility. Patients that fulfil the inclusion criteria and are willing to participate, will 
be included in the study after providing written informed consent.
Sample size
The sample size for this study was calculated based on the primary outcome, namely the 
difference in mean days per week corticosteroid use over 12 weeks between the Staphefekt 
arm and the placebo arm, in patients that are positive for S. aureus on the skin at baseline. 
This is the first study measuring clinical outcomes of Staphefekt in patients with AD. We 
expect to find a mean topical corticosteroid use of 5 days/week in the placebo group. This 
was based on a study of Hon et al.26 that showed decreased use of topical corticosteroids 
when taking bleach baths, an antistaphylococcal therapy. Based on the results of this study, 
we anticipate an effect size of 1.25 day/week reduction of topical corticosteroid use in the 
Staphefekt arm. A sample size was calculated using an unpaired t-test to compare means 
in a superiority trial design. With a power of 0.80, alpha of 0.05, and standard deviation 
(SD) of 2.0, 40 patients are needed per treatment arm. Assuming 10% drop out and 90% 
of the patients being positive for S. aureus on the skin lesions, 50 patients will be assigned 
to each of the two treatment arms.
Randomization and blinding
The participants are randomly assigned in a 1:1 fashion to either treatment with Staph-
efekt or placebo. Stratified block randomization for AD severity is performed to ensure 
equal distribution of patients with moderate and severe AD over the treatment arms (EASI 
7.1-21 and EASI 21.1-50). Randomization is done by an independent biostatistician of the 
Erasmus MC, using the statistical software package R version 3.2.2. The participants, the 
researchers and laboratory analyst are blinded for the intervention. The pharmacy manages 
the randomization list and provides blinded study medication.
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Intervention
After enrolment, all participants start a run-in phase of two weeks, in which they re-
ceive a standardized dosing regimen of topically applied triamcinolone acetonide 0.1% 
cream (Table 1). After the run-in period, the patient and the researcher evaluate further 
participation, with very severe AD (EASI >50.0) as a contraindication for continuation. 
The run-in period and randomization is followed by a 12-week treatment period and an 
eight-week follow-up period. During the treatment period, Staphefekt or placebo cream 
will be applied on the total skin surface twice daily to reach optimal reduction of S. aureus, 
as both lesional and non-lesional skin are often colonised.4 The Staphefekt endolysin is 
made available in a cetomacrogol-based cream. The placebo is composed of the same 
cetomacrogol-based cream, without Staphefekt. During the treatment and follow-up 
period triamcinolone will be used according to the corticosteroid dosing regimen (Table 1). 
Measurements and assessments will be performed at enrolment (start of the run-in phase, 
visit 1), baseline (start treatment with Staphefekt/placebo, visit 2a), 0.5 hours after baseline 
and 2, 6, 12, and 20 weeks after baseline (visits 2b to 6). Table 2 provides an overview of 
the measurements per visit. Unless it is in the best interest of the patients, for example in 
case of an eczema flare, patients are not allowed to use systemic or topical immunosup-
pressive medication (including calcineurin inhibitors), antibiotics or antiseptics during the 
study. Escape medication will be prescribed according to current treatment guidelines and 
its use will be registered. At start of the study, patients receive an emollient according to 
patient’s preference for use during the course of the study. The use of this emollient will be 
registered by weighing the tubes at each visit.
Detailed sample and laboratory procedures
Sampling procedures are based on the ‘Manual of Procedures’ for microbiome sampling 
of the Human Microbiome Project.32 All samples are obtained by one of the researchers 
wearing gloves (sterile for the skin scrub). Sterile Copan 490CE.A swabs are used to sample 
Table 1. Corticosteroid dosing regimen
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9
Saturday x x x x x
Sunday x x x x x x x
Monday x x x x x
Tuesday x x x x x
Wednesday x x x x x
Thursday x x x x x x x
Friday x x x x x
Start in week 1 or 2 depending on severity of the atopic dermatitis. If the symptoms allow, reduce the use of 




the skin, nasal cavity and pharynx. Skin samples are taken from lesional skin, preferably 
located at the antecubital folds or the popliteal fold. The skin surface is swabbed during 30 
seconds. The mucosal surfaces of both the anterior nares are gently rubbed going round 
the area for 10 seconds. The rear of the oropharynx is swabbed for 5 seconds, using a 
tongue depressor. For the skin scrub sample, a ring with an internal diameter of 4 cm will 
be placed on the same skin lesion where the swab was collected, but on a non-overlapping 
area: 1 ml of swab-solution (0,85% NaCl, 0.1% bacteriological peptone, 0.1% Tween 80) 
is pipetted in the ring. After rubbing over the skin with a Copan 480CE swab during 1 
minute, the swab solution will be pipetted out the ring into an Eppendorf tube. The swabs 
will be sent to the laboratory by mail at the day of collection. A semi-quantitative culture 
technique and matrix-assisted laser desorption ionization time-of-flight (MALDI-TOFF) for 
identification of S. aureus will be performed. The scrub samples will be stored at -80 ° at 
the Erasmus MC Rotterdam until 16S rRNA-sequencing and quantitative S. aureus analysis.
Primary and secondary outcomes
The primary outcome of this study is the days per week of corticosteroid use, compared 
between the Staphefekt and the placebo group over 12 weeks. Patients report their tri-
amcinolone use daily in a secured digital platform, ‘DermHome’.* Additionally, the use of 
triamcinolone cream will be measured in grams by weighing the study medication at time 
of issue and return (each visit). Secondary outcomes include clinical efficacy and QoL from 
baseline through week 12 and week 20, change of the microbial composition (includ-
ing S. aureus), and safety. Clinical efficacy is measured using the EASI, the Investigators 
Global Assessment (IGA), and registration of the number of flares.27 A flare is defined as 
an exacerbation that requires the need to intensify treatment, from a doctor or patient’s 
perspective. This implies any stronger topical therapy or the need for systemic treatment. A 
50% increase of the EASI score compared to baseline is used as an indication to intensify 
treatment. The Pruritus Numerical Rating Scale (NRS) and the Patient-Oriented Eczema 
Measure (POEM) are included as patient-reported efficacy outcomes.28,29 QoL is measured 
using the Skindex-29.30,31 Changes in the microbiome are evaluated by comparing the 
changes in bacterial composition between the treatment groups, determined by 16S rRNA 
sequencing of the skin scrub samples. Reduction of S. aureus is determined by quantitative 
polymerase chain reaction (qPCR), and culture for the comparison between visit 2a and 
visit 2b. Safety and tolerability is assessed by monitoring the incidence of (serious) adverse 
device events through the end of the study, evaluated by medical check-ups that include 
evaluation of vital signs. Reportable adverse events will be reported within the set timelines 
to the competent authorities. Table 2 gives a detailed overview of the measurements per 
visit.
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triamcinolone use (primary 
outcome)
Weight triamcinolone tube 
at issue and return
x x x x x x
EASI27 x x x x x x
IGA x x x x x
Pruritis NRS28
POEM29 x x x x x
Quality of life Skindex-2930,31 x x x x
Microbiome Swab skin x x x x x x
Scrub skin x x x x
Swab nose x x x x
Swab throat x x x x
Safety Medical check-up x x x x x x
Other Photograph (overview + 
close-up sampled lesion)
x x x x x
Questionnaire use of 
emollients and escape 
medication
x x x x x
Abbreviations: EASI, eczema area and severity index; IGA, investigators global assessment; NRS, numerical rat-
ing scale; POEM, patient-orientated eczema measure. Visit 1, enrolment in the trial and start of a two weeks 
run-in phase; Visit 2a, start of the intervention (baseline); Visit 2b, 0.5 hours after baseline; Visit 3, 2 weeks after 
baseline; Visit 4, 6 weeks after baseline; Visit 5, 12 weeks after baseline and end of the intervention; Visit 6, fol-
low-up visit 20 weeks after baseline. All visits take place plus or minus two days from the indicated timeframe.
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Data collection, monitoring and data analysis
Data collected during the visits are entered in Open Clinica. This data management system 
allows direct data entry. Data entry is monitored by an independent researcher according 
to a predefined monitoring plan. Triamcinolone use and itch scores filled in daily by the 
patients in ‘DermHome’ will be extracted in a SPSS format and combined with the Open 
Clinica database. Patients confidentiality will be ensured by using identification numbers. 
Data will be analysed on an intention-to-treat basis. A mixed linear regression model will 
be used to examine if there is a significant difference in corticosteroid use over 12 weeks 
between the intervention and the placebo group.33 This model accounts for repeated 
measurements in each patient and is valid in the case of missing data. Covariates that 
could influence the outcome variable will be included in the model. Subgroup analysis will 
be performed to analyse patients who are positive for S. aureus on the skin versus patients 
that are negative for S. aureus before the start of the intervention. Positive patients are 
defined as having positive cultures both at visit 1 and 2a. Negative patients must have 
two negative cultures. Patients that have one positive and one negative culture will not be 
included in the subgroup analysis. Secondary outcomes will also be analysed using a mixed 
model analysis (linear or logistic according to the type of data). The findings of this study 
will be published in national and international journals and will be communicated to the 
relevant patient associations.
*‘DermHome’ is a secured digital treatment and research platform, developed with Patient 
1 BV, Almere.34 The platform provides an user-friendly individual account that allows 
patients to report their pruritus score and triamcinolone use daily. Thereby, the platform 
provides digital information about the study, including the use of the study medication, 
and an option to contact the researcher and to upload photos in case of questions. After 
every visit the researcher can make notes in the digital file about findings, agreements, and 
future appointments.
dIscussIon
The MAAS trial is a randomized, placebo-controlled trial that investigates the effect of 
three-month antistaphylococcal therapy with Staphefekt on topical corticosteroid use, 
clinical symptoms, and QoL in adults with moderate-to-severe AD. Additionally, data will 
be collected about the growth characteristics of the skin microbiome, including S. aureus. 
Taking into consideration the current literature on antistaphylococcal therapy, a study 
design using a long-term antistaphylococcal intervention, measuring long-term outcomes, 
was chosen.
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Evidence for the clinical efficacy of Staphefekt, registered as a class 1 medical device in 
Europe, is based on in vitro studies and a case series.18-20 These in vitro studies showed 
that Staphefekt kills different strains of S. aureus (also methicillin-resistant strains), without 
harming the commensal flora or inducing bacterial resistance.19 A case series describes 
clinical improvement of S. aureus related symptoms, such as folliculitis and superinfected 
dermatitis, and no development of resistance during long-term daily treatment with Staph-
efekt based on the minimal inhibitory concentrations of the cultured S. aureus strains over 
time.35 The lack of resistance induction can be expected, as bacterial killing by an endolysin 
is independent of the involvement of the bacterial metabolism. The co-evolution of bac-
teriophages and their host bacteria over millions of years ensures that phage endolysins 
attack essential bonds in the bacterial cell wall that cannot be adapted by the host.22 
Thereby, the lytic activity of exogenously applied endolysins results in lysis of the target cells 
within seconds, restricting the possibility to adapt and develop resistance. Furthermore, 
attacking several bonds of the bacterial wall simultaneously by the use of more than one 
enzymatically active domain in the Staphefekt molecule makes resistance even less likely 
to develop.18
Because of the proteinaceous nature of endolysins, immunogenicity can be of concern. 
The literature shows the possibility of the formation of non-neutralizing antibodies against 
lysins other than Staphefekt.22 In a study in which the presence of anti-Staphefekt IgG was 
evaluated in serum from 21 Staphefekt-naive healthy human donors, pre-existent IgG an-
tibodies recognizing Staphefekt epitopes could be detected in all the donors (unpublished 
data). This can be explained as humans are exposed daily to S. aureus and, therefore, 
to bacteriophages and their lysins. However, Staphefekt is a large protein molecule (>50 
kDa), making penetration through the skin and mucosa and subsequent antibody reactions 
unlikely.36
Calculation of the sample size for this study was hampered as no information was available 
about the effect of Staphefekt on corticosteroid use and clinical efficacy in AD. Therefore, 
the study should be considered as hypothesis generating, giving insight into effect sizes and 
distributions of clinical outcomes. Our expected effect size was based on a study of Hon et 
al.26 that studies the effect of bleach on corticosteroid use in AD. We chose a slightly higher 
effect size, because we expect the effect of Staphefekt that specifically targets S. aureus to 
be more efficacious than bleach. We consider this effect size, a reduction in corticosteroid 
use of more than one day a week over 12 weeks, as clinically relevant because of the (low) 
risk of side effects and a general reluctance of patients to use corticosteroids, resulting in 
poor compliance and a lack of treatment efficacy.37,38
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No consensus has been reached yet on a standardized outcome for long-term AD control, 
the primary goal of our study. The Harmonising Outcome Measures for Eczema (HOME) 
initiative reached consensus on the use of EASI and POEM as doctor-based and patient-
based measures of AD severity, of which both are included as secondary outcomes in this 
trial.39 According to the authors of HOME, measures of long-term control could include 
time to flare and the use of rescue medicine.39 Next to corticosteroid use, both these study 
outcomes were included in this study as secondary parameters.
In conclusion, this study will evaluate the effects of a three-month targeted antistaphylo-
coccal therapy with Staphefekt in moderate-to-severe AD. The lack of resistance induction 
allows long-term treatment with this antistaphylococcal agent. This study will provide the 
first data on the use of antistaphylococcal therapy with Staphefekt in AD and may provide 
new insights into the role of S. aureus in the pathophysiology of AD.
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To the Editor:
Staphylococcus (S.) aureus density is increased in many patients with atopic dermatitis 
(AD) and is thought to contribute to the disease pathogenesis, interacting with an altered 
skin barrier and immunological changes.1 S. aureus might induce or aggravate inflamma-
tion via different mechanisms, for example through excretion of virulence factors, even 
if the S. aureus overgrowth is primarily caused by other factors.2 Current guidelines only 
recommend antimicrobial therapy directed against S. aureus in clinically infected AD based 
on a Cochrane review where no clinical benefit of short-term antimicrobial treatment in 
noninfected AD was found.3
Arguably, long-term anti-staphylococcal treatment, such as antibiotics, might reduce 
symptoms in AD.4 However, this is undesired because antibiotics can affect the commensal 
microbiota and could induce bacterial resistance.5 In contrast, long-term treatment of AD 
with an endolysin that targets only S. aureus is feasible. It might improve AD symptoms 
and reduce the use of corticosteroids consecutively.2,6 Therefore, we aimed to determine 
the topical corticosteroid (TCS)-sparing effect and safety of 12 weeks of endolysin treat-
ment against S. aureus in patients with AD.
We performed a double-blind, vehicle-controlled superiority trial (MAAS trial, ClinicalTrials.
gov NCT02840955) in 100 adult patients with TCS-treated, not clinically infected, moder-
ate-to-severe AD, which was defined by an Eczema Area and Severity Index (EASI) of 7.1 to 
50.0. After a two-week run-in period to standardize the TCS treatment with triamcinolone 
acetonide 0.1% cream, patients were randomly assigned 1:1 to a 12-week intervention 
with either a topical endolysin against S. aureus or a vehicle twice daily, followed by an 
eight-week follow-up period. The vehicle and recombinant chimeric endolysin, Staph-
efekt™ SA.100, were provided by Micreos Human Health (Bilthoven, The Netherlands) and 
topically applied in a cetomacrogol cream. Details on patient inclusion, randomization, and 
study procedures at six assessments are described in a previously published study protocol 
(Figure S1).2
The primary outcome, the TCS-sparing effect of endolysin treatment against S. aureus, 
was evaluated by the patients, who registered daily use of a TCS (yes/no) over 12 weeks. 
Secondary outcomes included differences in TCS use measured in grams, clinical efficacy, 
quality of life using the Skindex-29, S. aureus load on the skin, and safety and tolerability 
of endolysin treatment. Clinical efficacy was measured using the EASI, Investigators Global 
Assessment, Patient-Oriented Eczema Measure, pruritus Numeric Rating Scale, and by 
registration of the number of flares. The S. aureus load on the skin was assessed by a 
semi-quantitative culture and quantitative polymerase chain reaction (qPCR, Appendix 1).
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Generalized linear mixed-effect models for repeated measurements were used to analyze 
the primary and dichotomous secondary outcomes, and linear mixed-effect models were 
used for continuous secondary outcomes. Data were analyzed as intention-to-treat and 
per-protocol. Furthermore, a subgroup analysis was performed in patients with a positive 
S. aureus skin culture at two time points before start of the intervention.
Eighty-eight (88.0%) patients completed the intervention, and 87 (87.0%) completed 
follow-up (13% dropout rate, Figure S2). Patients’ characteristics were comparable be-
tween the endolysin and vehicle groups (Table 1). Over the 12-week intervention period 
(corresponding to 8400 days for 100 patients), patients in the endolysin group used a TCS 
for 1889 (45.0%) days compared with 1566 (37.3%) days in the vehicle group. There 
was no statistically significant difference in the probability of TCS use per day between 
the groups in the intention-to-treat analysis, per-protocol analysis, and in the subgroup of 
S. aureus-positive patients (p=0.97, p=0.40 and p=0.08, respectively, Table 2). Sensitivity 
analyses showed no differences in the odds ratio of TCS use per assessment day. Except 
for the number of doctor-reported AD flares during the intervention period (per-protocol, 
n=2 in endolysin group vs. n=10 in vehicle group, p=0.03), no statistically significant 
differences were found in the secondary outcomes after both intention-to-treat and per-
protocol analyses (Table S1 and S2). At baseline, 62 (64.6%) patients had positive results 
for S. aureus based on skin culture and 24 (24.7%) by qPCR. Both methods showed no 
significant difference in S. aureus reduction (Table S3 and S4). During the study, one serious 
adverse event occurred in the endolysin group eight weeks after the last application of 
endolysin cream (pleural effusion with hospitalization), which was considered unlikely to 
be related to the study intervention (Table S5).
Our results are in accordance with data from a Cochrane review showing no significant 
effect of short-term anti-S. aureus therapy in patients with noninfected AD.3 We cannot 
confirm the positive results of other longer-term studies. However, these studies used 
broad-spectrum antimicrobials and mainly included patients with signs of bacterial infec-
tion.4 Patients with clinically infected AD were excluded from our study, and a possible 
effect of anti-S. aureus endolysins in this patient group should be determined in future 
studies.
Several hypotheses could explain our results. First, use of triamcinolone in the run-in phase 
resulted in a decrease in AD severity (Table 1), which might have masked a possible benefit 
of endolysin treatment.
Second, daily use of an emollient and good compliance with the treatment could have 
resulted in a reduction of triamcinolone use in both the endolysin and vehicle groups.7 
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Table 1. Baseline characteristics
Total (n=100) Staphefekt (n=50) Vehicle (n=50)
Age
years; median (IQR) 33.5 (25.5-47.5) 36.5 (25.0-51.0) 32.5 (24.0-44.0)
Sex (male)
n (%) 55 (55.0) 24 (48.0) 31 (62.0)
Race, n (%)
American Indian or Alaska Native 5 (5.0) 2 (4.0) 3 (6.0)
Asian 10 (10.0) 2 (4.0) 8 (16.0)
Black or African American 8 (8.0) 5 (10.0) 3 (6.0)
White 77 (77.0) 41 (82.0) 36 (72.0)
Atopic disease, n (%)
Food allergy 43 (43.0) 18 (36.0) 25 (50.0)
Rhinoconjunctivitis 63 (63.0) 28 (56.0) 35 (70.0)
Asthma 47 (47.0) 25 (50.0) 22 (44.0)
EASI, median (IQR)
Screening (V1) 12.9 (9.2-19.0) 13.7 (8.9-19.1) 12.5 (9.2-19.0)
Baseline (V2) 8.0 (5.0-13.5)4 8.3 (5.0-14.7)5 8.0 (4.9-12.9)6
IGA, median (IQR)
Baseline (V2) 2.0 (2.0-3.0)4 2.0 (2.0-3.0)5 2.0 (2.0-3.0)6
POEM, mean (SD)
Baseline (V2) 12.9 (6.2)4 14.5 (8.3-17.0)5 13.0 (8.0-15.0)6
Pruritus NRS, median (IQR)
Baseline (V2) 3.0 (2.0-4.0)4 3.0 (2.0-4.0)5 3.0 (2.0-4.0)6
Skindex-29, mean (SD)
Baseline (V2) 35.1 (17.1)4 37.3 (15.3)5 32.9 (18.7)6
Use of topical corticosteroids at screening, n (%)
Class 1 3 (3.0) 1 (2.0) 2 (4.0)
Class 2 13 (13.0) 6 (12.0) 7 (14.0)
Class 2-3 11 (11.0) 3 (6.0) 8 (16.0)
Class 3 44 (44.0) 22 (44.0) 22 (44.0)
Class 3-4 3 (3.0) 2 (4.0) 1 (2.0)
Class 4 18 (18.0) 11 (22.0) 7 (14.0
Unknown 8 (8.0) 6 (12.0) 4 (8.0)
Staphylococcus aureus skin culture*, n (%)
Positive  56 (56.0) 32 (64.0) 24 (48.0) 
Intermediate 20 (20.0) 7 (14.0) 13 (26.0) 
Negative 20 (20.0) 9 (18.0) 11 (22.0) 
Missing 4 (4.0) 2 (4.0) 2 (4.0) 
Abbreviations: EASI, Eczema Area and Severity Index; IGA, Investigators Global Assessment; IQR, interquartile 
range; NRS, Numeric Rating Scale; POEM, Patient Oriented Eczema Measure; SD, standard deviation. Missings: 
1n=15 (15.0%), 2n=8 (16.0%), 3n=7 (14.0%), 4n=3 (3.0%), 5n=2 (4.0%), 6n=1 (2.0%). *Positive is defined as 
having a positive culture at visit 1 and visit 2a; intermediate is defined as having one positive culture and one 
negative culture at visit 1 and visit 2a; negative is defined as having two negative cultures at visit 1 and visit 2a.
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Because AD is a heterogeneous disease, anti-S. aureus treatment might not be suitable for 
all patients with AD, indicating the need for subphenotyping. Because only 56% of our 
study population had two consecutive positive S. aureus skin cultures (indicating persistent 
colonization) before start of the intervention, the target population that would probably 
benefit the most from endolysin treatment was small.
Our data suggest that endolysin treatment has no effect on S. aureus in vivo. However, 
patients might have been recolonized with S. aureus from the nose because 73% of 
them were nasal carriers (data not shown). Alternatively, cetomacrogol as the basis of the 
endolysin cream might have created a barrier on the skin that prevented the endolysin to 
reach and subsequently kill S. aureus. However, some reduction in S. aureus load would 
have been expected in both treatment groups because of the use of TCSs and emollients 
in this study, which both have been shown to reduce the S. aureus load on the skin.8,9 
Nonetheless, it is unclear whether complete eradication of S. aureus is required for clinical 
improvement because a case series showed a clear clinical improvement without S. aureus 
reduction using a qualitative culture in S. aureus-related dermatoses.6 In addition, the 
discrepant results between culture and qPCR indicate the complexity of the interpretation 
Table 2. Generalized Linear Mixed-Effect model results for the difference in topical corticosteroid use per day 
during the 12-week intervention period








use ‘yes’, n (%)












14 40 37 26 (65.00) 20 (54.05) 0.99 (0.95 – 1.03) 0.49
42 37 37 26 (70.27) 22 (59.46) 0.99 (0.78 – 1.24) 0.91
84 30 34 18 (60.00) 21 (61.76) 1.04 (0.87 – 1.23) 0.68
Per-protocol Intervention 0.40
14 22 21 14 (63.64) 10 (47.62) 1.09 (0.98 – 1.21) 0.10
42 17 18 12 (70.59) 11 (61.11) 1.36 (0.84 – 2.20) 0.21




14 26 16 17 (65.38) 7 (43.75) 0.87 (0.78 – 0.96) 0.01
42 22 17 16 (72.73) 8 (47.06) 0.85 (0.49 – 1.48) 0.56
84 18 15 11 (61.11) 11 (73.33) 1.29 (0.84 – 1.96) 0.24
NOTE: Given the low number of patients using escape medication (n=5), we did not correct for its use. 1Overall 
effect of endolysin treatment during intervention period was calculated with a Likelihood-Ratio test, the effect 
per time point using a Wald test with t-distribution. 2Defined as having a positive culture both at visit 1 and 
visit 2a (endolysin n=32, vehicle n=24). Sensitivity analyses, performed by adding/subtracting 0.25 times the 
standard deviation to/of the odds, showed no differences in the odds ratio of topical corticosteroid use per 
assessment day.
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of S. aureus testing. Despite the limitations and outcome, this study provides estimates of 
AD symptoms, use of TCSs, and the percentage of persistent S. aureus carriers that can be 
used for future clinical studies.
In conclusion, long-term targeted endolysin treatment against S. aureus in this study was 
well tolerated but had no TCS-sparing effect in patients with AD. However, an effect can-
not be excluded because good compliance with the treatment and concurrent application 
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RCT on targeted anti-staphylococcal therapy in atopic dermatitis
Table S3. Results for the difference in reduction of Staphylococcus aureus 0.5 hour after first application de-




culture of S. 
aureus1








Abbreviations: S. aureus, Staphylococcus aureus. 1Decrease is defined as a decrease of at least 1 point on semi-
quantitative scale (scale ranges from 0-4). 2Patients included in analysis in endolysin group: n=49. 3Patients 
included in in analysis in vehicle group: n=48. 3P-values were calculated using a Fisher’s Exact test for categorical 
data.
Table S4. Results for the difference in reduction of Staphylococcus aureus from baseline determined by qPCR
Analysis Time period Log10 reduction in qPCR for S. aureus P-value1
Endolysin, n (%) Vehicle, n (%)
Intention-to-treat2 Visit 2a to visit 3







Per-protocol3 Visit 2a to visit 3







S. aureus positive4-6 Visit 2a to visit 3







Abbreviations: S. aureus, Staphylococcus aureus; qPCR, quantitative polymerase chain reaction. 1P-values were 
calculated using a Fisher’s Exact test for categorical data. 2Patients included in endolysin and vehicle group: visit 
2a to visit 3, n=47 and n=47; visit 2a to visit 5, n=44 and n=44. 3Patients included in endolysin and vehicle 
group: visit 2a to visit 3, n=25 and n=29; visit 2a to visit 5, n=16 and n=15. 4Patients included in endolysin and 
vehicle group: visit 2a to visit 3, n=9 and n=13; visit 2a to visit 5, n=9 and n=12. 5Analysis additionally to analy-
ses described in the study protocol. 6Staphylococcus aureus positive is defined as having a positive qPCR at visit 
2a (endolysin group n=10, vehicle group n=14). Missings: 6n=1 (2.1%), 7n=1 (2.3%), 8n=1 (6.7%).
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Table S5. Incidence of (non-) Treatment Emergent Adverse Events – Overall and per study phase

















































At least 1 serious non-TEAE 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 non-TEAE leading to study discontinuation 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 non-TEAE leading to death 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Intervention (V2-V5) 







At least 1 serious TEAE 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
At least 1 TEAE leading to study discontinuation 3 (3.0) 3 1 (2.0) 1 2 (4.0) 2
At least 1 TEAE leading to death 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Follow-up (V5-V6)







At least 1 serious TEAE 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
At least 1 TEAE leading to study discontinuation 1 (1.0) 1 1 (2.0) 1 0 (0.0) 0
At least 1 TEAE leading to death 0 (0.0) 0 0 (0.0) 0 0 (0.0) 0
Abbreviations: TEAE, Treatment Emergent Adverse Event (adverse events after the first endolysin or vehicle 
administration); V, visit.
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Figure S2. Flowchart of the study design
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RCT on targeted anti-staphylococcal therapy in atopic dermatitis
Appendix 1. Microbial methods
a. Microbial sampling methods
Samples of the skin were collected using sterile Copan 490CE.A swabs for culture analysis 
and skin scrubs for qPCR analysis. Skin swabs were collected from a skin lesion at the first 
visit, preferably located at the antecubital fold or the popliteal fold. For all consecutive visits 
the swab was collected from the location chosen at the first visit. The scrubs were collected 
from the lower arm, adjacent to the antecubital fold according to methods described 
previously.23 Scrub samples were stored at -80 °C.
b. Semi-quantitative culture and qPCR for Staphylococcus aureus
Bacterial cultures were performed using routine diagnostic culture procedures, using blood 
agar plates and specific S. aureus culture plates (ChromID S. aureus Elite agar (SAIDE), 
Biomérieux, France) for overnight incubation and subsequent species determination by 
MALDI-TOF (Bruker Daltonics, Bremen, Germany). For DNA isolation 150 uL from the 
sample was added to 350 uL lysis buffer, 500 uL Phenol (Tris pH 8) and 500 uL 0.1 mm 
zirconium beads. This mixture was mechanically disrupted by bead beating twice for 2 
minutes, followed by centrifuging for 10 minutes at 1690 RCF to separate the aqueous 
and phenolic phases. The aqueous phase was purified using AGOWA mag Mini DNA isola-
tion kit. After elution, we used qPCR to determine the total load of S. aureus with the 
following primers and probes: 16S-S.aur-F1 (5’-GCG AAG AAC CTT ACC AAA TCT TG-3’), 
16S-S.aur-R1 (5’-TGC ACC ACC TGT CAC TTT GTC-3’), 16S-S.aur MGB Taqman® probe 








Primary immunodeficiency diseases (PIDs) are generally characterized by an increased risk 
of infectious complications due to specific inborn errors in immune cell function. However, 
patients with PIDs also present with features of significant immune dysregulation, often 
leading to autoimmunity, autoinflammation, (hematological) malignancies and allergic 
disorders.1-3 Previously, immunodeficiency and autoimmunity were considered to be mutu-
ally exclusive conditions. Increased understanding of the complex immune regulatory and 
signaling mechanisms involved, coupled with the application of genetic analysis, reveals 
more and more the relation between primary immunodeficiency syndromes and autoim-
mune diseases.4 Monogenic defects can cause rare diseases that predominantly present 
with autoimmune symptoms or recurrent infections (immunodeficiency). However, it has 
been increasingly recognized that various genetic variant give rise to a clinical phenotype of 
both immunodeficiency and autoimmunity. Also other features of immune dysregulation, 
like (hematological) malignancy, may be attributed to genetic variants found in PIDs. As 
an example, a major complication of activated phosphatidylinositol 3-kinase-δ (PI3K-δ) 
syndrome (APDS) is malignancy (especially B-cell lymphoma), which is the result of uncon-
trolled PI3K-δ activity in lymphocytes.5
The first aim of this thesis was to gain more insight in the nature and prevalence of infec-
tious and noninfectious skin disorders and manifestations within the atopic syndrome, 
including atopic dermatitis (AD), food allergy (FA), asthma and allergic rhinitis (AR), in 
patients with PIDs. Recognition of these symptoms could facilitate earlier diagnosis of 
PIDs. As skin disorders, including AD, and atopic manifestations were demonstrated as 
frequently occurring symptoms in PIDs, it suggests that immune dysregulation also plays a 
role in the multifactorial pathogenesis of AD and the atopic syndrome. Moreover, common 
pathways appear to be involved in the pathogenesis of these disorders and PIDs. Therefore, 
this thesis aimed to identify these common pathways of immune dysregulation in PIDs, 
atopy and AD. Knowledge on immune dysregulation processes in PIDs was used to gain 
more insight in the pathogenesis of AD and the atopic syndrome, in which endotypes 
were identified. Moreover, the antibody response and microbiome in AD were studied to 
better understand the interaction between various pathogenic factors in AD and immune 
dysregulation. Based on the predominance of S. aureus in the skin microbiome of AD 
patients, a clinical trial was performed using an endolysin selectively targeting S. aureus. In 
the following paragraphs the main findings of this thesis are summarized and discussed.
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maIn fIndIngs of the thesIs
Skin disorders are prominent clinical features in primary immunodeficiency 
diseases
PIDs are characterized by an increased risk of infections, autoimmune disease, autoin-
flammatory complications, malignancy and allergic disorders. In Chapter 2 of the thesis it 
was demonstrated that skin disorders are also frequently occurring symptoms in patients 
with PIDs, based on a systematic literature analysis of 67 mainly cross-sectional studies. 
A complete spectrum of skin disorders was composed, categorized in 15 main groups 
of cutaneous manifestations, across 30 PID phenotypes. Presence of skin manifestations 
characteristic for ataxia-telangiectasia (AT), hyper immunoglobulin (Ig) E syndrome (HIES), 
selective IgA deficiency (SIgAD), autoimmune polyendocrinopathy candidiasis ectodermal 
dystrophy (APECED) and chronic granulomatous disease (CGD) have been identified. For 
example, skin abscesses were found to be a well-defined characteristic for HIES and CGD, 
and alopecia and skin pigmentation disorders for SIgAD and APECED. In various PIDs skin 
disorders were already known to be among the clinical characteristics and frequently oc-
curring manifestations, such as telangiectasia in AT and granuloma and skin abscesses in 
CGD. However, this thesis also reveals infectious and noninfectious skin disorders of which 
an association with a PID was not generally recognized. Examples include alopecia in SIgAD 
and hypopigmented macules in AT. Although various skin conditions were described in 
patients with a PID, the prevalence of these skin conditions in a matched control group 
remains largely unknown. Interpretation of the data should, therefore, be done with cau-
tion. Nonetheless, the high prevalence of skin conditions in PIDs suggests that these could 
be used as an additional warning sign to raise suspicion for underlying PID. Linking skin 
disorders to PIDs provides a valuable tool that could raise PID awareness in clinical practice.
Skin infections and nail disorders are warning signs for primary 
immunodeficiency diseases
In Chapter 3.1 of the thesis, a Dutch cohort of 45 pediatric patients and 207 adult patients 
with a PID and 56 unaffected partner-controls was studied using a questionnaire. A history 
of skin disorders, in particular skin infections and nail disorders, was more frequently re-
ported in adult PID patients (80.2%) when compared with adult partner-controls (41.1%, 
p<0.001). As far as we know this was the first study evaluating the nature and prevalence 
of skin disorders in a mainly Western population of PID patients. Data retrieved from this 
cohort of PID patients were mostly consistent with the data summarized in our systematic 
review (Chapter 2), which included mainly data derived from Middle-Eastern countries. 
However, in the Dutch patient cohort viral and bacterial skin infections, erythematous skin 
lesions and skin rashes were more frequently reported than in current literature.
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Skin disorders were found to develop earlier in life in adult patients with PIDs (mean age 
20.9 (SD 22.0) years) when compared with unaffected partner-controls (mean age 33.7 
(SD 26.6) years, p=0.02) suggesting an association between the skin condition and im-
mune dysfunction in PID. Moreover, skin disorders preceded a diagnosis of PID on average 
20.3 (SD 20.5) years in adult patients, whereas classical PID symptoms, such as respiratory 
tract infections, developed on average 15.9 (SD17.7) years before the PID diagnosis in this 
patient cohort. Based on these results, skin disorders frequently appeared to be presenting 
symptoms, while they are not included in the warning signs for PIDs.
Current literature appointed eczematous dermatitis as common finding and presenting 
clinical manifestation among PIDs, especially in rare PIDs which are not well represented 
in our cohort.6 In our study, (atopic) dermatitis also was the most commonly reported 
presenting skin disorder in PID patients. However the prevalence did not significantly differ 
from partner-controls (29.5% vs. 25.0%, respectively) and even less adult patients reported 
(atopic) dermatitis as first developed skin disorder compared with partner-controls (15.0% 
vs. 52.2%, respectively). Moreover, the prevalence of a history of (atopic) dermatitis in 
both adult patients and partner-controls included in this study corresponds to the lifetime 
prevalence of atopic dermatitis in the Dutch population, which is up to 25% in children 
and 1-7% in adults.7,8 Therefore, we feel that (atopic) dermatitis is not a distinctive pre-
senting manifestation in the development of PIDs in general. By contrast, we hypothesize 
that (a combination of) other skin manifestations, like skin infections and nail disorders 
(prevalence in adult patients vs. adult controls 61.4% vs. 17.9%, p<0.001, and 38.6% vs. 
7.1%, p=0.005, respectively), are more useful in raising suspicion of an underlying PID in 
addition to the presence of the currently used warning signs for PIDs.9
Staphylococcus aureus -targeting treatment in patients with primary 
immunodeficiency diseases could be beneficial in reducing severity of skin 
disease
Staphylococcus (S.) aureus is involved in the pathogenesis of many common infectious 
skin disorders (i.e. S. aureus-induced skin infections) and the inflammatory skin disorder 
AD. In patients with PIDs, only a few studies reported culture-proven S. aureus-associated 
skin disorders (Chapter 2).6,10-12 These skin disorders included a papulopustular eruption, 
eczematous dermatitis, (cold) abscesses and wounds in HIES13-16, skin infections in Comèl 
Netherton syndrome17 and suppurative dermatitis in patients with CGD.18 Furthermore, 
colonization with S. aureus was found to be significantly correlated with skin disease sever-
ity in PID patients.19
In our Dutch population of adult PID patients, including mostly predominantly antibody 
deficiencies (PADs), a positive S. aureus culture at a single time point was found in 40.0% 
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(12/30) of the skin disorders with suspected S. aureus-related etiology (Chapter 3.1). These 
positive cultures originated from dermatitis lesions, ecthyma and folliculitis. The prevalence 
of lesional S. aureus in our PID population was lower than the prevalence of lesional S. 
aureus in patients with AD (70%).20 S. aureus colonization in less than half of the clinical 
suspected S. aureus-related skin lesions in our study could reflect intermittent carriage of 
S. aureus.21 We suppose that repetitive culturing during clinical examination to identify skin 
lesions colonized with S. aureus can contribute in selection of PID patients, which might 
have benefit from S. aureus-targeting treatment to reduce skin disease severity.
Atopic manifestations are underestimated clinical features in primary 
immunodeficiency diseases
The systematic review presented in Chapter 2 of the thesis shows that original data on 
atopic manifestations in PIDs are limited, as studies comprise small patient samples and 
the diagnosis of atopic manifestations is generally not based on diagnostic tests. Although 
atopic manifestations are described in various PID phenotypes, presence of these mani-
festations is mainly reported in immunodeficiencies affecting both cellular and humoral 
immunity (combined immunodeficiencies; CIDs), like DOCK8 deficiency, and CIDs with as-
sociated or syndromic features, such as Comèl Netherton syndrome.6,22 In addition, atopic 
manifestations have also been reported in PADs, like SIgAD, with a prevalence comparable 
to the general population.23-28
In Chapter 3.2 we showed that all atopic manifestations, including AD, FA, asthma and AR, 
were highly prevalent in 47 children and 206 adults with a PID based on the International 
Study of Asthma and Allergies in Childhood (ISAAC) questionnaire and diagnostic criteria 
or tests.29 Using the questionnaire, we found in adult patients a self-reported prevalence of 
49.5%, 10.7%, 55.7% and 49.8% for AD, FA asthma and AR, respectively. Remarkably, a 
discrepancy was shown between the prevalence of AD based on patient-reported skin dis-
orders (Chapter 3.1) and the ISAAC questionnaire (Chapter 3.2). Self-reported ever expe-
rienced atopic manifestations were significantly more common in adult PID patients when 
compared with 56 adult partner-controls. Although our study population mainly involved 
patients with PADs and CIDs, atopic manifestations were reported in a large spectrum of 
PIDs across the various phenotypes, which is in contrast with previous literature (Chapter 
2). The prevalence of FA, asthma and AR based on diagnostic test results was significantly 
lower than the prevalence reported by adult patients (FA 4.8%, asthma 16.4% and AR 
19.2%). This discrepancy could be due to overreporting of clinical symptoms related to 
atopy, the relapsing-remitting course of atopic manifestations over time, or because PID 
patients are known to commonly have asthma-like airway complaints without of a positive 
diagnostic test.30 Unfortunately, data on diagnostic tests from the control group or another 
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reference population were not available. Nonetheless, estimates of atopic manifestation 
prevalence in PID patients were provided in this study that can be used for future studies.
Compared with our review (Chapter 2), in which diagnosis of atopic manifestations was 
generally based on medical records, we found a significantly higher prevalence of atopic 
manifestations in patients with a PAD and comparable numbers of patients with atopic 
manifestations in CIDs. The exact mechanism underlying the development of atopic mani-
festations in PIDs remains to be elucidated. Nonetheless, the pathogenic pathway involved 
in the atopic syndrome, in which T lymphocytes play a central role, could suggest that 
patients with a PID affecting cellular immunity are more prone to develop atopic manifesta-
tions.31 However, it is known that also in PADs T lymphocyte abnormalities are found, which 
could contribute to development of the atopic syndrome in these patients.32,33 According 
to our data, we propose early evaluation of atopic manifestations in patients with CIDs 
and PADs to prevent clinical deterioration. Future studies should focus on identification of 
specific atopic characteristics of PIDs to evaluate whether they could serve as a potential 
warning sign for an underlying PID.
New clustering algorithm shows endotypes within the atopic syndrome 
based on expression profiles of immune cell lineages
As mentioned in the introduction of the thesis, the atopic syndrome has a heterogeneous 
clinical presentation, which probably is the result of an interaction between physiological, 
biological, immunological and genetic mechanisms.34 Atopic manifestations are prevalent 
comorbidities in PIDs, suggesting that genetic defects in pathways that are involved in 
monogenetic PIDs could also play a role in the pathogenesis of the atopic syndrome.6,35 In 
Chapter 4 we defined subclasses within the atopic syndrome via molecular clustering of 
atopy-related genes based on their expression profiles of immune cell lineages. We identi-
fied 160 atopy-related genes, of which 22 genes were overlapping with disease-causing 
genes of monogenic PIDs.36 Seven distinct clusters within the atopy-related genes were 
identified. The overlapping genes involved in both the atopic syndrome and PIDs were 
bundled in two of the atopy-related gene clusters suggesting that these endotypes of the 
atopic syndrome could be associated with the predisposition to develop a PID. However, 
these data should be confirmed in vivo as atopy-related variants in the overlapping genes 
might differ from disease-causing variants resulting in of PID.
Based on the known atopy-related genes and corresponding expression profiles of immune 
cell lineages, T helper (Th) lymphocytes seem to play a crucial role in the pathogenesis of 
the atopic syndrome, which is in accordance with previous findings. Disturbed T lympho-
cyte function has been described in AD, FA, asthma and AR.37-43 This finding supports 
the hypothesis that changes in the immune system underlie and could be involved in the 
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pathogenesis of the atopic syndrome next to genetic mechanisms, which have previously 
been reported in literature.44-53
Patients with atopic dermatitis have an increased IgE response against 
Staphylococcus aureus
In Chapter 5 of the thesis a systematic review on the antibody response against S. aureus 
was performed to gain more insight in how the immune system of AD patients counter-
acts the bacterium. This might help us to better understand the role of S. aureus in AD 
pathogenesis, as well as the mechanisms by which S. aureus causes inflammation. We 
significantly more often found an IgE response against S. aureus immune modulating supe-
rantigens (33% for staphylococcal enterotoxin (SE) A and 35% for SEB) in patients with AD 
as compared with healthy controls (pooled odds ratio with 95% confidence interval 8.37 
(2.93-23.92) for SEA and 9.34 (3.54-24.93) for SEB). Subgroup analyses to explain the high 
heterogeneity in the pooled analyses suggest that the antibody response is dependent on 
the method of antibody identification (ELISA vs. RIA) and the geographical region of the 
study centre (Asia vs. Europe) in accordance with the study of Taylor et al.54 The increased 
IgE response against immune modulating antigens suggests that S. aureus encourages 
epithelial damage via direct T lymphocyte stimulation and subsequent T lymphocyte pro-
liferation and cytokine release.55-57 Nonetheless, it is unclear whether the increased IgE 
response is specific for patients with AD as comparable studies in other S. aureus-related 
diseases (i.e. S. aureus bacteraemia, folliculitis) are not available. Furthermore, it is un-
known whether the elevated IgE response in AD is a consequence of the increased skin 
permeability, abundance of SEA and SEB carrying S. aureus strains or an altered immune 
response against S. aureus. For example, the anti-SEA and anti-SEB IgE responses could 
be the result of increased expression of these antigens by AD-specific S. aureus strains, 
indicating SEA and SEB expression as possible bacterial mechanisms to aggravate or even 
initiate inflammation in AD. However, previous studies describe absence of a prevailed S. 
aureus genotype, suggesting that the IgE response is the result of immune dysregulation in 
AD in contrast to colonization with an AD-specific S. aureus strain.58-61
Targeted intervention against Staphylococcus aureus had no effect on 
symptoms of atopic dermatitis
The effect of long-term treatment of AD with an endolysin that selectively targets S. aureus 
was studied using a double-blind, vehicle-controlled design and described in Chapters 
6.1 and 6.2 of this thesis. Over the 12-week intervention period (corresponding to 8400 
days for 100 patients), patients in the endolysin group used a topical corticosteroid (TCS) 
for 1889 (45.0%) days compared with 1566 (37.3%) days in the vehicle group. There 
was no statistically significant difference in the probability of TCS use per day between 
the groups nor a difference in reduction of clinical disease severity scores. These data 
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are in accordance with data from a Cochrane review showing no significant effect of 
short-term nonspecific anti-S. aureus therapy (e.g. antibiotics and antibacterial therapeutic 
clothes) in patients with noninfected AD.62 We could not confirm the positive results of 
other longer-term studies. However, these studies used broad-spectrum antimicrobials and 
mainly included patients with signs of bacterial infection.63 Patients with clinically infected 
AD were excluded from our study. A possible effect of anti-S. aureus endolysins in patients 
with clinically infected AD should be determined in future studies.
Several other hypotheses could explain our results, which has implications for future stud-
ies. First, use of triamcinolone in the run-in phase resulted in a decrease in AD severity, 
which could have masked a possible benefit of endolysin treatment. Second, anti-S. aureus 
treatment might not be suitable for all patients with AD because it is a heterogeneous 
disease, indicating the need for subphenotyping. Since only 56% of our study population 
had two consecutive positive S. aureus skin cultures (indicating persistent colonization) 
before start of the intervention, the target population that would probably benefit the 
most from endolysin treatment was small.
However, the most likely reason for the absence of a significant reduction in TCS use in 
this study might be that there was no difference in S. aureus load reduction between the 
endolysin and vehicle treated groups determined by semi-quantitative culture and qPCR. 
Possibly, patients were recolonized with S. aureus from the nose since 73% of them were 
nasal S. aureus carriers.64,65 Furthermore, cetomacrogol used as basis of the cream could 
have formed a barrier on the skin that prevents the endolysin to reach and subsequently 
kill S. aureus. Some reduction in S. aureus load could, however, have been expected in 
both treatment groups due to the use of corticosteroids and emollients in this study, which 
both have shown to reduce the S. aureus load on the skin.66-70 Nonetheless, it is unclear 
whether complete eradication of S. aureus is required for clinical improvement as a case 
series showed a clear clinical improvement without significant S. aureus reduction using a 
qualitative culture in clinically infected AD.71
In conclusion, endolysin treatment as studied in this randomized controlled trial did not 
contribute to unraveling the contribution of the microbiome in the pathogenesis of AD 
due to absence of a clinical effect on AD and reduction of S. aureus load. Nonetheless, 
endolysin treatment was well tolerated and this study provides estimates of AD symptoms, 




Immune dysregulatIon: a model for research on 
PrImary ImmunodefIcIency dIseases, skIn dIsorders 
and atoPy
Primary immunodeficiency disease as immune dysregulation disorder
PIDs are characterized by a compromised or entirely absent function of a part of the immune 
system, which makes people vulnerable for infections. Therefore, PIDs are generally consid-
ered to be immunodeficiency diseases, as implied by its name. However, there is increasing 
evidence that non-infectious complications, including autoimmune and autoinflammatory 
complications, (hematological) malignancies and allergic disorders, are involved in PIDs 
as well.1-3 Autoimmune disorders, such as type 1 diabetes mellitus, rheumatoid arthritis 
and psoriasis, are the result of an immune response directed against normal parts of the 
body, termed auto-antigens. In autoinflammatory disorders, like familiar mediterranean 
fever (FMF) and tumor necrosis factor receptor-associated periodic syndrome (TRAPS), 
the innate immune system is abnormally activated, leading to recurrent episodes of fever 
and inflammation.72 Both autoimmune and autoinflammatory conditions are character-
ized by disruption of the normal function of the immune system, also called immune 
dysregulation. Interestingly, different forms of immune dysregulation, both as primary or 
as accompanying problem, next to the immunodeficiency seem to occur in one and the 
same PID. Therefore, PIDs should be considered as immune dysregulation disorders instead 
of immunodeficiency diseases.73
Immune dysregulation in skin disorders and atopy
Immune dysregulation also plays a role in the multifactorial pathogenesis of skin disorders 
and atopy.74 For example, chronic inflammation caused by different triggers, such as bio-
logical agents (e.g. bacteria, viruses), physical agents (e.g. UV radiation) and immunologic 
disorders (e.g. PIDs), is suggested as one of the hallmarks in skin carcinogenesis.75 In AD, a 
number of immunological abnormalities have been described, such as increased serum IgE 
levels, elevated Th2-type cytokines in acute lesions and Th1-type cytokines in chronic le-
sions, and decreased expression of antimicrobial peptides.76 The immunological dysregula-
tion might precede barrier changes (inside-out hypothesis) or could be the effect of barrier 
dysfunction and subsequent penetration of environmental stimuli into the skin (outside-in 
hypothesis).77 It could be suggested that immune dysregulation is primary affected in AD 
as not all patients with AD have a genetic polymorphism in one of the barrier genes (e.g. 
FLG, KIF3A, OVOL1 and ADAMTS).78,79 The fact that a significant amount of genes involved 
in AD is associated with immune dysregulation further supports a genetic predisposition 
of immunological alterations in AD.44 More than half of the patients with AD will develop 
asthma and other allergic diseases (i.e. FA and AR) involved in the atopic syndrome, which 
indicates that both local and systemic immunity are involved.80,81 In a Dutch study group 
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of children with moderate-to-severe AD more than 60% of the patients had a diagnosis 
of FA and even more than 80% of the patients were diagnosed with asthma and AR.82 
The pathway involved in the atopic syndrome could be characterized by auto-allergy, in 
which atopy seems to stand at the boundary between allergy and autoimmunity. Herein, 
the presence of IgE antibodies against self-proteins is an important pathogenic feature, 
emphasizing the role of immune dysregulation in the atopic syndrome.83-85
Spectrum of immune dysregulation
The spectrum of clinical features associated with PIDs has broadened due to the recent 
identifi cation of many novel causative genes.86 Patients with a PID and noninfectious 
complications are increasingly recognized with features of immune dysregulation, in-
cluding autoimmunity, infl ammation, lymphoproliferation and malignancy.87 Depending 
on the pathways involved and the corresponding number and functionality of immune 
cells involved, the clinical manifestations of diseases involving immune dysregulation are 
characterized by a higher susceptibility to infections or, on the other hand, an increase 
in manifestations of autoimmunity.4 Moreover, it has been increasingly recognized that 
various genetic variants give rise to a clinical phenotype of both immunodefi ciency and 
autoimmunity. One could visualize immune dysregulation as a spectrum with infections on 
one end and autoimmunity on the other end. PIDs can present with a variety of symptoms 
covering the entire spectrum (Figure 1). Within PIDs, for example, patients with severe 
combined immunodefi ciency (SCID) are particularly susceptible to opportunistic infections, 
whereas patients with APECED usually present with autoimmune manifestations in the 
endocrine glands.
Patients with (mild) AD and other atopic manifestations are characterized by an infectious 
phenotype as the immune system in these diseases is directed against external factors. On 
the other hand, patients with increased severity of atopic manifestations may be character-
ized by autoimmunity as levels of IgE autoantibodies have been shown to be associated 
with disease severity.84
Overlap in immune dysregulation: a model for future studies
Taking the hypothesis of a spectrum one step further, different variants of immune dys-
regulation result in a diversity of clinical manifestations within the same patient. We found 
that 80% percent of the patients with a PID has a history of skin disorders and around 
 
 
INFECTIONS                                                  AUTOIMMUNITY 
Figure 1. Spectrum of immune dysregulation
Chapter 7
212
one third suffered from AD during life, which 
was higher as compared with controls. Fur-
thermore, atopic manifestations were found 
significantly more prevalent in PID patients 
than in a matched control group. These 
results show a clinical overlap in presence of 
skin disorders, atopic manifestations within 
the atopic syndrome and PIDs. Expression 
profiles of immune cell lineages substantiated 
a genetic overlap between (monogenic) PIDs 
and endotypes within the atopic syndrome 
as well. Therefore, we propose a model that 
assumes overlap between immune dysregula-
tion disorders (PID, skin disorders and atopy) (Figure 2). AD is a clinical example of the 
overlap between skin disorders and the atopic syndrome, in CGD both (non-atopy related) 
skin disorders and PID are involved and HIES is an example of disease in which all three 
components are affected.
Presence of manifestations of immune dysregulation could fluctuate throughout life, sug-
gesting immune dysregulation has a dynamic spectrum of diseases involved. Our assump-
tion emphasizes that more attention should be paid to simultaneous presence of multiple 
immune dysregulation disorders in clinical care. The model as shown in Figure 2 should 
be used both in clinical care and for research purposes. Caretakers should consider other 
immune dysregulation disorders in patients who present with one of the disorders. In this 
context, detailed registration of these clinical manifestations of each of the components 
within the model could give further insight in the clinical overlap of immune dysregulation 
manifestations within a patient (group). Additionally, the model can help design future 
studies getting more insight in the pathogenesis and role of immune dysregulation within 
the associated diseases.
clInIcal ImPlIcatIons of results of the thesIs
The diagnostic delay of primary immunodeficiency diseases might be 
reduced by using skin symptoms as warning signs
As mentioned in the introduction of the thesis, the delay between onset of the first symp-
toms and diagnosis of PIDs in the Netherlands is up to 14.5 years and might result in 
a reduced quality of life.88-93 In our questionnaire-based studies (Chapters 3.1 and 3.2), 













Figure 2. Overlap in immune dysregulation
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such as respiratory tract infections. Skin disorders were shown to precede the diagnosis of 
PIDs for many years. Moreover, patients with a PID appear to develop skin disorders at a 
younger age compared with people without a PID.
Within the spectrum of PIDs, skin infections and nail disorders, were significantly more 
prevalent in adult patients compared with partner controls. In addition, a history of asthma 
and AR was reported significantly more often by adult patients than controls. Although 
(atopic) dermatitis was the most frequently noted skin disorder in patients, is was not 
found to be a specific skin condition related to PIDs.
Although current literature appointed eczematous dermatitis as common finding and pre-
senting clinical manifestation among PIDs, we feel that reduction of the diagnostic delay 
of PIDs in general could be achieved by recognition of non-dermatitis-like skin disorders, 
like skin infections and/or nail disorders in addition to the presence of the currently used 
warning signs for PIDs. Moreover, data shown in this thesis indicate that atopic mani-
festations, of which at least asthma and AR, might serve as a potential warning sign for 
an underlying PID as well. To further discriminate between the different types of PIDs 
based on patients’ clinical symptoms, we composed an overview of PIDs per skin disorders 
that could serve as a valuable support tool for PID awareness in clinical practice and for 
registries (Chapter 2). However, skin disorders as well as atopic manifestations are also 
frequently described in the general population.6 Therefore, it is of importance to realize 
that presence of specific skin symptoms alone does not necessarily point towards a (spe-
cific) PID. Nonetheless, recognition of specific cutaneous manifestations in combination 
with other clinical features suggestive of an immunodeficiency, like the warning signs for 
PIDs, should raise awareness to an underlying PID and may facilitate earlier diagnosis of 
PIDs.9 Moreover, identification of specific atopic characteristics of PIDs in future studies 
could further increase the suspicion of an underlying PID. In this context, the diagnosis 
of suspected PIDs or PID-classes based on clinical symptoms, for example multiple skin 
disorders and recurrent upper airway infections, could be confirmed with laboratory tests. 
Using the multi-stage diagnostic protocol of de Vries3 or the phenotypic approach for PID 
classification and diagnosis by Bousfiha et al.94, a first diagnostic step in case of a supposed 
antibody deficiency or neutropenia could be blood count and differentiation, IgG, IgA, IgM 
and IgE. In case of a possible combined immunodeficiency disease, these tests should be 
supplemented by lymphocyte subpopulations.
Extended registration of clinical features will improve the diagnostic and 
therapeutic processes in patients with primary immunodeficiency diseases
Data from our review and questionnaire-based studies (Chapters 2, 3.1 and 3.2) dem-
onstrate a high prevalence of skin disorders and atopic manifestations in patients with 
Chapter 7
214
a PID. However, most PIDs are rare and a reliable prevalence of skin disorders and atopic 
manifestations in PIDs can only be obtained by reporting these clinical features in larger 
cohorts. The international PID database of The European Society for Immunodeficiencies 
(ESID) registers, among others, data on warning signs of PIDs. These currently applied 
warning signs focus on the presence of infectious skin disorders. Noninfectious cutaneous 
symptoms and atopic manifestations are not included. Based on data of studies included 
in this thesis, showing skin disorders and the atopic syndrome as highly prevalent and po-
tentially distinctive symptoms of PIDs, we suggest to collect more detailed data on all skin 
disorders and atopic manifestations in the ESID registry in order to improve the diagnostic 
and therapeutic processes in patients with PIDs. In this context, higher number of data 
on these manifestations reported per PID might further improve our composed support 
tool for PID awareness in clinical practice, creating the possibility to better discriminate 
between PID phenotypes based on cutaneous and/or atopic symptoms. Furthermore, 
extensive registration of these symptoms in patients with a PID might provide reliable data 
on the prevalence of cutaneous and atopic manifestations of rare PID phenotypes. Second, 
collection of data on cutaneous S. aureus carriage on skin lesions in PIDs might identify 
patients that could have benefit from S. aureus-targeting treatment to reduce skin disease 
severity.19 In this thesis, a discrepancy between the self-reported prevalence of atopic 
manifestations and the prevalence based on diagnostic criteria or tests was demonstrated 
indicating the need for registration of test results as well. For example, the standardized 
use of skin biopsies to confirm the diagnosis of cutaneous manifestations histopathologi-
cally should be considered, as clinically comparable skin lesions could demonstrate differ-
ent histopathological images in patients with PIDs due to an altered immune system.95 In 
addition, we recommend having skin conditions diagnosed by a dermatologist within the 
diagnostic process to increase its reliability.
recommendatIons for future studIes
Genome sequencing should be further implemented in the diagnostics of 
primary immunodeficiency diseases
The last two decades there has been an exponential growth in genome sequencing with 
immense increase in speed and efficiency concomitantly with reduction in cost. Genome 
sequencing has proved its usefulness in diagnostics for PIDs and is the gold standard in 
most of the (monogenic) PID diagnoses, but is currently not used as first-line diagnostic. 
As genome sequencing becomes cheaper and more convenient, both supply and demand 
will rise. Subsequently, sequencing will be used as standard in care for patients with a 
PID, which will shorten the diagnostic delay and reduce chronic deterioration due to PID-
associated symptoms. By identification of genetic variants in patients with PIDs, we would 
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be able to correlate clinical features, including cutaneous and atopic manifestations, to 
specific genetic variants. Moreover, sequencing could identify patients based on detected 
genetic variants, that require additional specialist care or screening because of an increased 
risk of associated comorbidities (e.g. dermatologist because of high probability of develop-
ment of skin disorders, pulmonologist because of association with asthma or other airway 
complaints). Routine diagnostic genetic testing of patients with a CVID phenotype was 
recently suggested to improve diagnostics in these patients.96
Clustering of atopy-related genes might unravel the heterogeneous 
presentation of the atopic syndrome
Currently, atopic patients have already been stratified based on clinical and immunological 
characteristics, including the type of immune response involved.97 In this thesis, subclasses 
within the atopic syndrome were for the first time defined via molecular clustering of 
atopy-related genes based on their expression profiles of immune cell lineages of healthy 
mice, as reported in Chapter 4. These gene expression profiles may not be identical to 
those in (atopic) humans and may explain why we could not cluster all human atopy-
related genes including FLG, which is an important atopy gene based on the number of 
atopy-related variants (n=62). Furthermore, data from mice cannot directly be applied for 
subgrouping of the atopic syndrome in humans. Therefore, the genetic material of large 
cohorts of patients with the atopic phenotype should be sequenced to investigate whether 
atopy clusters could be generated based on the gene expression profiles of immune cell 
lineages of atopic human. If clusters could be identified, it would be of interest to correlate 
these genetic endotypes to atopic phenotypes and, secondly, to study the overlap with dis-
ease causing genes of monogenic PIDs. Subsequently, in atopic patients with an endotypic 
profile associated with PID (based on overlapping genes) referral to an immunologist may 
be considered in case of warnings signs of a PID.
Overlap in genes involved in atopy and primary immunodeficiency 
diseases identifies (new) therapeutic targets for the atopic syndrome
In PIDs and the atopic syndrome common pathogenic pathways seem to be involved. 
Therefore, several gene-targeted and/or pathway-targeted treatment strategies for PIDs 
could be of clinical benefit in the atopic syndrome as well. The clustering model as shown 
in Chapter 4 creates possibilities for identification of novel therapeutic targets for sub-
groups of the atopic syndrome, leading to more personalized and targeted treatment. For 
example, STAT3 and CTLA4 polymorphisms were found to be both involved in atopy and 
PID (HIES, STAT3 gain-of-function disease and large granular lymphocytosis, and CTLA4-
deficiency, respectively). Jakinibs, such a tofacitinib and ruxolitinib, were described as safe 
and effective treatment modalities in patients with a STAT3 gain-of-function variant to 
treat the autoimmune and autoinflammatory manifestations.98 In patients with a CTLA4-
Chapter 7
216
deficiency, treatment with a CTLA4 mimetic (e.g. abatacept) was shown to improve pa-
tient’s autoimmune symptoms.99 Furthermore, abatacept is registered and used as therapy 
for autoimmune diseases, like rheumatoid artritis.100 Based on their mode of action, these 
therapies could also be effective in patients with (severe) atopic manifestations and an 
autoimmunity phenotype, based on genetic variants in these genes.
The Th lymphocyte mediated pathway was found to be most often involved in the atopic 
syndrome. Acute AD lesions and FA, asthma and AR are predominantly characterized by a 
Th2 response with production of, among others, interleukin (IL)-4 and IL-13.37-43 Dupilumab 
is a human monoclonal antibody that blocks IL-4 and IL-13 signaling by binding to the 
IL-4 receptor alpha chain, modulating Th2-mediated inflammation.101 Blockade by dupil-
umab of these key drivers of Th2-mediated inflammation has already proved effective in 
AD, but could potentially reduce symptoms of other atopic manifestations (i.e. FA, asthma 
and AR) as well.
Using the antibody response against Staphylococcus aureus to gain 
insight in the pathogenesis of atopic dermatitis
In Chapter 5 of the thesis we studied the humoral antibody response against S. aureus 
antigens and found an increased IgE response against immune modulating antigens sug-
gesting S. aureus encourages epithelial damage via direct T lymphocyte stimulation.55-57 To 
investigate further the role of S. aureus and the immune response against this bacterium 
in the AD pathogenesis, future studies should focus on other antibody subtypes than the 
IgE mediated response and other S. aureus antigens, like microbial surface components 
recognizing adhesive matrix molecules (MSCRAMMs), membrane-damaging molecules, 
housekeeping antigens and other types of immune modulating proteins. Totté et al. showed 
that the IgG mediated immune response against immune modulating (non-superantigen) 
S. aureus antigens was associated with the disease severity in children with AD.102 It can 
be argued that children with more severe AD have an altered immune response against 
S. aureus antigens or the association might be the result of a higher S. aureus load in 
children with more severe AD. However, in the latter hypothesis the IgG response against 
all S. aureus antigens would be increased instead of a subset. Following the inside-out 
hypothesis, in which immunologic dysregulation precedes barrier changes, alterations in 
the immunologic function of AD patients may allow or stimulate cutaneous colonization 
of S. aureus, which expresses several antigens resulting in persistence or exacerbation of 
AD symptoms.77 On the other hand (outside-in hypothesis), S. aureus strains involved in 
AD may express more immune modulating antigens, which leads to a more severe AD 
phenotype and immunologic activation. In this context, it would be of interest to study 
whether AD patients are colonized by specific S. aureus strains. However, previous studies 
describe absence of a prevailed S. aureus genotype, which suggests that a primary immune 
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dysregulation precedes and stimulates microbial alterations, including abundance of S. 
aureus, within the pathogenesis of AD.58-61
Pitfalls in the design of a randomized controlled trial to study new 
antimicrobial treatment options in patients with atopic dermatitis
In Chapter 6.1 and 6.2 of the thesis we studied a targeted intervention directed against 
S. aureus using an endolysin. However, endolysin treatment as studied in this randomized 
controlled trial did not contribute to unraveling the contribution of the microbiome within 
the pathogenesis of AD due to absence of a clinical effect on AD and reduction of S. 
aureus load. According to the limitations in the design of our study, it might be relevant 
to investigate the effects of a targeted anti-S. aureus treatment using a wash-out period, 
in which topical corticosteroid and other (systemic) AD medications are not allowed, as 
their (long-term) effect on AD severity may mask an additional effect of the S. aureus 
targeting therapy. Furthermore, inclusion of patients based on two consecutive positive S. 
aureus cultures or clinically infected AD seems to be important to select a more appropriate 
population for S. aureus targeted therapy.
It can be doubted whether endolysins are the most convenient treatment strategy to target 
the microbiome based on results of our study. However, antibiotics are no suitable alterna-
tive as they induce bacterial resistance and have influence of the commensal flora. On the 
other hand, different promising (non-antibiotic) treatment strategies for modulation of the 
microbiome, including monoclonal antibodies and probiotics, are under development at 
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Chapter 1 gives a general introduction and provides the aims of the thesis. Primary 
immunodeficiency diseases (PIDs) encompass a heterogeneous group of more than 430 
inheritable defects of immunity. The prevalence of symptomatic PIDs is estimated at 1 in 
10,000-12,000 in the general population. PIDs are clinically typically characterized by an 
increased risk of recurrent and/or severe infections due to a compromised or entirely absent 
function of a part of the immune system. In addition, patients may suffer from autoim-
mune and autoinflammatory complications and have an increased risk of development of 
(hematological) malignancies and allergic disorders. To raise suspicion of a PID, ten general 
warning signs of PID have been composed, mainly focusing on the presence of infectious 
complications. Despite the use of these warning signs to improve earlier recognition of an 
underlying PID, diagnosis of PIDs is still delayed.
It has been well recognized that a wide spectrum of both infectious and noninfectious skin 
manifestations are common in PIDs and may be among the presenting clinical symptoms. 
Overall, Staphylococcus (S.) aureus-induced skin infections are the most common infectious 
skin manifestations reported in PIDs. On the other hand, autoimmune, autoinflammatory, 
malignant and allergic manifestations are reported, that can be attributed to immune 
dysregulation. Dermatitis is considered as one of the most prominent noninfectious skin 
manifestations in PIDs. Although skin manifestations are frequently occurring in PIDs and 
may even precede the diagnosis of a PID, they are currently not considered as one of the 
warning signs for PIDs.
In Chapter 2 of the thesis a systematically obtained overview of literature of the nature 
and prevalence of skin and atopic manifestations in PIDs is provided. The usefulness of 
these manifestations as (early) warning signs for suspicion of PIDs was evaluated in order 
to improve earlier diagnosis of PIDs. The relation between PIDs and S. aureus-related skin 
manifestations was reviewed in more detail. Based on the collected data, it was dem-
onstrated that both infectious and noninfectious skin manifestations frequently occur in 
patients with PIDs. These included also PIDs in which an association with skin disorders 
was not generally recognized. The high prevalence of skin manifestations in PIDs suggests 
that these manifestations can be used as an additional warning sign to raise suspicion 
for an underlying PID. Through linking skin disorders to specific PIDs, a valuable tool was 
provided that could raise PID awareness in clinical practice. Data on culture proven S. 
aureus-associated skin disorders in PIDs was limited.
In Chapter 3.1 the nature and prevalence of (presenting) skin disorders were evaluated 
in a Dutch population of patients with a PID. A history of skin disorders, in particular skin 
infections and nail disorders, was found to be more prevalent in patients with a PID com-
pared with partner-controls. Data retrieved from this cohort of PID patients were mostly 
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consistent with the data summarized in our systematic review, which includes mainly data 
derived from Middle-Eastern countries (Chapter 2). However, in the Dutch patient cohort 
viral and bacterial skin infections, erythematous skin lesions and skin rashes were more fre-
quently reported than in current literature. In addition, skin disorders preceded a diagnosis 
of PIDS for many years and developed earlier in life in patients compared with unaffected 
partner-controls. As skin disorders were frequently reported as presenting symptoms, we 
suggest to consider skin disorders as a potential warning sign for an underlying PID. In 
our cohort, a positive S. aureus culture at a single time point was found in 40% of the 
skin disorders with suspected S. aureus-related etiology, which could reflect intermittent 
carriage of S. aureus. We suppose that repetitive culturing during clinical examination to 
identify skin lesions colonized with S. aureus can contribute in selection of PID patients, 
that could benefit from S. aureus-targeting treatment to reduce skin disease severity.
In particular patients with severe (atopic) dermatitis (AD) have an atopic constitution and 
show tendency towards development of other atopic manifestations, including food al-
lergy (FA), asthma and allergic rhinitis (AR). The atopic manifestations encompass allergic 
disorders, which are already known as prevalent comorbidities in various PIDs. However, 
original data on atopic manifestations in PIDs are limited, mainly based on small numbers of 
patients with PIDs and the diagnosis of atopic manifestations is generally not confirmed by 
diagnostic tests (Chapter 2). Chapter 3.2 focused on the nature and prevalence of atopic 
manifestations in in a cohort of adult and pediatric patients with a PID to identify specific 
PIDs with a higher chance of developing the atopic syndrome. All atopic manifestations 
were found to be highly prevalent in patients with PIDs and more common when com-
pared with partner-controls. Moreover, atopic manifestations were reported by patients in 
a large spectrum of PIDs across the various phenotypes, which is in contrast with previous 
literature (Chapter 2). Compared with our review (Chapter 2), we found a significantly 
higher prevalence of atopic manifestations in patients with a predominantly antibody 
deficiencies (PADs) and comparable numbers of patients with atopic manifestations in 
combined immunodeficiencies (CIDs). Based on our data, we propose early evaluation 
of atopic manifestations in patients with PADs and CIDs to prevent clinical deterioration. 
Future studies should focus on identification of specific atopic characteristics of PIDs to 
evaluate whether they could serve as a potential warning sign for an underlying PID.
Development of atopic manifestations not always follows the classic sequence and not all 
atopic patients will develop the complete spectrum of atopic manifestations. Subgroups of 
the atopic phenotype, termed endotypes, are possibly responsible for the heterogeneous 
presentation of the atopic syndrome. Atopic manifestations are prevalent comorbidities 
in various (monogenic) PIDs, which may be due to overlapping pathogenic pathways. 
Therefore, current insights in the pathways involved in PIDs could be used to define the 
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endotypic profile of atopic patients in more detail, contributing to determination of more 
homogeneous subclasses of these patients and additionally better stratification of patients 
for future pathway-targeted or gene-targeted treatment strategies. Chapter 4 shows 
a new clustering algorithm to define endotypes within the atopic syndrome that were 
obtained via molecular clustering of atopy-related genes based on their expression profiles 
in immune cell lineages. Seven distinct clusters within the atopy-related genes were identi-
fied. Genes that are involved in the atopic syndrome as well as in PIDs were mainly located 
in two of the seven atopy-related gene clusters. This suggests that these subgroups of the 
atopic syndrome could be associated with the predisposition to develop PID. Furthermore, 
T helper lymphocytes were found to play a crucial role in the pathogenesis of the atopic 
syndrome based on the known atopy-related genes and corresponding expression profiles 
in immune cell lineages. These findings support the hypothesis that changes in the im-
mune system are involved in the pathogenesis of the atopic syndrome next to genetic 
mechanisms.
AD is an important skin manifestation within the atopic syndrome and one of the most 
common chronic inflammatory skin disorders. AD has a multifactorial pathogenesis char-
acterized by three major pathophysiological changes, including (i) abnormalities of the skin 
barrier; (ii) changes in the immune response; and (iii) alterations in the skin microbiome 
including abundance of S. aureus. However, studies on the interaction between the im-
mune system and S. aureus are still scarce. Further evaluation of the antibody response 
against antimicrobial antigens could provide insights in the antigens that are expressed by 
the skin microbiome in vivo and will reveal how the immune system in AD patients coun-
teracts these antigens. In Chapter 5 the prevalence of human antibody responses against 
S. aureus antigens was evaluated in patients with AD and compared to healthy controls. 
Therefore, a systematic literature search and meta-analysis was performed. Patients with 
AD significantly more often showed an IgE antibody response directed against S. aureus 
immune modulating superantigens (SEA, SEB and TSST-1) when compared to healthy 
controls. Data on other antibodies as well as other S. aureus antigens were limited. This 
suggests that S. aureus encourages epithelial damage via direct T lymphocyte stimulation 
and subsequent T lymphocyte proliferation and cytokine release.
The specific contribution of each of the three factors to the AD phenotype is still unknown. 
However, it is suggested that S. aureus plays a pivotal role in AD. Therefore, it would be 
of interest to study a treatment targeting S. aureus. Chapter 6.1 describes the protocol of 
a randomized vehicle controlled trial that studied the effect of topical treatment with an 
endolysin that targets S. aureus in patients with AD. Subsequently, the results of this trial 
are reported in Chapter 6.2 of the thesis. In this study, long-term targeted endolysin treat-
ment against S. aureus was found to be well tolerated. However, there was no statistically 
Chapter 8
230
significant difference in the probability of topical corticosteroid (TCS) use per day between 
the groups nor a difference in reduction of clinical disease severity scores, which might 
be the result of a decrease in AD severity in the run-in phase due to use of triamcinolone 
cream combined with emolliens. Moreover, there was no difference observed in the reduc-
tion of S. aureus load between the endolysin and vehicle treated groups determined by 
semi-quantitative culture and qPCR, corresponding with the results of the clinical outcome. 
Therefore, endolysin treatment as studied in this randomized controlled trial, in patients 
with relatively mild and noninfected AD at start of the treatment, did not contribute to 
unravel the role of S. aureus in the pathogenesis of AD. Nonetheless, endolysin treatment 
was well tolerated and this study provides estimates of AD symptoms, use of TCSs and 
the percentage of persistent S. aureus carriers that can be used for future clinical studies.
Finally, a general overview of the main findings and suggestions for clinical implication and 
future research is provided in Chapter 7. Recent identification of many novel causative 
genes has broadened the spectrum of clinical features associated with PIDs. Patients with a 
PID and noninfectious complications are increasingly recognized with features of immune 
dysregulation, including autoimmunity, autoinflammation, lymphoproliferation and malig-
nancy. Therefore, we suggest to consider PIDs as immune dysregulation syndromes rather 
than immune deficiency syndromes. Depending on the pathways, genetic variants and 
number and functionality of immune cells involved, the clinical picture could be dominated 
by a higher susceptibility to infections or an increased risk of autoimmune or autoinflam-
matory manifestations. In this thesis immune dysregulation is therefore visualized as a 
spectrum with infections on one end and autoimmunity on the other end. Patients with 
PIDs typically show various symptoms within this spectrum, but predominance of specific 
manifestations can be PID specific. Moreover, results of our studies support the hypothesis 
that immune dysregulation also plays a role in the multifactorial pathogenesis of skin 
disorders and atopy. In both AD and other atopic diseases, patients can be characterized 
by having either a predominant infectious phenotype or an autoimmune phenotype. As 
immune dysregulation may result in a diversity of clinical manifestations within the same 
patient, a model that assumes overlap between immune dysregulation disorders (PID, skin 
disorders and atopy) is proposed in this thesis. Our assumption emphasizes that more 
attention should be paid to the concurrent presence of various symptoms related to im-
mune dysregulation in clinical care. For example, in order to further consider (specific) skin 
disorders as a potential warning sign for an underlying PID. In addition, gene-targeted 
and/or pathway-targeted treatment strategies registered for specific immune dysregulation 
disorders could be effective in other diseases with clinically overlapping symptoms in which 
immune dysregulation is involved.
231
Samenvatting
Hoofdstuk 1 geeft een algemene inleiding en tevens de doelstellingen van het proefschrift 
weer. Primaire immuundeficiënties (PID’s) omvatten een heterogene groep van meer dan 
430 erfelijke aandoeningen van het immuunsysteem. De prevalentie van symptomatische 
PID’s kan worden geschat op 1 op 10.000-12.000 in de algemene bevolking. PID’s worden 
klinisch typisch gekenmerkt door een verhoogd risico op recidiverende en/of ernstige 
infecties als gevolg van een verminderde of volledig afwezige functie van een deel van 
het immuunsysteem. Daarnaast kunnen patiënten klachten hebben van auto-immuun- 
en auto-inflammatoire complicaties en hebben zij daarnaast een verhoogd risico op het 
ontwikkelen van (hematologische) maligniteiten en allergische aandoeningen. Om het 
vermoeden op een PID te wekken, zijn er tien alarmsignalen van PID’s beschreven, welke 
voornamelijk zijn gericht op de aanwezigheid van infectieuze complicaties. Ondanks het 
gebruik van deze alarmsignalen ter bespoediging van het bemerken van een onderlig-
gende PID, is de diagnose van PID’s nog steeds vertraagd.
Het is algemeen erkend dat een breed spectrum van zowel infectieuze als niet-infectieuze 
huidmanifestaties frequent voorkomt bij patiënten met een PID en mogelijk zelfs tot de 
presenterende klinische symptomen behoort. Over het algemeen zijn door Staphylococcus 
(S.) aureus geïnduceerde huidinfecties de meest voorkomende infectieuze huidmanifes-
taties van PID’s. Anderzijds zijn auto-immuun, auto-inflammatoire, maligne en allergische 
manifestaties beschreven, welke kunnen worden toegeschreven aan immuundysregulatie. 
Dermatitis wordt beschouwd als een van de meest prominente niet-infectieuze huidmani-
festaties van PID’s. Hoewel huidmanifestaties frequent voorkomen bij PID’s en zelfs vooraf 
kunnen gaan aan de diagnose van een PID, worden ze momenteel niet beschouwd als een 
van de alarmsignalen voor PID’s.
In Hoofdstuk 2 van het proefschrift wordt een systematisch verkregen literatuuroverzicht 
met betrekking tot de aard en prevalentie van huid- en atopische manifestaties van PID’s 
gegeven. Het gebruik van deze manifestaties als (vroege) alarmsignalen voor de verdenking 
op een PID werd geevalueerd ter bevordering van vroegdiagnostiek van PID’s. De relatie 
tussen PID’s en S. aureus-gerelateerde huidmanifestaties werd hierbij nader bekeken. 
Op basis van de verzamelde gegevens werd aangetoond dat zowel infectieuze als niet-
infectieuze huidmanifestaties freuent voorkomen bij patiënten met PID’s. Deze omvatten 
ook PID’s waarvan een verband met huidaandoeningen nog niet algemeen bekend is. De 
hoge prevalentie van huidmanifestaties van PID’s suggereert dat deze manifestaties kunnen 
worden gebruikt als additioneel alarmsignaal om de verdenking op een onderliggende PID 
te wekken. Door huidaandoeningen aan specifieke PIDS te koppelen, werd een waardevol 
hulpmiddel verschaft dat het bewustzijn van een PID in de klinische praktijk zou kun-
nen vergroten. Gegevens van door middel van kweek bewezen S. aureus-geassocieerde 
huidaandoeningen in patiënten met PID’s bleken beperkt gepubliceerd.
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In Hoofdstuk 3.1 zijn de aard en prevalentie van (presenterende) huidaandoeningen geëva-
lueerd in een Nederlandse populatie van patiënten met een PID. Een belaste voorgeschie-
denis met huidaandoeningen, met name huidinfecties en nagelaandoeningen, werd vaker 
gerapporteerd bij patiënten met een PID in vergelijking met partner controles. Gegevens 
uit het cohort van PID-patiënten kwamen grotendeels overeen met de resultaten van ons 
systematische literatuuronderzoek, wat voornamelijk gegevens bevat afkomstig uit landen 
in het Midden-Oosten (Hoofdstuk 2). In het Nederlandse patiënten cohort werden echter 
virale en bacteriële huidinfecties, erythemateuze huidlaesies en huiduitslag vaker gemeld 
dan in de reeds gepubliceerde literatuur. Daarnaast gingen huidaandoeningen jaren vooraf 
aan de diagnose van PID’s en ontwikkelden ze zich eerder in het leven van patiënten 
met PID’s in vergelijking met onaangedane partner controles. Aangezien huidaandoenin-
gen frequent worden gerapporteerd als presenterende symptomen, suggereren wij om 
huidaandoeningen te overwegen als potentiaal allarmsignaal voor een onderliggende PID. 
In ons cohort werd een positieve S. aureus-kweek op één tijdstip gevonden bij enkel 40% 
van de huidaandoeningen met vermoedelijke S. aureus-gerelateerde etiologie. Dit zou 
het intermitterende dragerschap van S. aureus kunnen weerspiegelen. We veronderstel-
len dat herhaaldelijk kweken tijdens klinisch onderzoek noodzakelijk is om huidlaesies te 
identificeren die zijn gekoloniseerd met S. aureus. Dit kan bijdragen aan het selecteren van 
PID-patiënten, die baat zouden kunnen hebben bij een op S. aureus gerichte behandeling 
om de ernst van huidziekten te verminderen.
Voornamelijk patiënten met ernstig (constitutioneel) eczeem (CE) hebben een atopische 
constitutie en tonen de neiging om andere atopische manifestaties, bestaande uit voedsel-
allergie (VA), astma en allergische rhinitis (AR), te ontwikkelen. De atopische manifestaties 
omvatten allergische aandoeningen, die reeds bekend zijn als veelvoorkomende comorbi-
diteit van verschillende PID’s. Originele gegevens over atopische manifestaties van PID’s zijn 
echter beperkt, voornamelijk gebaseerd op kleine aantallen patiënten met een PID en de 
diagnose van atopische manifestaties is over het algemeen niet bevestigd door middel van 
diagnostische tests (Hoofdstuk 2). Hoofdstuk 3.2 richtte zich op de aard en prevalentie 
van atopische manifestaties in een cohort van volwassen en pediatrische patiënten met een 
PID, zodat specifieke PID’s kunnen worden geïdentificeerd die een grotere kans hebben op 
het ontwikkelen van het atopisch syndroom. Alle atopische manifestaties bleken zeer vaak 
voor te komen bij patiënten met PID’s en waren prevalenter in vergelijking met partner 
controles. Bovendien werden atopische manifestaties door patiënten gerapporteerd bin-
nen een groot spectrum van PID’s verspreid over de verschillende fenotypen. Dit is in te-
genstelling met eerdere literatuur (Hoofdstuk 2). Vergeleken met ons literatuuronderzoek 
(Hoofdstuk 2), vonden wij een significant hogere prevalentie van atopische manifestaties 
bij patiënten met overwegend antilichaamdeficiënties (PAD’s) en vergelijkbare aantallen 
patiënten met atopische manifestaties bij gecombineerde immunodeficiënties (CID’s). Op 
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basis van deze gegevens stellen wij voor om bij patiënten met PAD’s en CID’s vroegtijdige 
evaluatie van atopische manifestaties uit te voeren om klinische achteruitgang te voor-
komen. Toekomstige studies zouden zich moeten concentreren op de identificatie van 
specifieke atopische kenmerken van PID’s met als doel te evalueren of deze manifestaties 
zouden kunnen dienen als mogelijk waarschuwingssignaal van een onderliggende PID.
Atopische manifestaties presenteren zich niet altijd volgens de klassieke volgorde en 
niet alle atopische patiënten zullen het volledige spectrum van atopische manifestaties 
ontwikkelen. Subgroepen van het atopische fenotype, endotypes genoemd, zijn mogelijk 
verantwoordelijk voor de heterogene presentatie van het atopische syndroom. Atopische 
manifestaties zijn veel voorkomende comorbiditeiten van verschillende (monogene) PID’s, 
wat mogelijk te wijten is aan overlappende processen. Daarom zouden huidige inzichten 
in de processen die betrokken zijn bij PID’s kunnen worden gebruikt om het endotypische 
profiel van atopische patiënten in meer detail te definiëren. Dit zou vervolgens kunnen 
bijdragen aan de identificatie van meer homogene subgroepen van deze patiënten en 
bovendien tot een betere stratificatie van patiënten voor toekomstige procesgerichte of 
gen-gerichte behandelstrategieën. Hoofdstuk 4 toont een nieuw clusteringalgoritme 
om endotypen binnen het atopische syndroom te definiëren, welke werden verkregen via 
moleculaire clustering van atopie-gerelateerde genen op basis van hun expressieprofielen 
in immuun cellijnen. Zeven onderscheidende clusters binnen de atopie-gerelateerde ge-
nen werden geïdentificeerd. Genen die betrokken zijn bij zowel het atopische syndroom 
als PID’s waren met name gelokaliseerd in twee van de zeven atopie-gerelateerde gen 
clusters. Dit suggereert dat deze subgroepen van het atopische syndroom geassocieerd 
zouden kunnen zijn met de aanleg om een PID te ontwikkelen. Bovendien bleken T-helper 
lymfocyten een cruciale rol te spelen in de pathogenese van het atopische syndroom op 
basis van de bekende atopie-gerelateerde genen en bijbehorende expressieprofielen in 
immuun cellijnen. Deze bevindingen ondersteunen de hypothese dat veranderingen in 
het immuunsysteem betrokken zijn bij de pathogenese van het atopische syndroom ad-
ditioneel aan genetische mechanismen.
CE is een belangrijke cutane manifestatie binnen het atopisch syndroom en een van de 
meest voorkomende chronische inflammatoire huidaandoeningen. CE heeft een multi-
factoriële pathogenese die wordt gekenmerkt door drie belangrijke pathofysiologische 
veranderingen, bestaande uit (i) afwijkingen van de huidbarrière; (ii) veranderingen in de 
immuunrespons; en (iii) veranderingen in het huidmicrobioom, waaronder een overvloed 
aan S. aureus. Studies naar de interactie tussen het immuunsysteem en S. aureus zijn echter 
schaars. Evaluatie van de antilichaamrespons tegen antimicrobiële antigenen zou inzicht 
kunnen geven in de antigenen die in vivo door het huidmicrobioom tot expressie worden 
gebracht en zal tevens openbaren hoe het immuunsysteem in patiënten met CE tegen 
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deze antigenen reageert. In Hoofdstuk 5 werd de prevalentie van menselijke antilichaam-
reacties tegen S. aureus antigenen bij patiënten met CE geëvalueerd en vergeleken met 
gezonde controles. Hiervoor werd een systematisch literatuuronderzoek en meta-analyse 
uitgevoerd. Patiënten met CE vertoonden significant vaker een IgE-antilichaamrespons 
gericht tegen immuunmodulerende superantigenen van S. aureus (SEA, SEB en TSST-1) 
in vergelijking met gezonde controles. Gegevens van andere antistoffen evenals andere 
S. aureus antigenen waren beperkt. Dit suggereert dat S. aureus epitheliale schade stimu-
leert via directe T-lymfocyten stimulatie en daaropvolgende T-lymfocyten proliferatie en 
cytokine-afgifte.
De specifieke bijdrage van elk van de drie factoren aan het CE-fenotype is nog onbekend. 
Echter, er wordt gesuggereerd dat S. aureus een cruciale rol speelt in CE. Een  behandeling 
gericht tegen S. aureus zou daarom interessant kunnen zijn om te bestuderen. Hoofdstuk 
6.1 beschrijft het protocol van een gerandomiseerde vehikel gecontroleerde studie, die 
het effect van een topicale behandeling middels een endolysine gericht tegen S. aureus in 
patiënten met CE onderzoekt. Vervolgens worden de resultaten van dit onderzoek gerap-
porteerd in Hoofdstuk 6.2 van het proefschrift. In deze studie bleek een langdurige endo-
lysine behandeling gericht tegen S. aureus goed te worden verdragen. Er was echter geen 
statistisch significant verschil in de waarschijnlijkheid van topicaal gebruik van corticostero-
iden (TCS) per dag tussen de behandelgroepen, noch een verschil in vermindering van de 
klinische ernstscores, wat het gevolg zou kunnen zijn van een afname van de ernstscores 
van CE tijdens de inloop periode door het gebruik van triamcinoloncrème gecombineerd 
met een emollient. Bovendien was er geen verschil in de geobserveerde vermindering van 
de S. aureus-belasting tussen de met endolysine en met vehikel behandelde groepen, wat 
werd vastgesteld middels een semi-kwantitatieve kweek en qPCR, wat overeenkomst met 
de resultaten van de klinische uitkomsten. Daarom heeft de behandeling met endolysine 
zoals onderzocht in dit gerandomiseerde gecontroleerde onderzoek, in patiënten met real-
tief mild en niet-geïnfecteerd CE aan het begin van de behandeling, geen bijdrage gehad 
aan de ontrafeling van de rol van S. aureus binnen de pathogenese van CE. Desalniettemin 
werd de behandeling met endolysine goed verdragen en geeft deze studie voorspellingen 
van CE-symptomen, gebruik van TCS’s en het percentage persisterende S. aureus-dragers, 
welke kunnen worden gebruikt voor toekomstige klinische studies.
Ten slotte wordt in Hoofdstuk 7 een algemeen overzicht gegeven van de belangrijkste 
bevindingen en suggesties voor klinische implicaties en toekomstig onderzoek. Recente 
identificatie van nieuwe causatieve genen heeft het spectrum van klinische kenmerken 
die geassocieerd zijn met PID’s verbreed. Patiënten met een PID en niet-infectieuze com-
plicaties worden steeds vaker gediagnosticeerd met kenmerken van immuundysregulatie, 
waaronder auto-immuniteit, auto-inflammatie, lymfoproliferatie en maligniteiten. Daarom 
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stellen we voor om PID’s te beschouwen als immuundysregulatie syndromen in plaats van 
immuundeficiëntie syndromen. Afhankelijk van de processen, genetische varianten en 
het aantal en functionaliteit van de betrokken immuuncellen, worden het klinisch beeld 
gedomineerd door een hogere gevoeligheid voor infecties of een verhoogd risico op auto-
immuun of autoinflammatoire manifestaties. In dit proefschrift wordt daarom immuundys-
regulatie gevisualiseerd als een spectrum met infecties aan de ene kant en auto-immuniteit 
aan de andere kant van het spectrum. Patiënten met een PID vertonen doorgaans verschil-
lende symptomen binnen dit spectrum, echter dominantie van specifieke manifestaties 
kan PID-specifiek zijn. Bovendien ondersteunen de resultaten van onze studies de hypo-
these dat immuundysregulatie ook een rol speelt in de multifactoriële pathogenese van 
huidaandoeningen en atopie. In zowel CE als andere atopische ziekten kunnen patiënten 
worden gekenmerkt door een overwegend infectieus fenotype of door een auto-immuun 
fenotype. Aangezien immuundysregulatie kan resulteren in een diversiteit aan klinische 
manifestaties binnen dezelfde patiënt, wordt in dit proefschrift een model voorgesteld dat 
veronderstelt dat er overlap is tussen immuundysregulatie aandoeningen (PID’s, huidaan-
doeningen en atopie). Onze aanname benadrukt dat meer aandacht zou moeten worden 
besteed aan de gelijktijdige aanwezigheid van verschillende symptomen gerelateerd aan 
immuundysregulatie in de klinische zorg. Bijvoorbeeld om (specifieke) huidaandoeningen 
verder te overwegen als potentieel alarmsignaal voor een onderliggende PID. Daarnaast 
zouden gen-gerichte en/of proces-gerichte behandelstrategieën, die zijn geregistreerd voor 
specifieke immuundysregulatie aandoeningen, effectief kunnen zijn bij andere ziekten met 















AD-HIES autosomal dominant hyper IgE syndrome
AE adverse event
APECED autoimmune polyendocrinopathy candidiasis ectodermal dystrophy
AR allergic rhinitis
AR-HIES autosomal recessive hyper IgE syndrome
AT ataxia-telangiectasia
CDLQI Children’s Dermatology Life Quality Index
CGD chronic granulomatous disease
CI confidence interval
CID combined immunodeficiency
ClfA clumping factor A
CVID common variable immunodeficiency disorder
DLQI Dermatology Life Quality Index
EASI Eczema Area and Severity Index
ELISA enzyme-linked immunosorbent assay




GLME generalized linear mixed-effect
HIES hyper IgE syndrome
HOME Harmonising Outcome Measures for Eczema
HR-QoL health-related quality of life
IDQOL Infant’s Dermatitis Quality of Life Index
Ig immunoglobulin
IGA Investigators Global Assessment
IHE  Institute of Health Economics
IPEX immunodysregulation polyendocrinopathy enteropathy X-linked
IQR interquartile range
ISAAC International Study of Asthma and Allergies in Childhood
IUIS International Union of Immunological Societies
LAD leukocyte adhesion defect
LME linear mixed-effect
LTA lipoteichoic acid
MOOSE Meta-analysis Of Observational Studies in Epidemiology





NOS Newcastle Ottawa Scale
NRS Numeric Rating Scale
OR odds ratio
PAD predominant antibody deficiency
PID primary immunodeficiency disease
PLAID PLCG2 associated antibody deficiency and immune dysregulation
PLCG2 Phospholipase C Gamma 2
POEM Patient Oriented Eczema Measure
PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QoL quality of life
qPCR quantitative polymerase chain reaction
RIA radioimmunoassay
S. aureus Staphylococcus aureus
SCC squamous cell carcinoma
SCID  severe combined immunodeficiency
SCORAD SCORing Atopic Dermatitis
SD standard deviation
SE staphylococcal enterotoxin
SF36 Short Form 36
SIgAD selective IgA deficiency
sIgE specific IgE
SR-QoL skin-related quality of life
Staphefekt Staphefekt SA.100
TAPQOL TNO-AZL Preschool Children’s Quality of Life questionnaire
TCS topical corticosteroid
TSST toxic shock syndrome toxin
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